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SUMMARY
The human retinoid X receptor α (hRXRα) is a member of the nuclear 
receptor super-family of ligand-activated transcription factors.  The Doyle 
laboratory has previously engineered a variety of functional hRXRα variants 
that activate gene expression in response to synthetic ligands (LG335 and γ-
oxo-1-pyrenebutyric acid), compounds that are poor activators of wild-type 
hRXRα.  The variants generally no longer respond to the wild-type ligand 9-
cis retinoic acid.
To enable targeting of these engineered receptors to arbitrary DNA 
sequences, we developed a program, ESPSearch, for identifying short or 
specific sequences in DNA or protein.  ESPSearch enables identification of 
combinations of known zinc finger motifs to target arbitrary genes, as well 
having several other applications.  The ability to target any DNA sequence 
means that the engineered receptors can be directed to control any gene.
The ligand binding, self-association, coactivator interactions, and 
unfolding properties of the ligand binding domain of wild-type hRXRα were 
characterized.  Our expression and purification protocol improves upon 
existing methods, providing high purity protein in a single step with more 
than twice prior yields.  A general fluorescence-based method for measuring 
ligand affinity with hRXRα was developed, and used to determine binding 
constants for the small molecules.  The presence of a peptide containing the 
binding motif from coactivator proteins (LxxLL) differentially increased the 
affinity of the receptor for the ligands.  Assays to determine the self-
association give a Kd for the dimer-tetramer equilibrium of 35 µM.  hRXRα 
was found to denature irreversibly when heated, but shifts in apparent Tm 
due to ligands correlates strongly with the ligand binding affinities.  Our 
results clarify disparities in existing reports and provide a benchmark for 
xix
comparison.  Reliable analysis of our data led to the development of a 
computer program for rigorous, automated data fitting.
Nine functional variants of hRXRα were characterized to probe 
correlations between biophysical properties and the observed functional 
activity of the receptors, which differ significantly from wild-type.  Although 
the correlation between ligand binding affinity and melting temperature was 
strong for all variants, there was essentially no correlation between ligand 
binding and activation of the variants.  The mutations, which are all 
contained within the binding pocket, have significant long-range effects on 
the protein, causing changes in ligand-LxxLL interactions and 
oligomerization of the variants.  Experimental and computational analysis of 
selected mutations suggests that they are highly coupled, complicating 
protein design.  However, the large variation in properties amongst the 
variants also suggests that hRXRα can be mutated extensively while still 
retaining function.  The long-range impact of binding pocket mutations will 
need to be taken into account in future engineering projects, as hRXRα is a 
flexible, dynamic protein.
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1CHAPTER 1
RETINOID X RECEPTORS
1.1 Overview of Nuclear Receptors
The retinoid X receptors (RXRs) are members of the nuclear receptor 
super-family of ligand-activated transcription factors (1).  Nuclear receptors 
are found only in animals and plants, although recent evidence has 
suggested that fungi may share a nuclear receptor-like ancestral protein 
with the nuclear receptor superfamily (2).  Current evidence suggests that 
the first nuclear receptor was most similar to the present-day estrogen 
receptor, and that other nuclear receptors evolved later (3).  The nuclear 
receptor superfamily is composed of several groups, and a rational 
nomenclature based on sequence alignments and a constructed phylogeny 
has been proposed to name receptors based on their subfamily and gene(s) 
(4, 5).  One of the largest subfamilies is the classical steroid receptors, while 
includes the estrogen receptors (subfamily NR3A), the androgen receptor 
(subfamily NR3C, gene C4), the glucocorticoid receptor (subfamily NR3C, 
gene C1), and the mineralocorticoid receptor (subfamily NR3C, gene C2). 
Another large subfamily is composed of receptors that tend to 
heterodimerize with RXRs (see below), including the pregnane X receptor 
(subfamily NR1I, gene I2), the retinoic acid receptors (subfamily NR1B), the 
peroxisome proliferator-activated receptors (subfamily NR1C), the vitamin D 
receptor (subfamily NR1I, gene I1), the thyroid receptors (subfamily NR1A), 
the ecdysone receptor (subfamily NR1H, gene H1), and the retinoid-related 
orphan receptors (subfamily NR1F).  The retinoid X receptors (subfamily 
NR2B) are part of a much smaller group of related receptors.
As transcription factors, nuclear receptors regulate gene expression, 
and are important in a wide variety of biological processes, including steroid 
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signaling, metabolism, and  xenobiotic sensing (5, 6).  A single nuclear 
receptor is likely to be involved in numerous pathways within the cell, and 
many nuclear receptors have been shown to be involved in pathways that do 
not directly involve gene regulation (5).
Nuclear receptors exert their gene-regulation by binding to specific 
DNA sequences in gene promoters called response elements (7, 8).  These 
response elements are generally composed of six specific DNA bases; which 
six varies somewhat across the nuclear receptor groups.  For example, the 
androgen receptor binds the DNA sequence AGAACA, while RXRs instead 
recognizes AGGTCA (7).  In addition, many nuclear receptors bind groups of 
closely related DNA sequences or are sensitive to DNA bases outside the six 
being directly bound (9-18).  Although a few nuclear receptors can bind to 
DNA and regulate gene expression as a single, monomeric unit, most require 
another nuclear receptor as a binding partner (7, 8).  In some cases, such as 
the estrogen receptors and RXRs, the partner may be another identical 
protein, and hence they form homodimers, while other receptors require a 
different nuclear receptors as partner to form a heterodimer (7).  A small 
number of nuclear receptors are able to form higher order units: the thyroid 
receptor has been reported to form trimers (19), while RXRs can form 
tetramers (20, 21).
In addition to DNA and each other, nuclear receptors bind coactivator 
and corepressor proteins, which respectively help activate and suppress 
activity of the nuclear receptors (5).  The coactivator proteins contain 
specific motifs, generally a helical LxxLL amino acid sequence (where x 
designates any amino acid), which bind to the surface of the nuclear 
receptors and stabilize active conformations (5, 22).  Some nuclear 
receptors have also been reported to interact directly with members of 
additional protein families (23, 24).
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Nuclear receptors can also be regulated by post-translational 
modifications, including phosphorylation, sumoylation, and ubiquitination. 
Specific effects of these modifications are different for each receptor; the 
transcription activity of RXRs is generally reduced by these mechanisms. 
Phosphorylation can upregulate the activity of RXR-retinoic acid receptor 
heterodimers (25), or deactivate RXRs by reducing DNA binding affinity (26-
31) and triggering export from the nucleus (32).  Sumoylation has been 
shown to deactivate RXRs (33).
Most nuclear receptors can be regulated by transport mechanisms. 
As transcription factors, nuclear receptors are inactive unless they are 
within the nucleus of the cell.  Chaperone proteins, in response to some 
other signal, have been identified as transporters of nuclear receptors 
across the nuclear membrane (34, 35).  Some evidence for shuttling of RXRs 
exists (36), but other reports suggest that RXRs exist predominantly in the 
nucleus unless specifically exported (37, 38).  Nuclear receptors not present 
in the nucleus may still be involved in other roles not related to regulation of 
transcription (5).
One method of nuclear receptor control that is of particular interest to 
the medical community is regulation via small molecule binding; it is this 
interest which caused the rapid growth of publications and maintained 
interest in nuclear receptors such as RXRs (see Figure 1.1).  Nuclear 
receptors undergo a conformational change to an active state upon binding 
agonist ligands, while antagonist ligands tend to block the conformational 
change (5, 39-41).  An extensive vocabulary now exists to classify the precise 
effect of ligands on receptors, which takes into account factors such as how 
much additional factors (e.g., cell-type specific effects) influence the degree 
of activation by an agonist (5).  For our purposes, small molecules that bind 
a receptor a ligands; those that also happen to cause some degree of 
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activation are called agonists.
1.2 Function and Structure of RXRs
Like most nuclear receptors, the retinoid X receptors are composed of 
four primary domains (see Figure 1.2).  The N-terminal domain is designated 
the A/B domain, and is the most variable domain between different nuclear 
receptors; some nuclear receptors lack this domain entirely or have a 
domain much larger than the A/B domain in RXRs (5, 42).  This domain 
contains the activation-function domain 1, which plays a role in binding DNA 
and coactivator protein interactions (43-46).  The next domain is the DNA-
binding domain (DBD), designated C, which is composed of two Cys4 zinc 
finger domains (47).  This domain is the most highly conserved domain, and 
is the primary domain used to classify receptors into subfamilies, although a 
very few nuclear receptors lack this domain (4, 5).  Next comes the hinge, or 
D, domain, which is a variable linker region, although recent reports have 
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Figure 1.1.  History of RXR-related publications.  Bars represent the 
number of publications mentioning "RXR," "retinoid X receptor," or 
"ultraspiracle AND receptor" in the abstract of PubMed indexed journals. 
*=projected based on first 9 months.  The few cases "RXR" having other 
meanings were removed.
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suggested that the domain is functionally important (48-50).  Finally, the 
ligand binding domain (LBD), or E, contains the ligand binding pocket and 
activation-function domain 2 (AF-2) (5, 42).  AF-2, which contains the final α-
helix of RXRs, folds over the binding pocket when ligands activate the 
receptor.
As is common to nuclear receptors, multiple subtypes1 of RXRs exist in 
vertebrates, designated α, β, and γ (genes B1, B2, and B3, respectively) (42, 
51).  Although the three subtypes are separate genes and have considerable 
variation, especially in the A/B domain, they are very closely related from a 
functional and practical standpoint; no ligand has yet been found that 
discriminates between the three subtypes to any appreciable extent (42). 
The bulk of the publications to date focus on RXRα or make no distinction 
between subtypes; we use the α-subtype exclusively in the work described 
below.  Each subtype also exists as two isoforms that differ somewhat in the 
A/B domain, but no significant work has yet been performed on the 
importance of these isoforms (42).  In addition to all these variations, the 
invertebrate homolog is designated the ultraspiracle receptor (USP, 
subfamily NR2B, gene B4) (52).
The domain codes, in addition to species and subtype, will be used 
throughout this manuscript to specify precisely which RXR is being 
discussed.  For example, hRXRα(CDE) refers to human RXRα lacking the A/B 
1 Use of the words "subtype" and "isoform" conform to the standard nuclear 
receptor nomeclature (4).
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Figure 1.2.  hRXRα domains.  Numbers indicate the amino acid position at 
the beginning or end of each domain.
1 135 200 225 462
DBD Hinge LBD
A/B C D E
domain, while mRXRα(E) refers to the mouse RXRα ligand binding domain. 
In addition, the D (hinge) domain may also be designated as Dα or D  to referᵦ  
to only the first or second half of the domain, respectively, so that 
hRXRα(D E) refers to the second half of the hinge and all the LBD (aminoᵦ  
acids 212-462) of human RXRα.
The retinoid X receptors serve a variety of roles in animals (53). 
Inactivation of RXRα leads to the death of mice during embryonic 
development (54, 55).  Only half of RXRβ knockout mice died before birth, 
but the survivors were sterile (56); another report suggests that only RXRα 
is essential, as it can fill the roles of RXRβ and RXRγ (57).  The three 
subtypes have somewhat different expression patterns in cells, which leads 
to some differences in function simply due to differing concentrations in 
specific cell types (42).  In addition to their roles as a heterodimer partner 
and sometimes regulatory element for numerous other nuclear receptors, 
RXRs (generally RXRα) have been found to be have direct roles in 
differentiation (51, 58-84), metabolism and diabetes (85-97), and the 
immune system and autoimmune diseases (98-122).  RXRγ may have 
specialized roles in formation of memories (123) and metabolic processes 
(124, 125).  Agonists for RXRs are currently a focus of much medical 
research for cancer treatments (126-168), and RXRs have a role in the 
progression of some viral diseases (169-175).
The first agonist identified for RXRs, 9-cis retinoic acid (9cRA) (176, 
177), is still the most potent naturally occurring ligand.  While it has 
generally been assumed to be the biologically relevant agonist for RXRs, a 
significant body of work has carefully examined the question, and concluded 
that this assumption is incorrect (178-181).  Other ligands that may instead 
naturally activate RXRs include docosahexanoic acid and other fatty acids 
(178, 182-187).
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No crystal structure for a full-length nuclear receptor yet exists.  The 
report closest to this goal is a low-resolution structure of hRXRα(CDE) (188). 
hRXRα(E) was the first nuclear receptor ligand binding domain to be 
crystallized (189).  Since this initial report, RXRα(E) (from several species) 
has been crystallized many times, both alone (190-193) and as part of a 
heterodimer (194-200).  In addition, an NMR solution structure of hRXRα(E) 
has been reported (201).  Crystal structures have also been reported for 
RXRβ(E) (202-204) and USP(E) (205-209).  As it was the first LBD structure 
solved, RXRα is frequently used as a general model for descriptions of 
nuclear receptors.  The ligand binding domain of RXRα is predominantly 
made up of α-helices, with only two short β-strands; although the exact 
composition varies within the nuclear receptor superfamily, the general fold 
and dominance of α-helices is common to all known ligand binding domains 
(5).  In addition to these structures, several NMR solution structures have 
been reported for the hRXRα DBD (210-214).
1.3 Engineering RXRα
Nuclear receptors are modular, meaning that the natural DNA binding 
domain can be replaced with a different DBD, leaving an intact and 
functional LBD (5).  Because it is already activated by small molecules and 
can be made to regulate an essential gene, RXRs (and nuclear receptors in 
general) are attractive targets for protein engineering, the numerous 
applications of which have recently been reviewed (215).
Previous work in the Doyle laboratory (216-221) has used a variety of 
techniques to engineer orthogonal ligand-receptor pairs (222).  Orthogonal 
receptors are protein variants that are inactive in the presence of the wild-
type ligand, but respond to a ligand that does not activate the wild-type 
receptor (see Figure 1.3).  Methods used to create receptors with this 
functionality include site-directed mutagenesis (216, 217) and genetic 
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selection of receptors from libraries constructed using structure-guided 
codon randomization (219-221).  The genetic selection technique, chemical 
complementation, was developed in the Doyle laboratory and is depicted in 
Figure 1.4.  Briefly, yeast lacking an essential gene are transformed with a 
plasmid containing the essential gene with a specific promoter (the DNA in 
Figure 1.4).  A second plasmid contains a coactivator protein fused to the 
GAL4 activation domain.  A third plasmid contains the gene for an 
engineered hRXRα(DE) fused to the GAL4 DNA binding domain.  The 
promoter chosen to regulate the essential gene is one that is activated by 
GAL4, a modular (ligand-independent) yeast transcription factor.  The result 
is a system whereby yeast transcription machinery only "sees" yeast 
proteins, but the assembly of the "complete" GAL4 transcription factor 
requires that the two human proteins bind together.  For this to occur, a 
ligand that activates hRXRα must be present in the system.  Hence, when a 
large library of hRXRα variants is transformed at once, genetic selection 
experiments on the library in the presence of the desired target ligand will 
result in survival of only the yeast containing a receptor activated by the 
ligand.
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Figure 1.3.  Orthogonal ligand-receptor pairs.  Wild-type receptors respond 
to the wild-type ligand (red triangle, ▶), but not the synthetic ligand 
(magenta hexagon, ).  The variant receptors, which contain mutations in 
the LBD, respond to the synthetic ligand, but not to the wild-type ligand.
wtLBD wtLBD vLBD vLBD
DBD DBD DBD DBD
X
X
Two (of many) potential applications of these engineered variants are 
shown in Figures 1.5 and 1.6.  In the first example, a gene used in gene 
therapy, perhaps to supply a protein that is otherwise missing and therefore 
causing a disease, is delivered into the patient as part of a larger construct 
containing an engineered hRXRα and a response element for the engineered 
receptor.  Unlike traditional gene therapy, where dosing is controlled 
entirely by the quantity of gene injected and hence is difficult to regulate, 
this system instead constitutively expresses the orthogonal hRXRα variant. 
Unless an oral drug is administered, this engineered variant is inactive (as it 
is selected to not respond to the small molecules naturally present in the 
body), and the therapeutic gene is not transcribed (Figure 1.5, top).  This 
scheme allows for more precise control of the therapeutic protein levels 
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Figure 1.4.  Schematic of chemical complementation.  hRXRα(DE) (blue 
ellipse, ●) is fused to the GAL4 DBD (turquoise circle at bottom, ●) while a 
human coactivator (magenta ellipse, ●) is fused to the GAL4 activation 
domain (turquoise circle at top, ●).  Human proteins interact with each 
other in the presence of an activating ligand (red triangle, ▼), while only 
GAL4 is exposed to other proteins in the cell and the DNA response element 
(green rectangle, ▬).  When the ligand activates the receptor and recruits 
the coactivator-GAL4 AD fusion protein, the essential gene (dark red 
rectangle, ▬) is transcribed.
RXRα
LBD
RXRα
LBD
GAL4
DBD
GAL4
DBD
GAL4 Resp. Elem. Essential Gene
Human
Coactivator
Human
Coactivator
GAL4
AD
GAL4
AD
ultimately present in the patient.  A similar system could be imagined for 
agricultural use, where crops are engineered to express pesticides only 
when a specific trigger activates the nuclear receptor, such as an otherwise 
benign chemical sprayed on the crops, or a compound present only when 
crops are being actively attacked by pests.
A second application is in building sensors.  The first step is to 
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Figure 1.5.  Gene therapy using an engineered receptor.  (A) Only the 
engineered RXRα gene (blue rectangle, ▬) is transcribed in the absence of 
drug, not the therapeutic gene (red rectangle, ▬).  The engineered receptor 
remains in the inactive conformation.  (B) When the drug (magenta hexagon, 
) is delivered and binds to the receptor, the engineered RXRα undergoes a 
conformational change and the therapeutic gene is transcribed.
DBD
Resp. Elem. Therapeutic GeneEngineered RXRα
vLBD vLBD
DBD
Coactivators
and transcription
machinery
DBD
Resp. Elem. Therapeutic GeneEngineered RXRα
vLBD vLBD
DBD
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engineer many receptors, each with a unique profile in response to a variety 
of chemicals, but not necessarily specific for any one.  Next, the variants are 
coupled to some output triggered by the active conformation of the receptor. 
Finally, the variants are individually placed into wells on a plate, to create a 
general sensor that is able to "fingerprint" potentially thousands of 
compounds.  By coupling activation of the receptor to a reaction that 
produces visible light, a system such analagous to shown in Figure 1.6 could 
be constructed, where two compounds that share one property (shape) but 
differ in another (color) yield distinct patterns.
Both site-directed mutagenesis and chemical complementation have 
produced receptors with varying degrees of activity and selectivity toward 9-
cis retinoic acid and synthetic ligands LG335 and γ-oxo-1-pyrenebutyric acid 
(OPBA).  Although some early variants were characterized for ligand affinity 
(216), most of the variants have only been examined from a functional 
standpoint.  The specific causes for the range in selectivities, maximal 
activities, and minimal ligand concentrations necessary for survival have not 
been apparent from functional and computational analyses.  The 
characterization of several variants, as well as a more rigorous 
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Figure 1.6.  Sensor array using engineered RXRα variants.  Each well 
contains a single variant receptor.  One ligand activates a selection of 
receptors (left), while a second activates a partially-overlapping second set 
(right).  The pattern associated with each ligand serves as a "fingerprint."
characterization of wild-type hRXRα than has previously been undertaken, is 
the focus of most of the work that follows.  The remainder of the work 
focuses on other aspects of the engineering problem, including how to target 
the variants to unique sites in the genome and rigorous data analysis 
methods.
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2CHAPTER 2
ESPSEARCH: A PROGRAM FOR FINDING EXACT SEQUENCES AND 
PATTERNS IN DNA, RNA, OR PROTEIN 
2.1 Introduction
The availability of protein and genomic databases makes identifying 
specific sequences from within long sequences and databases a common 
activity, such as for small interfering RNAs (siRNAs), artificial transcription 
factor binding sites, and protein motifs.  However, currently available tools 
tend to be highly specialized and suited for only a small number of 
applications.  In addition, no general tool exists for identifying patterns 
made of up several other sequences when those sequences can be arranged 
in a large number of ways, such as identifying specific or unique DNA 
binding sites for a protein constructed from a pool of zinc finger domains. 
We are interested in this problem as a method of specifically targeting an 
engineered nuclear receptor to an arbitrary, specific gene, but the problem 
is the same regardless of context.
We designed a computer program, ESPSearch (Exact Sequence and 
Pattern Search), to address this lack.  ESPSearch was designed with five 
specific requirements in mind.  First, the program must allow the user to 
specify exactly which target sequences are being searched for, and allow for 
several sequences at once.  Most current tools fail this requirement, 
especially fixed databases of predetermined target sequences, such as the 
TRANSFAC® (223) transcription factor database tools (only transcription 
factors) and tools for identifying restriction enzyme recognition sites, as well 
as BLAST (224) and the PROSITE (225) database tools that can only search 
 Material from this chapter has previously been published as Watt, T. J. 
and Doyle, D. F. (2005) ESPSearch: A Program for Finding Exact Sequences 
and Patterns in DNA, RNA, or Protein, Biotechniques 38, 109-115. 
Reprinted with permission.
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for a single sequence at a time.  Moreover, while BLAST is excellent at 
identifying related sequences of sufficient length, it makes several 
assumptions useful for some applications but poorly suited for identifying 
shorter sequences with particular constraints; one example is the use of a 
"word size" to increase search speed by forcing a certain number of 
consecutive exact matches between the sequence being searched for and 
the sequence being searched in.
Second, the program must be able to identify target sequences of any 
length, and with possibly highly variable composition (i.e., the targets may 
contain wildcards or built-in gaps).  Some PROSITE (225) and European 
Molecular Biology Open Software Suite (226) tools also have this capability, 
but only for a single sequence at a time.
Third, the program must be able to match a pattern of the identified 
target sequences meeting arbitrary (user-specified) criteria, through an 
optional, separate logical step.  Although many existing tools search for 
"patterns," these are equivalent to what we define as a "target sequence," 
which is a single sequence that may contain wildcards, specific gaps, and 
mismatches.  When we refer to "patterns," we mean a more complex 
sequence consisting of groups of individual target sequences.  For example, 
a simple pattern is the binding site of a heterodimeric protein on DNA, 
which can be represented as AB, where each letter represents any target 
sequence from a database; the pattern corresponds to the entire 
heterodimer binding site.  The web application PatSearch (227) is a powerful 
tool based on regular expressions for matching patterns, but it only searches 
for a single pattern at a time and must refer explicitly to subunits (target 
sequences), so complex searches with PatSearch might require millions of 
individual searches.  A tool to search all these combinations in one step does 
not exist elsewhere.
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Fourth, the program should have an intuitive input format that does 
not require knowledge of regular expression formatting.  Most general tools 
currently available are based on the use of regular expressions (such as in 
PROSITE and PatSearch), which are powerful but difficult to learn and 
understand.  In addition, programs that rely on regular expression 
formatting tend to avoid searching for multiple, distinct sequences at once. 
Instead, search utilities tend to focus on how to represent all target 
sequences with a single regular expression, which can be difficult or 
impossible for some searches, meaning that multiple searches must be 
performed serially.
Finally, the program must be free and available for modification. 
Many excellent search tools are commercially available, but are expensive 
and frequently allow little or no user-control over most parameters and 
assumptions.  A general-purpose tool should not only be widely available, 
including running on many different operating systems, but also should have 
all search parameters and the source code available for modification.
We demonstrate some applications of ESPSearch by designing a 
variety of possible artificial transcription factors, estimating the specificity 
of artificial transcription factors and siRNAs, and identifying possible 
protein-protein binding sites.
2.2 Program Description
ESPSearch was written in Python, a scripting language available for 
nearly any operating system, and should run on any computer with Python 
installed.  Our searches were performed on a PC with a 1.8 GHz Pentium® 4 
processor and 1 GB of RAM running Microsoft® Windows® 2000, but 
ESPSearch has also been tested on various other hardware and operating 
systems.  All searches were performed under non-stringent conditions (i.e., 
background applications such as antivirus software and firewall present with 
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a live network connection).  ESPSearch, instructions, and examples 
(including the files used for the examples below) may be downloaded at 
http://web.chemistry.gatech.edu/~doyle/espsearch/ (and in the Appendices). 
Also available is a graphical user interface for setting up runs.
ESPSearch loads a user-specified database of target sequences (the 
sequences to be searched for).  All variations of target sequences due to 
wildcards and mismatches are expanded, and each sequence is assigned a 
unique memory address.  For nucleic acid searches, reverse complements to 
each sequence are also generated to identify matches on the complement 
strand without actually generating or searching the complement. 
ESPSearch loads a specified rule set that allows it to interpret the target 
sequences and source sequence, and how they relate to each other (e.g., 
that A and T are complements, or that X represents any amino acid).  The 
source sequence (the sequence to be searched) is loaded in steps into a 
buffer, by default approximately 1,000 positions long.  The program 
automatically determines and uses a fixed "window" length  to examine the 
sequence in the buffer, stepping through it to examine each possible window. 
The window size is automatically set, and varies with the specifics of each 
database.  The memory address that corresponds to each window is 
generated, and that address is checked to determine if one or more target 
sequences match: if the address does not exist, then no sequences match; if 
it does exist, the matching sequences are output in one of several available 
formats.  Databases containing target sequences with gaps or with a 
variable length use a fixed window to determine if the first part of the 
sequence matches, and then searches forward in the buffer to determine if 
the next positions correspond to the remaining portions of the tentatively 
identified target sequences.  Upon output, the location, sequence, and 
matching target sequence name are stored for pattern processing.
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Upon completing the scan of a buffer for individual target sequences, 
pattern processing is performed on the identified sequences.  Each located 
target sequence is sequentially assigned to the first position in each pattern. 
The following positions are then checked for target sequences that match 
the remaining pattern positions at the specified relative distance (gaps may 
be specified at particular locations in patterns).  When evaluating whether a 
target sequence is acceptable in the pattern, the following variables may be 
specified: the strand the target sequence occurs on relative to the first 
position in the pattern (for nucleic acid searches); whether the position is 
marked as required to be unique (i.e., the target sequence found at that 
position must not be found anywhere else in the pattern); whether the target 
sequence in the position needs to be identical to some other position in the 
pattern; and for positions marked as identical, whether the sequences are 
physically identical (i.e., the same sequence) or simply recognized by the 
same target(s), which is an important distinction when wildcards and 
mismatches are used.  Upon completing the scan of a buffer for all patterns, 
a new buffer is loaded, retaining the necessary information from the 
previous buffer to ensure that patterns that occur across buffer loads are not 
missed.  The patterns used here are represented in a slightly simplified 
form, where uppercase and lowercase letters represent target sequences 
found on different strands (e.g., Aa represents two sequential target 
sequences, but one on each strand of the source sequence) and gaps are 
represented as a subscripted numerical range.
The speed of a search varies linearly with the length of the source 
sequence.  A typical search of the Saccharomyces cerevisiae genome, 12.1 
million base pairs, takes 4-12 seconds.  In addition, the amount of output 
generated by a search also affects the speed; when the output generated (in 
bytes) is less than the source sequence, this factor is relatively unimportant. 
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The complexity of the target sequences also influences search speed, but 
only tremendously complex target sequences (e.g., multiple gaps with very 
large ranges in each target sequence, many wildcards, and numerous 
mismatches tolerated) have a significant effect.  Memory usage is dependent 
on the total number of expanded sequences to be identified, but only 
exceptional searches use more than a few megabytes of RAM.
2.3 Applications
2.3.1 Identification of Heterodimeric Artificial Transcription Factors
ESPSearch was used to design possible dimeric artificial transcription 
factors that utilize human zinc fingers to bind DNA.  The artificial 
transcription factors were designed to target p53 binding sites, because 
p53-regulated genes involved in apoptosis are frequently turned off in 
cancerous cells due to mutations in p53 (228).  Zinc fingers are common, 
modular peptide units that recognize three base pair (triplet) DNA 
sequences and can be fused in a single protein to recognize longer 
sequences and activate genes (229, 230).  Reactivation of a p53-regulated 
gene using a zinc finger-based artificial transcription factor has recently 
been demonstrated (231).
To identify possible artificial transcription factors, we created a 
database containing the DNA triplet(s) reported to be recognized by 56 
human zinc fingers, which include several wildcard positions (232), and used 
a rule set corresponding to standard IUPAC notation for DNA.  A dimeric 
construct was used for four reasons: dimeric proteins tend to be more 
specific (more likely to recognize a sequence that is unique) than monomeric 
proteins (233-235); most artificial transcription factors to date are 
monomeric, but an example of a dimeric protein based on engineered zinc 
fingers was recently reported (236); nuclear receptors, and RXRα in 
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particular, generally function as dimers; and because a dimeric system is a 
more challenging design problem that illustrates the complexity ESPSearch 
can address.
We searched for binding sites in 12 known human p53 recognition 
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Figure 2.1.  Artificial transcription factor design using zinc fingers.  (A) 
Heterodimer design.  (B) Homodimer design.  (C) Repeat patterns used to 
find homodimer binding sites: direct (ABAB), inverted (ABba), and everted 
(abBA).
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sites (in nine p53-regulated genes) (237-241).  The majority of the p53 
recognition sites are fewer than 25 base pairs long.  The total number of 
base pairs to be recognized is 18; therefore each monomer needs to contain 
three zinc fingers (Figure 2.1A).  A variable gap of 0-6 base pairs is allowed 
between the binding sites for each monomer.  The pattern corresponding to 
these constraints is ABC0-6DEF: any three zinc finger binding sites, a gap of 
up to six base pairs, and any three additional zinc finger binding sites.  Each 
group of three triplets could be on either strand, so we also used the pattern 
ABC0-6def.
ESPSearch scans the source sequence for sequences matching the 
desired patterns.  The matches are the number of possible binding sites for, 
and therefore the specificity of, each pattern, based on the selectivity for 
DNA of the zinc fingers that comprise the pattern.  Of the twelve p53 
recognition sites searched, ESPSearch identified sequences matching the 
pattern in six (regulating five genes); the identified sequences and 
corresponding zinc finger proteins are shown in Table 2.1.  Several p53 
recognition sites contain more than one possible heterodimer (e.g., BAX).  In 
addition, several human zinc fingers bind the same triplet, so there are often 
several choices for a zinc finger at a given position within a monomer.  The 
specific zinc fingers shown in Table 2.1 were chosen on the basis of 
specificity, and arbitrarily in the event of multiple zinc fingers with 
comparable specificity.  Binding affinity or selectivity of individual zinc 
fingers could be used to further refine choices, but that information has not 
yet been reported for all of the zinc fingers.
Each of the six sites where a heterodimer was not identified contain at 
least one set of three sequential recognized triplets (i.e., half a heterodimer). 
By extending the source sequence three additional base pairs 5' and 3' 
beyond the p53 recognition site in the search, heterodimers for two 
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additional genes were identified (data not shown).
Despite using human zinc fingers that recognize only 27 of 64 possible 
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Table 2.1.  Heterodimers and recognized sequences in p53 recognition sites 
matching the pattern ABC0-6DEF or ABC0-6def.
Identified Zinc Fingers for Heterodimersα
(Recognized Sequenceβ)
Gene
(reference)
p53 site
(bpγ) First Protein Second Protein
APAF1 (237) 27 VSTR;DSAR;VSTR
(GCWRTCGCW
RDER1;HSNK;RSHR
GGGRACGHG)
APAF1 (237) 33 QSHR3;RDHT;DSAR
(RTCNGGRGA N5
QSNI;QSHT;QSHR2
GGAHGAMAA)
BAX (238) 39 DSCR;QSNI;QSHR3
(RGAMAAGCC
RDHT;RDER2;RDHT
NGGGCGNGG)
RDHT;DSCR;QSNI
(MAAGCCNGG
VSTR;RDHT;RDER2
GCGNGGGCW)
QSHR3;HSSR;QSNI
(MAAGTTRGA N2
RDHT;DSCR;QSNI
MAAGCCNGG)
HSNK;QSHR3;HSSR
(GTTRGARAC N2
RDER2;RDHT;DSCR
GCCNGGGCG)
DSCR;QSNI;QSHR3
(RGAMAAGCC N3
VSTR;RDHT;RDER2
GCGNGGGCW)
QSHR3;HSSR;QSNI
(MAAGTTRGA N5
RDER2;RDHT;DSCR
GCCNGGGCG)
HSNK;QSHR3;HSSR
(GTTRGARAC N5
RDHT;RDER2;RDHT
NGGGCGNGG)
IGF-BP3 (239) 152 68 pairs
(not shown)
p53AIP1 (240) 20 DSCR;QSNI;QSHT
(HGAMAAGCC
QSHR3;QSSR1;RDHT
NGGGCWRGA)
DSCR;QSNI;QSHT
(HGAMAAGCC N
RSNR;QSNI;RSHR
GGGMAAGAG)
PTEN (241) 34 DSCR;QSNI;RSNR
(GAGMAAGCC
VSTR;DSCR;RDHT
CCNGGCWGC)
DSCR;QSNI;RSNR
(GAGMAAGCC N3
QSSR1;VSTR;DSCR
GGCWGCTRC)
α Zinc fingers are named after the four amino acids expected to contact DNA 
(232).
β H = A, C, or T; M = A or C; N = A, C, G, or T; R = A or G; W = A or T
γ bp = base pairs.
DNA triplets, ESPSearch identifies possible heterodimers in half of the p53 
recognition sites searched, including one as short as 20 bases.  A majority of 
the sites where a heterodimer was not identified are only 20 bases long, and 
all are shorter than 27 bases.  The number of recognition sites for the zinc 
fingers, and the possible ways to arrange them into heterodimers, leads to 
millions of possible arrangements.  ESPSearch identifies possible targets for 
each of the genes in Table 2.1 by determining which sequences matched at 
least one of those arrangements, and does so nearly instantaneously.
2.3.2 Identification of Homodimeric Artificial Transcription Factors
We next searched for sequences expected to be bound by 
homodimers, because homodimers are encoded in half the DNA required to 
encode a heterodimer and are of particular interest for applications 
involving RXRα.  For therapeutic applications it is often desirable to deliver 
as little DNA as possible.  Homodimers are a more challenging design 
problem, because the likelihood of finding a target sequence is dramatically 
reduced.  However, as nuclear receptors only naturally contain two zinc 
finger domains (47), the additional complexity can be compensated for.  To 
identify a variety of hits, the search pattern was changed to contain only two 
zinc fingers in each monomer, allow a greater gap between units, and 
identify dimers in three orientations.
ESPSearch simultaneously searched for direct, inverted, and everted 
repeats recognized by human zinc fingers, all of which RXRα is known to 
recognize under some circumstances (7, 47).  Specifically, the patterns 
AB0-15AB and AB0-15ba were used, which correspond to homodimers 
containing two zinc fingers recognizing direct repeats (ABAB) and inverted 
(ABba) or everted repeats (abBA), with a variable gap of 0-15 bases (Figures 
2.1B and 2.1C).  We chose BAX as the gene to be regulated, and used the 
1,000 base pairs before the transcription start site as the source sequence. 
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The p53 recognition site occurs in the middle of this region (238).  We are 
unaware of any property that makes homodimers particularly easy or 
difficult to identify in the BAX promoter; other genes may require more or 
less stringent patterns to identify a reasonable variety of targets.
Table 2.2 shows the identified sequences and corresponding zinc 
finger proteins after discarding hits in a likely non-unique region of AT 
repeats.  No sequence overlaps the p53 recognition site, but several of them 
are within approximately 100 base pairs.  ESPSearch identified numerous 
possible dimeric artificial transcription factors in this relatively short 
promoter region, of a variety of types.  Dimeric activation domains often 
prefer a particular orientation, so the ability to chose different repeat types 
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Table 2.2.  Homodimers and recognized sequences in the BAX promoter 
matching the patterns AB0-15AB or AB0-15ba.
Identified Zinc 
Fingers for 
Monomersα Recognized Sequencesβ Repeat Type Positionγ
DSCR;RDER2 GCGGCC N10 GCGGCC Direct -68
RDHR1;RDER2 GCGGGG N13 GCGGGG Direct -76
RDER2;QSSR1 CGCTRC N30 GYAGCG Everted -80
DSAR;DSCR GCCRTC N50 GCCRTC Direct -197
RDHT;QAHR GGANGG N50 GGANGG Direct -198
RDHT;QAHR GGANGG N90 GGANGG Direct -202
QSNI;DSAR RTCMAA N90 RTCMAA Direct -204
HSNK;QSNT AAARAC N11 GTYTTT Inverted -376
HSNK;QSHT HGARAC N30 GTYTCD Inverted -565
RDER1;QSSR1 GYAGHG N14 CDCTRC Inverted -612
VSTR;KSNR GAGGCW N70 GAGGCW Direct -652
ISNR;VSTR GCWGAW N20 WTCWGC Inverted -909
α Zinc fingers are named after the four amino acids expected to contact DNA 
(232).
β D= A, G, or T; H = A, C, or T; M = A or C; N = A, C, G, or T; R= A or G; 
W = A or T, Y = C or T.
γ Relative to transcription start.
allows for many different activation domains to be used in the artificial 
transcription factor.  The ability of ESPSearch to identify numerous possible 
target sequences for these zinc finger constructs suggests that natural 
human zinc fingers may be sufficient for activating any gene, without the 
need for engineering specificity, provided a tool is available to analyze the 
DNA sequence and identify possible target sequences.
2.3.3 Estimating the Specificity of Artificial Transcription Factors
To reduce possible side effects in therapeutic applications, the 
artificial transcription factor should be highly specific for the desired target 
site.  A count of the occurrences of other likely binding sites in the genome 
is a reasonable estimate of the specificity.  To identify the most promising 
potential artificial transcription factor for each gene in Tables 2.1 and 2.2, 
we used ESPSearch to search the entire human genome for each identified 
sequence.  A target sequence database of the binding sites for the dimers 
was constructed, and individual GenBank® chromosome sequences of draft 
34 of the human genome were searched; ESPSearch can automatically 
search multiple files for the same set of target sequences.  No pattern 
processing was performed during this step.  The resulting number of sites 
likely to be bound by each dimeric artificial transcription factor are shown in 
Table 2.3.  Using this information, we can distinguish between the multiple 
choices for each gene and choose the artificial transcription factor that is 
likely to be most specific.
A typical search speed with ESPSearch was approximately one million 
bases per second, with peak speeds of nearly three million bases per second 
(data not shown).  Artificial transcription factor binding sites were identified 
in the whole genome in approximately twenty minutes.
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2.3.4 Estimating the Specificity of siRNAs
A similar approach can be applied to determine the likely specificity of 
siRNAs.  Recent work suggests that the common practice of using BLAST to 
determine the uniqueness of siRNA binding sites fails to identify many 
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Table 2.3.  Number of occurrences of dimer recognition sequences in the 
human genome.
Sequenceα Occurrences
GCWRTCGCW GGGRACGHG 1
RTCNGGRGA N50 GGAHGAMAA 16
RGAMAAGCC NGGGCGNGG 9
MAAGCCNGG GCGNGGGCW 4
MAAGTTRGA N20 MAAGCCNGG 8
GTTRGARAC N20 GCCNGGGCG 40
RGAMAAGCC N30 GCGNGGGCW 1
MAAGTTRGA N50 GCCNGGGCG 3
GTTRGARAC N50 NGGGCGNGG 5
HGAMAAGCC NGGGCWRGA 43
HGAMAAGCC N00 GGGMAAGAG 6
GAGMAAGCC CCNGGCWGC 5
GAGMAAGCC N30 GGCWGCTRC 2
GCGGCC N10 GCGGCC 270
GCGGGG N13 GCGGGG 1,219
CGCTRC N30 GYAGCG 46
GCCRTC N50 GCCRTC 441
GGANGG N50 GGANGG 41,438
GGANGG N90 GGANGG 47,304
RTCMAA N90 RTCMAA 12,503
AAARAC N11 GTYTTT 5,958
HGARAC N30 GTYTCD 91,618
GYAGHG N14 CDCTRC 375,440
GAGGCW N70 GAGGCW 2,781
GCWGAW N20 WTCWGC 4,646
α D = A, G, or T; H = A, C, or T; M = A or C; N = A, C, G, or T; R = A or G; 
W = A or T; Y = C or T.
possible target sites (242).  BLAST identifies sequences in the source 
sequence homologous to the target sequence using a scoring function.  The 
result is not necessarily the same as a search for a sequence with specific 
variation.  For example, BLAST produces different scores for sequences 
depending on the location of mismatches: mismatches on the ends penalize a 
sequence slightly, mismatches as a group in the middle of a sequence 
penalize the sequence moderately, and mismatches scattered throughout the 
sequence penalize the sequence heavily.  Depending on the exact 
parameters used for the BLAST search, some sequences may not be 
identified that have the same number of mismatches as sequences that are 
identified.  ESPSearch evaluates a sequence strictly on how many 
mismatches occur, not where they occur, and so will find all sequences 
containing a particular number of mismatches.
We arbitrarily chose six 21-mers from the BAX mRNA as test 
sequences for siRNA specificity, and used three mismatches as the threshold 
for possible binding.  We used both NCBI's BLAST (version 2.2.9) and 
ESPSearch to search for each sequence in the whole human genome and in 
the set of known and predicted human mRNAs.  The number of matches 
identified by each program are shown in Table 2.4.  In should be noted that 
in every mRNA and genome search, BLAST found hundreds to thousands of 
sequences, but the majority were sequences with greater than three 
mismatches.  ESPSearch identified only sequences with three or fewer 
mismatches, and found many missed by BLAST.
ESPSearch took approximately fifty minutes to identify hits on the 
whole genome and less than ninety seconds on the mRNAs.  Individual 
BLAST searches were typically ten-fold or more faster than ESPSearch 
searches, but the time required to compile the BLAST database (in the case 
of mRNA, run using stand-alone BLAST) or wait for the web server response 
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(in the case of whole genome search) meant that the total time investment 
was comparable for the two programs.  Because finding genes that might be 
affected by siRNAs is critical for evaluating their effectiveness, especially for 
medical applications (242), ESPSearch is a superior tool for this application.
2.3.5 Identifying Possible Protein-Protein Binding Sites
We also applied ESPSearch to determine the frequency of protein 
motifs in the human proteome.  The nuclear receptor family of transcription 
factors is known to interact with coactivators via an LxxLL motif present in 
coactivators (22).  Chang and coworkers (243) used phage display libraries 
to determine the importance of residues flanking the core LxxLL region. 
Three different classes of LxxLL peptides were found, each with different 
activity; the three classes vary in the three amino acids N-terminal to the 
LxxLL core.  We searched the non-redundant set of human proteins for the 
LxxLL motif and the three identified classes.  Table 2.5 shows the resulting 
number of hits identified for each motif and the number of proteins 
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Table 2.4.  Number of siRNA sequences found with BLAST and ESPSearch. 
Searches results are divided into exact matches and matches containing up 
to 3 mismatches.
Human Genome Human mRNA
BLASTα ESPSearch BLASTα ESPSearch
Sequence 0 1-3 0 1-3 0 1-3 0 1-3
GCGGCGGTGATGGACGGGTCC 1 0 1 3 6 0 6 1
ATGGGGGGGGAGGCACCCGAG 1 1 1 34 0 0 5 0
AGGATGATTGCCGCCGTGGAC 1 2 1 7 4 1 4 2
AGCAAACTGGTGCTCAAGGCC 0β 11 0β 63 4 1 4 4
TGGGTGAGACTCCTCAAGCCT 1 5 1 49 1 0 1 1
TGGTGCCCTCTCCCCATCTTC 1 16 1 177 1 0 1 5
α Using NCBI's default "short or nearly exact sequence" parameters: word 
size = 7, expect = 1000.
β No hits are found because the final two bases of this sequence are on a 
separate exon from the other bases in the sequence.
containing at least one of each motif.  A casual survey of the list of proteins 
identified for each of the three peptide motifs identified by phage display 
turns up several coactivators, suggesting that these motifs may play a role in 
natural proteins as well.  This type of search was not performed in the 
original study, but took less than thirty seconds with ESPSearch.  ESPSearch 
can not only rapidly identify protein motifs, but can also be used to 
determine if a hypothetical, designed, or library-selected motif is present in 
known proteins of a particular type.
2.4 Discussion
ESPSearch is able to identify essentially any target sequence within 
any source sequence to find the exact desired sequence(s).  Specific 
strengths include searching any number of sequences simultaneously, 
identifying target sequences of any length and considerable complexity, the 
ability to match patterns composed of hits from individual target sequences, 
and the ability to easily modify the databases, wildcards, and rules to allow 
user-defined groups and non-standard nucleic acids or amino acids.  In 
addition, ESPSearch functions without a network connection, requires no 
knowledge of regular expression design, and can have functionality added or 
modified if necessary.
ESPSearch may not be the best choice for specific applications where 
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Table 2.5. Number of occurrences of LxxLL motifs and proteins containing 
the motifs.
Sequenceα Occurrences Number of Proteins
LXXLL 54,255 28,554
SRLXXLL 212 212
HPLLXXLL 27 27
UJLXXLL 1,824 1,742
α J = I, L, or V; U = S or T; X = any amino acid.
specialized tools exist for the search.  BLAST is a much superior tool for 
general alignments, especially when it is not practical to designate all 
variability (e.g., that a gap can appear anywhere).  ESPSearch is a 
generalized tool useful for user control and many applications, but it 
therefore lacks some of the specialized features available using TRANSFAC® 
or other tools focused on a more specific application.  ESPSearch may be 
slower than specialized tools for some searches and it does not analyze the 
output, although it is straightforward to feed the resulting output to a 
spreadsheet or another program for analysis.
We have demonstrated the identification of target sites for and design 
of artificial transcription factors containing human zinc fingers, estimated 
the genome-wide specificity of the possible artificial transcription factors 
and a variety of siRNAs, and identified possible sites for protein-protein 
interactions.  The limiting temporal factor for these applications has been 
reduced to obtaining source sequences to search, not ESPSearch searching 
the sequences or identifying patterns.  ESPSearch should be useful for 
identifying DNA target sequences when engineering transcription factors, 
enzymes, and even small molecules, as well as when designing small 
interfering RNAs.  In addition, ESPSearch could be used to identify almost 
any nucleic acid or protein motif by using the corresponding target 
sequences and patterns, without the need to design or use a specialized tool. 
It can be used as an alternative to alignment tools such as BLAST when 
exact control over the sequence is required, and is fast enough to do whole 
genome scans for many sequences and patterns of those sequences for 
various analyses: ESPSearch can currently search the human genome in as 
little as a few minutes, and the yeast genome in seconds.  The program was 
recently adapted by researchers at the University of Georgia for use via the 
web with RoseoBase (http://www.roseobase.com) to search for short 
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sequences in the Roseobacter database.  ESPSearch could also be applied to 
analyzing the frequency of particular sequences in the human genome, 
determining where specific transcription factor binding sites occur in 
relation to each other, and identifying cofactor binding sites in proteomes.
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3CHAPTER 3
EXPRESSION AND PURIFICATION OF hRXRα
3.1 Introduction
Retinoid X receptor α, and portions thereof, have previously been 
expressed and purified in a variety of systems: mammalian (176, 216, 244-
251), baculovirus (insect) (20, 177, 178, 247, 250, 252, 253), yeast (253), 
and bacterial (21, 176, 187, 188, 190-193, 199, 201, 210-214, 247-250, 254-
276) cells, as well as using in vitro expression (277).  Full-length RXRα has 
not been expressed to high levels in any of these systems, as is common to 
many nuclear receptors (278).  All work with biophysical characterization of 
RXRα(ABCDE) (see Section 1.2 for nomenclature) has been done using 
unpurified protein in cellular extract, generally from mammalian cells (20, 
176-178, 216, 244-247, 249, 250, 252, 261) or in vitro expression (277).  The 
majority of work has been done on specific domains: RXRα(C) (212-214, 
255);  RXRα(CD) (210, 211); RXRα(CDE) (21, 188, 247, 248, 250, 257-259, 
261-264, 270, 271); RXRα(DE) (187, 249, 256, 272, 273); and RXRα(E) (190-
192, 199, 201, 249-251, 254, 260, 265, 266, 268-270, 274-276).  There are 
also a few reports of isolation of domains from USP (193, 205-209, 267, 279, 
280), RXRβ (185, 202, 203, 251, 281-283), and RXRγ (186).
The approaches for RXRα expression and purification taken to date 
suffer from three problems.  First, the majority of protocols call for two or 
more chromatographic steps (21, 188, 190-193, 199, 201, 247, 250, 257-259, 
261, 262, 264-269, 271, 272), which are very time-intensive.  The first step is 
generally metal-based affinity chromatography (284) using a His6 tag, 
although a few investigators have used glutathione-s-transferase (GST) tags 
(249, 254, 270, 276).  Second, the yields are relatively low.  When reported, 
they have been in the range of 5-15 mg L-1 of culture (247, 248, 256, 260); 
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because those protocols reporting yields are often the basis for the others, it 
is unlikely any have significantly improved upon these yields.  The exception 
is expression done in extremely rich terrific broth media, where up to 45 mg 
L-1 has been reported (270).  Third, the expressions in bacteria have 
frequently led to inconsistent and contradictory results.  For example, some 
authors report explicitly that they observe batch-to-batch variation in 
protein behavior (247, 249).  In addition, although it is generally not 
commented on in the context of expression variability, there are a wide 
range of oligomeric states and behaviors reported for RXRα.  Specifically, 
some groups isolate what they identify as a pure dimeric species (192, 201, 
248, 256, 265, 266, 268, 269, 275), while others observe dynamic 
equilibrium between monomer and dimer (244), dimer and tetramer (188, 
261, 262, 271, 272), monomer and tetramer (20, 250), and all three states 
(21, 257, 258).  As a careful review of the literature shows, even individual 
research groups are not consistent with the observations they report, 
suggesting batch-to-batch variations.  A large number of reports simply 
ignore this issue altogether, although it is not clear that this approach is 
justified.
We desired an expression and purification scheme that would address 
the problems described above.  The most important goal was to ensure that 
batch-to-batch consistency was extremely high.  As we also wished to apply 
this system to a large number of RXRα variants, a single chromatographic 
step generating at least 95% purity was desirable.  Finally, to minimize the 
time and effort required during expression, we sought a significant increase 
in the yield of purified protein.  To meet these requirements, both the 
expression and purification procedures for hRXRα(D E) were extensivelyᵦ  
optimized, and additional work was performed using other hRXRα domains.
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3.2 Materials and Methods
3.2.1 Materials
The oligonucleotides used for cloning were as follows: F1, 5'-CTA GCT 
AGC AAC ACC AAA CAT TTC CTG CCG-3'; F2, 5'-CAT GCC ATG GGC AAG 
GAC CGG AAC GAG-3'; F3, 5'-CTA GCT AGC TGC GCC ATC TGC GGG-3'; F4, 
5'-CTA GCT AGC AAG CTA CTG TCT TCT ATC GAA CAA GC-3'; R1, 5'-CCG 
CTC GAG AGT CAT TTG GTG CGG CGC-3'; R2, 5'-CCG CTC GAG ATC ACT 
ACG CTG CCG CTC CTC CT-3'; R3, 5'-CCC AAG CTT AGT CAT TTG GTG CGG 
CGC-3'.
The plasmids containing the pregnane X receptor gene 
(pRSETAPXRW299M) and coactivator fragment (pACYC184_SRC1(623-710)) 
were generous gifts from Dr. Matt Redinbo.
SYPRO® Red was purchased from Molecular Probes (Eugene, OR). 
Pfu, QuikChange® Mutagenesis kits, BL21-CodonPlus®-RIL cells, and BL21-
CodonPlus®-RP cells were obtained from Stratagene (La Jolla, CA).  All other 
enzymes were obtained from New England Biolabs (Ipswich, MA).  Gel DNA 
Recovery Kits and Z-competent™ Transformation Kits were obtained from 
Zymo Research (Orange, CA).  pET28a was purchased from Novagen (San 
Diego, CA).  Miniprep kits were obtained from Qiagen (Valencia, CA). 
BL21(DE3)pLysS cells were purchased from Invitrogen (Carlsbad, CA).  The 
PRO™ Tet 6xHN Bacterial Expression System and Talon® Co2+ resin were 
purchased from Clontech (Mountain View, CA).  Gel electrophoresis was 
performed using the Bio-Rad (Hercules, CA) Mini-Protean® III system. 
Trypsin and ProteoPrep™ reduction and alkylation kits for mass 
spectrometry were obtained from Sigma-Aldrich (St. Louis, MO).
3.2.2 Cloning of hRXRα Domains
hRXRα(D E) (amino acids 212-462) was amplified from a vectorᵦ  
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containing hRXRα using oligonucleotides F2 and R1 and Pfu to create the 
gene insert.  The insert was digested with NcoI and XhoI and gel cleaned. 
pET28a was similarly digested, treated with calf intestinal alkaline 
phosphatase, ligated to the insert using Quick Ligase, transformed into Z-
competent™ XL1-Blue E. coli, plated on Luria-Bertani (LB) media containing 
30 µg mL-1 kanamycin, and grown overnight at 37 °C.  The resulting pET28-
hRXRα(D E) plasmid was isolated via miniprep and confirmed byᵦ  
sequencing.
Alternative constructs were cloned similarly.  hRXRα(ABCDE) was 
amplified from the hRXRα vector with oligonucleotides F1 and R1 and 
digested with restriction enzymes NheI and XhoI, and ligated into similarly 
digested pET28a.  hRXRα(ABCDα) was cloned identically, except R2 was 
substituted for R1, and then QuikChange® mutagenesis was used to 
correctly insert two stop codons following residue 212, using primers 5'-GGT 
GGT GGT GGT GCT CGA GCT ATC ACG CTG CCG CTC CTC C-3' and 5'-GGA 
GGA GCG GCA GCG TGA TAG CTC GAG CAC CAC CAC CAC C-3'. 
hRXRα(CDE) was first created using Quick-Change mutagenesis to delete 
the A/B domain of hRXRα using primers 5'-CCC AAG CTT CTA GGT ACC ATG 
TGC GCC ATC TGC GG-3' and 5'-CCG CAG ATG GCG CAC ATG GTA CCT 
AGA AGC TTG GG-3'.  hRXRα(CDE) was then amplified with primers F3 and 
R1, digested with NheI and XhoI and ligated into similarly digested pET28a. 
GBDhRXRα(DE) was amplified from a plasmid containing GBDhRXRα(CDE) 
with primers F4 and R3, digested with NheI and HindIII, and cloned into 
pET28a.  QuikChange® Mutagenesis was then used to remove the RXRα 
DBD from GBDhRXRα(CDE) to create the final GBDhRXRα(DE) using 
primers 5'-GTT GAC TGT ATC GCC GGA ATT CAT GAA GCG GGA AGC CGT 
G-3' and 5'-CAC GGC TTC CCG CTT CAT GAA TTC CGG CGA TAC AGT CAA 
C-3'.
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3.2.3 Expression and Purification of hRXRα(D E)ᵦ
Detailed here is the final, optimized protocol for hRXRα(D E); forᵦ  
details of alternative approaches and other constructs, see Section 3.3.2.
For expression, pET28-hRXRα(D E) was transformed into Z-ᵦ
competent™ BL21(DE3) and plated on fresh LB media containing 30 µg mL-1 
kanamycin and grown overnight at 37 °C.  5 mL of LB containing 30 µg mL-1 
kanamycin was inoculated with a single colony and grown in 5 mL of 
overnight at 37 °C with shaking.  250 mL of LB containing 30 µg mL-1 
kanamycin was inoculated with 2.5 mL of the overnight culture and grown at 
room temperature (20-25 °C) with vigorous shaking in a 1 L Erlenmeyer 
flask until the OD600 was 0.4-0.6 (approximately three hours).  Isopropyl-β-D-
thiogalactopyranoside (IPTG) was then added to a final concentration of 0.5 
mM, and the culture grown under the same conditions for a further 20-24 
hours.  Cells were harvested by centrifuging for 20 minutes at 3,000 xg at 4 
°C.  The media was removed and the cell pellet was immediately used for 
purification.
The cell pellet was resuspended in 5 mL of 4 °C Lysis Buffer (300 mM 
NaCl, 50 mM NaPi, 10 mM imidazole, pH 7.0) in a 15 mL polypropylene 
tube.  Lysozyme was added to a final concentration of 250 µg mL-1.  The 
mixture was kept on ice for 30 minutes, then sonicated using a Fisher 
Scientific Model 60 Sonic Dismembrator (Pittsburgh, PA).  Sonication was 
performed on ice for 3x10 seconds with 30 second pauses between pulses, at 
an average power of 12 watts.  The lysed cells were then centrifuged for 20 
minutes at 27,000 xg at 4 °C.  The insoluble protein content was estimated 
by resuspending the cell pellet in Lysis Buffer containing 1% SDS, mixing 
vigorously for 60 seconds, allowing the tube to sit at room temperature for 
20 minutes, then mixing again and centrifuging at 27,000 xg for 20 minutes. 
The supernatant then contained all the remaining hRXRα(D E) present inᵦ  
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the pellet, and more aggressive lysis procedures did not increase the 
hRXRα(D E) content despite an increase in the amount of total protein.ᵦ
hRXRα(D E) was purified by Coᵦ 2+ (Talon®) affinity chromatography, 
with all steps performed at 4 °C; the following details are calibrated for 0.5 
mL (bed volume) resin, but all volumes can be doubled for 1.0 mL resin.  0.5 
mL of Co2+ resin was transfered to a 15 mL polypropylene tube and prepared 
by washing with 2x5 mL of Lysis Buffer, centrifuging for 2 minutes at 700 xg 
after each wash and removing the buffer.  The cell lysis supernatant was 
decanted onto the resin and gently mixed on an orbital rotator for 45 
minutes.  The resin was pelleted by centrifugation at 700 xg for 5 minutes 
and the supernatant removed.  The pellet was then washed twice with 5 mL 
of Wash Buffer (300 mM NaCl, 50 mM NaPi, pH 7.0) for 20 minutes on an 
orbital rotator, centrifuging at 700 xg for 5 minutes after each wash and 
removing the supernatant.  The cell pellet was transfered to a column 
housing by adding 1 mL of Wash Buffer, gently mixing, and pipetting the 
slurry to the housing.  The resin was allowed to settle for 5 minutes, packed 
by draining most of the Wash Buffer, and washed with a further 5 mL of 
Wash Buffer.  The protein was then eluted using 3.5 mL of Elution Buffer 
(300 mL NaCl, 50 mM NaPi, 150 mM imidazole, pH 7.0) in a single fraction. 
The elution fraction was then dialyzed into at least 250 mL of Storage Buffer 
(500 mM NaCl, 10 mM NaPi, 35% glycerol, 1 mM tris(2-carboxyethyl) 
phosphine, pH 7.0) using 10,000 molecular mass cutoff dialysis tubing, 
changing the buffer once after at least four hours and then dialyzing 
overnight.  The recovered protein, generally concentrated approximately 
three-fold due to the high glycerol content in the dialysis buffer, was stored 
at -20 °C.
The Talon® resin was rinsed with 5 mL of 50 mM 2-(N-
morpholino)ethanesulfonic acid (pH 5.0) and 5 mL of dH2O, then mixed with 
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0.5 mL of 0.1% sodium azide in 20% ethanol and stored at 4 °C.  Aliquots of 
resin were used at most twice for a single protein before stripping the metal 
and recharging for additional use, following the instructions in the Talon® 
manual.
SDS-PAGE of the purified protein was done using 0.05% SDS in tris-
glycine buffer through a 12% (29:1 acrylamide:bisacrylamide) 
polyacrylamide gel with a 4% polyacrylamide stacking gel.  SYPRO® Red was 
used to stain gels.
3.3 Results
3.3.1 Initial Characterization of hRXRα(D E)ᵦ
The final concentration of the protein in the storage buffer was 
determined by absorption at 280 nm (285) using a molar absorptivity of 
16960 cm-1 M-1.  Following the procedure detailed in Section 3.2.3, the final 
hRXRα(D E) concentrations from several purifications were 240-300 µMᵦ  
(7.0-8.7 mg mL-1 in 1.3 mL), indicating a yield of 36-45 mg L-1 of culture. 
Purity of the protein was determined by SDS-PAGE, using multiple 
concentrations of protein, including a massively overloaded lane.  A typical 
gel is shown in Figure 3.1.  Identity of the protein as hRXRα(D E) wasᵦ  
confirmed by digestion with trypsin and mass spectrometry.  The resulting 
peaks were matched to those expected from a theoretical digest for 
hRXRα(D E).  In addition, a database search was performed against the mostᵦ  
intense signals, and the only statistically significant match was hRXRα.
As detailed in Section 4.3, several different batches of hRXRα(D E)ᵦ  
and variants had identical binding, thermal, and oligomeric behavior.
3.3.2 Factors Influencing Yield and Purity
Many factors are important in maximizing the purity and yield of 
hRXRα(D E) throughout the procedure, while others have little or noᵦ  
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influence on the outcome.  Here we outline the alternative approaches we 
explored before settling on the final procedure in Section 3.2.3.
Expression using strains of E. coli other than BL21(DE3) or in 
alternative expression systems significantly reduced expression levels.  The 
BL21(DE3)pLysS strain is designed to reduce pre-induction expression and 
aid in lysis, but the pLysS strain had a significantly decreased yield 
compared to BL21(DE3).  No pre-induction expression of hRXRα(D E) wasᵦ  
detectable in any strain at temperatures below 25 °C.  Results using the 
BL21-CodonPlus® strains, which are designed to increase expression when 
genes (such as RXRα) contain codons that are infrequently used by the 
expression organism, were similar to those for BL21(DE3)pLysS.  The PRO™ 
Tet 6xHN expression system failed to yield detectable protein levels.
Media and temperature also had dramatic impact on the expression 
levels.  Expression in M9ZB minimal media, which aided in expression of 
full-length vitamin D receptor (286), led to very large reductions in yield. 
Richer media than LB, such as terrific broth, did not increase yield of soluble 
protein, although total protein content did increase.  Regardless of media 
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Figure 3.1.  Purity of hRXRα(D E).ᵦ   Lane 1 is molecular weight markers. 
Lane 2 is 50 ng of protein, to estimate intensities of weak bands.  Lane 3 is 
25 µg of protein, to show contaminants as low as 0.1% the total 
concentration.  Lane 4 is 2.5 µg of protein, showing contaminants at the 1 % 
level.
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type, room temperature was found to be optimal for expression levels, as 
temperatures below 20 °C reduced bacteria growth significantly, while 
significant background of insoluble protein was observed at temperatures 
above 25 °C prior to induction, which seems to have triggered expression of 
predominantly insoluble protein following induction.
We tried two approaches to improve the protein folding.  Adding 6% 
ethanol upon induction is expected to trigger stress and production of 
chaperone proteins (287).  Although the insoluble hRXRα(D E) was reducedᵦ  
to undetectable levels when ethanol was added, the overall yield was also 
reduced by approximately 70%.  Other nuclear receptors, such as the 
pregnane X receptor, benefit from the presence of a coactivator protein 
fragment containing an LxxLL motif (288).  However, while we were able to 
reproduce the effect of the motif on the pregnane X receptor (i.e., the 
protein only expressed in the presence of the LxxLL motif), the coactivator 
fragment had the opposite effect for hRXRα(D E): it completely eliminatedᵦ  
expression.
Several variables were of only minor importance.  The IPTG 
concentration used for induction needed to be approximately 0.5 mM for 
maximum expression, but higher IPTG concentrations had no additional 
effect.  The age of the colony used for the expression was not important, 
provided the plate used was not so old that the cells were mostly dead (i.e., 
greater than one month).  The OD600 at induction was not a major factor, and 
the same final yield was observed with an induction at an OD600 anywhere in 
0.15 to 1.0 range.
Several factors were tested during cell lysis.  The lysozyme 
concentration was the least important, as it helped lysis only slightly at 250 
µg mL-1, and higher concentrations were no more effective.  Sonication 
provided most of the lysis power, but we used less sonication than generally 
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called for, as in the Talon® manual and in the RXRα purification protocols 
with explicit details (188, 249).  The 3x10 second protocol consistently gave 
> 75% lysis, and usually essentially complete lysis, while not damaging the 
protein.  Sonication was optimal when performed in relatively small volumes 
(< 7 mL) and in as vertical a liquid column as possible (i.e., a narrow 15 mL 
tube was superior to a wider 50 mL tube).  Performing the lysis at 4 °C 
throughout the process rather than room temperature seemed to prevent 
conversion of soluble protein to insoluble.  Finally, freezing the cell pellet at 
-80 °C for at least 12 hours was very effective in aiding lysis, but the half-life 
of soluble protein at -80 °C was less than 24 hours due to conversion to 
insoluble aggregates.  We therefore avoided freezing due to the large yield 
penalty and the possibility of more subtle effects on structure.
Purification was tolerant to variations, with most variables being of 
only minor or insignificant importance.  The specific buffer (tris or 
phosphate), pH (7-8), salt concentration (100-500 mM), glycerol 
concentration (0-10%), and presence of reducing agents or protease 
inhibitors all had negligible effects on the final yield.  Performing the 
purifications at room temperature instead of 4 °C led to a small drop in both 
yield and purity.  Use of polystyrene instead of polypropylene tubes also 
caused a small drop in yield, possibly due to adsorption of hRXRα(D E) toᵦ  
the polystyrene.
A few variables were fine-tuned to balance yield and purity.  A resin 
bed of approximately 0.5 mL per 250 mL culture gave maximum purity while 
retaining the large majority of the protein.  Although pooling two 250 mL 
cultures together and doubling the resin gave comparable results, but 
pooling more than two cultures into a single purification decreased purity 
significantly, possibly due to less efficient mixing.  In addition, the use of 10 
mM imidazole in the Lysis Buffer and a longer equilibration time on the 
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resin dramatically improved purity while not decreasing yield, most likely by 
providing appropriate conditions for hRXRα(D E) to occupy the maximumᵦ  
number of binding sites.  The use of imidazole at later steps prior to elution 
was not helpful in increasing purity further and led to significant loss of 
protein during washes.
Figure 3.2 shows a typical gel monitoring the purification procedure, 
illustrating that the overwhelming majority of protein is in the soluble 
fraction and that most becomes bound to the resin.  Based on the weak band 
in Lane 2, and that all the hRXRα(D E) in the insoluble fraction wasᵦ  
recovered with a relatively mild procedure (see Section 3.2.3), we suspect 
most of the "insoluble" protein was small amounts left behind after 
decanting the lysis supernatant and in a small number of unlysed cells. 
Figure 3.2 also shows that some protein remains bound following elution 
(Lane 8), but this fraction may be of a different conformation than the eluted 
fraction, as it only elutes in the presence of low pH and not imidazole.  The 
very weak additional bands present in the elution fraction could not be 
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Figure 3.2.  Monitoring the purification of hRXRα(D E).ᵦ   Lane 1, molecular 
weight markers.  Lane 2, soluble fraction.  Lane 3, insoluble fraction.  Lane 
4, soluble fraction after equilibration with resin.  Lanes 5 and 6, sequential 
washes.  Lane 7, pre-elution flow-through after loading resin into the column 
housing.  Lane 8, resin flush with low pH after elution.  Lane 9, elution 
fraction.  Note that lanes 2-4 are diluted five-fold with respect to the other 
lanes.
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eliminated by any modification to the protocol.  Additional gel filtration or 
ion exchange chromatography following the affinity chromatography did not 
eliminate these bands or significantly improve purity.
3.3.3 Expression of Alternative Constructs
In addition to the hRXRα(D E) construct, nine hRXRα(D E) variantsᵦ ᵦ  
containing up to five mutations were purified using the same procedure. 
Expression of four different combinations of domains was also explored: 
hRXRα(ABCDE), hRXRα(ABCDα), GBDhRXRα(D E), and hRXRα(CDE).  In allᵦ  
cases expression was initially attempted using the protocol developed for 
hRXRα(D E), then modified as described below for each construct.ᵦ
The hRXRα(D E) variants generally behaved similarly to the wild-typeᵦ  
protein.  With one exception, yields were at least as good as for wild-type 
(35-80 mg L-1), and purities were over 95%.  The sole exception gave yields 
of 10-15 mg L-1 and purities of approximately 90%, and has significantly 
different self-association properties from the other receptors (see Chapter 
5).
hRXRα(ABCDE) had very low levels of expression under all conditions, 
and induction generally led to a rapid halt in bacterial growth.  Although 
very low levels of protein were detectable in 1-2 hours, additional time did 
not increase the quantity of protein.  Use of minimal media, addition of 6% 
ethanol, addition of the coactivator fragment, or the presence of zinc 
chloride generally reduced expression to undetectable levels, and in all 
cases cellular growth was halted.  At 37 °C, the cells did not seem affected 
by induction (i.e., they continued to grow rapidly), but expression of 
hRXRα(ABCDE) was undetectable.  hRXRα(ABCDα) showed essentially the 
same behavior as hRXRα(ABCDE) under all conditions, except that it tended 
to express at slightly higher levels.
hRXRα(CDE) expressed well using the hRXRα(D E) protocol, andᵦ  
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could be purified easily using tris instead of sodium phosphate (to avoid zinc 
phosphate precipitation).  Yields were as high as 80 mg L-1.  However, 
addition of equimolar zinc following purification led to rapid precipitation of 
the protein, which was reversed upon addition of ethylenediamine 
tetraacetic acid.  This behavior was observed regardless of whether or not 
hRXRα(CDE) was expressed in the presence of zinc chloride.  Purification 
using Talon® resin with Zn2+ substituted for Co2+ also induced precipitation.
GBDhRXRα(DE), which contains the yeast Gal4 DNA binding domain 
(GBD) fused to the hinge and ligand binding domain of hRXRα, is used by 
the Doyle laboratory in genetic selection for hRXRα variants (218-221).  It 
was successfully expressed to levels similar to hRXRα(CDE), and could easily 
be purified without precipitation.  However, BL21(DE3) apparently contains 
a protease that cleaves in the middle of the GBD, as the purified product was 
a mixture of the expected product (minor) and a truncated product (major) 
approximately midway in size between GBDhRXRα(DE) and hRXRα(D E).ᵦ  
Use of protease inhibitors during purification did not influence the final 
yield, suggesting that the protease is present during expression.  Expression 
at 37 °C produced exclusively truncated protein.  Expression at 15 °C did 
not change the fraction of truncated protein relative to our standard 
expression protocol at 22 °C.
3.4 Discussion
Compared to previous purification protocols for RXRα containing the 
LBD  (21, 187, 188, 190-193, 199, 201, 247-250, 254, 256-258, 260-276), our 
approach has several advantages.  First, the C-terminal His6 tag ensures that 
no incompletely translated products are co-purified with the intended 
protein target.  Although the C-terminal His6 tag might be expected to 
influence the structure of function of the protein, it is not clear that an N-
terminal tag attached to the hinge is any "safer," due to recent reports 
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suggesting important roles for the hinge region in ligand binding and 
activation (48-50).  Both the N- and C-termini are disordered in RXRα crystal 
structures (189-200), so neither terminus is an obvious choice.  Moreover, by 
keeping the tag as short as possible (LEHHHHHH), we minimize the risk of 
undesired effects; even designing a longer tag and cleaving using a protease 
generally leaves several amino acids.  For example, in at least one prior 
RXRα report, twenty extra amino acids were still attached to the N-terminus 
following tag cleavage (249).  Thrombin, the most common enzyme used to 
cleave tags, leaves a minimum of four amino acids, and some pET plasmids 
also have a T7 tag, which leaves twelve amino acids after cleavage.
Second, relative to the more commonly used ampicillin marker 
plasmids (21, 187, 190-192, 199, 201, 247-250, 254, 256-276), the pET28a 
plasmid has the advantage of lower background expression due to the 
reversed orientation of the gene, preventing simple read-through from 
transcription of the antibiotic resistant gene; to date only two other reports 
of pET28-based RXRα expression exist (188, 193).  The use of kanamycin 
instead of ampicillin may also offer an advantage, as kanamycin works by 
inhibiting the ribosome and thus ensures that all cells are constantly under 
selection and reliably producing protein, whereas ampicillin is deactivated 
extracellularly and only ensures that enough cells retain the expression 
plasmid to convey resistance to all cells.
Our protocol also simplifies the purification procedure.  Nearly all 
prior purification protocols required at least two chromatographic steps 
(21, 188, 190-193, 199, 201, 247, 250, 257-259, 261, 262, 264-269, 271, 
272).  Unlike many previous investigators, by optimizing the affinity 
chromatography, we obtained very high purity from a single step, and that 
an additional gel filtration step simply produced a loss in yield with no 
further purification.  Most of our improvement in yield, compared to prior 
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protocols, is probably due to the elimination of subsequent chromatographic 
steps.  Although we see a mixture of oligomers during gel filtration 
chromatography, the peaks were overlapping and not cleanly separable; 
repeated chromatography did not change the distribution, and which 
suggest an equilibrium of two states rather than distinct conformations.  The 
clear equilibrium could be due to the C-terminal His6 tag, which eliminates 
nearly-complete protein sequences that may adopt a slightly different fold 
from full-length protein, avoidance of freezing, and/or minimization of 
sonication.  Finally, use of SYPRO® Red as a stain to check for purity ensured 
much higher sensitivity than the commonly used Coomassie stains (289), 
and so provided confident purity estimates.
The yield of hRXRα(D E) from the affinity chromatography is nearlyᵦ  
double the expected yield (10 mg mL-1 of resin, according to the Talon® 
manual).  This result is not entirely unexpected, as RXRα forms dimers and 
tetramers (42) (see also Chapters 4 and 5).  A recent report demonstrated 
that oligomeric proteins may bind to affinity resins using only a single His6 
tag, and so "overload" the resin (290).  Moreover, under no circumstances 
did was yield of more than 40 mg mL-1 of resin (four times the expected 
loading) obtained, which is in line with the expectation that hRXRα(D E) isᵦ  
adopting dimeric and tetrameric forms, but not higher order structures. 
Moreover, as detailed in Chapter 5, the single hRXRα(D E) variant weᵦ  
expressed that shows reduced self-association also had dramatically reduced 
yield and purity.
One alternative purification strategy not pursued was that of a 
denaturing protocol, including possible recover from inclusion bodies.  This 
method has been used for hRXRα(C) (212, 213), but not reported for other 
domains of RXRα.  We felt it safer to retain a native structure throughout 
rather than risk improper refolding.  A recent report has also demonstrated 
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that proteins recovered from inclusion bodies are of inferior quality (291).
We have only performed initial trials on hRXRα(ABCDE), 
hRXRα(ABCDα), hRXRα(CDE), or GBDhRXRα(DE), and have not pursued 
them further.  The results from these trials suggest that the A/B domain of 
hRXRα is likely fatal to E. coli.  This could be due to some unpredictable 
protein-protein interaction, the fact that A/B is intrinsically disordered (5) 
and so may form a toxic aggregate, or that when the A/B domain is coupled 
to the DBD, it leads to inhibition of expression of an essential gene due to 
enhanced DNA interactions (43-46).  Alternative expression systems are 
probably required to obtain significant quantities of hRXRα(ABCDE) and 
hRXRα(ABCDα), although the yield may still be low.  The toxicity of the A/B 
domain, but not the DBD, is supported by our successful expression of 
hRXRα(CDE), as well as similar constructs from other groups (21, 188, 247, 
248, 250, 257-259, 261-264, 270, 271).  In addition, there are reports of 
successful expression of the hRXRα DBD alone (210-214, 255), although in 
many cases they required the C195A mutation to prevent aggregation 
(cysteine 195 is not involved in DNA binding).  hRXRα(CDE) is problematic 
because zinc is required for proper folding of nuclear receptor DBDs (212, 
213, 292), but the zinc-induced precipitation suggests that some portion of 
the protein is improperly folded.  The protease cleavage problem of 
GBDhRXRα(DE) could possibly be worked around by using an N-terminal 
His6 tag instead of a C-terminal tag or both concurrently, but increases the 
risk of obtaining partially translated protein after affinity chromatography.
In summary, we have designed a single-step expression and 
purification system that produces hRXRα(D E) of consistent quality and highᵦ  
yield.
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4CHAPTER 4
CHARACTERIZATION OF WILD-TYPE hRXRα(D E)ᵦ
4.1 Introduction
Although it is generally accepted that RXRα is functionally active as a 
dimer (7, 8, 42), and may also be active as a tetramer (262, 271), the 
oligomeric states that RXRα adopts are not entirely clear-cut.  As mentioned 
in Section 3.1, the reported oligomeric state(s) of RXRα following expression 
and purification are quite variable.  Indeed, multiple reports from single 
research groups are not always consistent, which demonstrates the 
complexity of the issue.  Table 4.1 summarizes published research where 
some analytical measure of the oligomericity was reported and the LBD was 
part of the construct studied.  In short, claims of a monomeric (20, 21, 244, 
249-251, 256-258, 263, 294), dimeric (21, 188, 192, 201, 244, 248-251, 256-
258, 262, 265, 266, 268, 269, 271, 272, 275, 293, 294), and tetrameric (20, 
21, 188, 192, 201, 250, 257, 258, 262, 263, 265, 266, 271, 272) state have 
been made regardless of the domains investigated, with some reports noting 
more than one state.  Some investigators observe that multiple states are 
separable (192, 201, 256), suggesting that one of the states is an aggregate 
or "defective" form; others report an equilibrium between two or three 
states (20, 21, 188, 244, 249-251, 257, 258, 261-263, 265, 271, 272, 294). 
When bound to 9cRA, investigators have reported both solely monomers 
(249, 250, 263) and solely dimers (21, 192, 201, 244, 248, 251, 261, 265, 
266, 269, 271, 272, 293, 294), as well as an unchanged monomer-tetramer 
equilibrium (20) and a shift away from tetramer to a monomer-dimer 
equilibrium (258).  The published crystal structures show similar diversity. 
hRXRα(DE) and hRXRα(E) (see Section 1.2 for nomenclature) have been 
crystallized as a monomer (189) and tetramer (191) in the absence of ligand. 
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Table 4.1.  Published oligomerization states of RXRα.
Oligomerizationα
Authors Year Ref.β Sp.γ Domains
No 
Ligand
With 
9cRA Kd (nM)
Zhang et. al. 1992 (244) h ABCDE M, D D
 Chen & Privalsky 1995 (20) h ABCDE M, T M, T
Sanchez-Andres et. al. 2005 (294) h ABCDE M, D D
Chen et. al. 2005 (293) h ABCDE D D
Kersten et. al. 1997 (261) m ABCDE D, T D
Chen et. al. 1998 (250) m ABCDE M, T M
Fischer et. al. 2003 (188) h CDE D, T - ~100,000's
Leid 1994 (248) m CDE D D
Kersten et. al. 1995 (21) m CDE M, D, T D 155 & 4.4
Kersten et. al. 1995 (257) m CDE M, D, T -
Kersten et. al. 1995 (258) m CDE M, D, T M, D 130 & 2.8
63 (9cRA)
Kersten et. al. 1997 (261) m CDE D, T D
Kersten et. al. 1998 (262) m CDE T D
Chen et. al. 1998 (250) m CDE M, T M
Schimerlik et. al. 1999 (263) m CDE M, T M
Yasmin 2004 (271) m CDE D, T D
Cheng et. al. 1994 (249) h DE M, D M
Bourguet et. al. 1995 (256) h E M, Dδ -
Egea & Moras 2001 (266) h E T D
Egea et. al. 2001 (265) h E D, T D
Egea et. al. 2002 (192) h E D, Tδ D
Chen et. al. 2003 (251) h E M, D D
Harder et. al. 2004 (269) h E M, D - 0.38 ± 0.03
Harder et. al. 2004 (269) h E D D
Yan et. al. 2004 (268) h E D -
Lengqvist et. al. 2005 (272) h E D, T D
Lu et. al. 2006 (201) h E D, Tδ D
Yan et. al. 2006 (275) h E D -
Chen et. al. 1998 (250) m E M, D M
α M = monomer, D = Dimer, T = Tetramer, - = Not reported.
β Ref. = Reference.
γ Sp. = Species, h = Human, m = Mouse.
δ Non-equilibrium mixture.
When bound to various ligands, hRXRα(E) has been crystallized as a 
monomer (190) and dimer (192).  In addition, hRXRα(E) has been observed 
as a dimer regardless of ligand binding by NMR (201).
The variation in reported affinities for 9cRA is also quite broad, 
ranging from a minimum Kd of 1.44 nM (253) to 200 nM (249).  Table 4.2 
summarizes the previously reported Kd values for RXRα and 9cRA.  An open 
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Table 4.2.  Published binding constants for 9cRA and RXRα.
Authors Year Ref.α Sp.β Domains Kd (nM) Technique
Levin 1992 (176) h ABCDE 9.5 Radioligand
Heyman et. al. 1992 (177) h ABCDE 11.7 Radioligand
Allegretto et. al. 1993 (253) h ABCDE 1.62 ± 0.34 Radioligand
Allegretto et. al. 1993 (253) h ABCDE 1.44 ± 0.40 Radioligand
Kitareewan et. al. 1996 (178) h ABCDE 10.2 ± 1.5 Radioligand
Lala et. al. 1996 (252) h ABCDE 6.7 Radioligand
Peet et. al. 1998 (216) h ABCDE 13 ± 3 Radioligand
Allenby et. al. 1993 (245) m ABCDE 15.7 Radioligand
Chen et. al. 1994 (247) m CDE 14 ± 6 Fluorescence
Kersten et. al. 1995 (258) m CDE 5 - 20 Fluorescence
Kersten et. al. 1996 (259) m CDE 20 ± 3 Fluorescence
Kersten et. al. 1998 (262) m CDE 14 ± 0.6 Fluorescence
Schimerlik et. al. 1999 (263) m CDE 7.6 ± 3.8 Fluorescence
Budhu & Noy 2000 (264) m CDE 41 ± 12 Fluorescence
Budhu & Noy 2000 (264) m CDE 31 ± 10γ Fluorescence
Cheng et. al. 1994 (249) h DE 3 ± 0.5 Fluorescence
Cheng et. al. 1994 (249) h DE 5.6 Radioligand
Cheng et. al. 1994 (249) h DE 1.8δ Radioligand
Cheng et. al. 1994 (249) h E 10 - 200 Fluorescence
Bourguet et. al. 1995 (256) h E 13.8 ± 1.2 Fluorescence
Li et. al. 1997 (260) h E 17 Radioligand
Vivat et. al. 1997 (254) m E 15 ± 3δ Radioligand
α Ref. = Reference.
β Sp. = Species, h = Human, m = Mouse.
γ AF-2 region deleted.
δ N-terminally GST-tagged.
question is how the binding of coactivator proteins affects ligand affinity; the 
question has only been examined in reverse, where the effect of ligand 
binding on recruitment of coactivator peptides has been reported (276, 283, 
295).
To address these issues, and to ensure a reliable reference point for 
comparison when investigating hRXRα variants, we undertook a thorough 
investigation of the oligomeric and ligand-binding properties of hRXRα(D E).ᵦ  
Investigating many properties at once, using a single hRXRα construct and 
consistent assay conditions, allows for a greater opportunity to draw 
correlations between observed results.  Finally, to our knowledge there has 
been only one report examining the folding thermodynamics of hRXRα (269), 
so we also investigated the (un)folding of hRXRα(D E).ᵦ
4.2 Materials and Methods
4.2.1 Materials
hRXRα(D E) was expressed, purified, and stored as previouslyᵦ  
described (Section 3.2.3).  9-cis retinoic acid was purchased from Biomol 
(Plymouth Meeting, PA) at 99% purity, which was confirmed by UV-vis 
absorbance spectroscopy and high performance liquid chromatography. 
LG335 (172) was previously synthesized in the Doyle laboratory (115).  All-
trans retinoic acid (atRA) and γ-oxo-1-pyrenebutyric acid were purchased 
from Sigma-Aldrich (St. Louis, MO) at 98% purity.  9cRA, atRA, and LG335 
were used as concentrated stock solutions in ethanol, and concentrations 
determined by UV-vis spectroscopy.  We used previous reported molar 
absorptivities for 9cRA (ε344 = 36,700 cm-1 M-1 (296, 297)) and atRA (ε350 = 
45,300 cm-1 M-1 (296)), and determined the value for LG335 (ε255 = 22,500 
cm-1 M-1).  OPBA was used as concentrated stock solutions in 1:9 dimethyl 
sulfoxide:ethanol, and the molar absorptivity determined in the same solvent 
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(ε354 = 18,400 cm-1 M-1).  Retinoic acid stocks were protected from light 
during storage and used under reduced lighting, and all ligands were stored 
in the dark at -20 °C when not in use.  The LxxLL peptide was synthesized by 
the Parker H. Petit Institute for Bioengineering & Bioscience Core Facilities 
(Atlanta, GA).  The nonsense peptide was a generous gift from Dr. Jing Li 
and Dr. Christoph Fahrni.
4.2.2 Ligand Binding
Fluorescence assays to determine receptor-ligand binding constants 
were performed using a modification of previously described methods (247, 
249).  Measurements were made on a Shimadzu (Hong Kong) RF-5301PC 
using 5 nM slits, 1 nm resolution, 1 second integration time ("slow" speed), 
excitation at 280 nm, and emission monitored from 300-360 nm.  All assays 
used 50 nM hRXRα(D E) in 100 mM NaCl, 10 mM NaPᵦ i (pH 7.0), and 1 mM 
dithiothreitol.  Each measurement was obtained by taking a baseline scan of 
a clean 1 cm cuvette containing buffer and ligand(s), then adding 
hRXRα(D E) from a 10 µM stock in the same buffer to a final volume of 1 mLᵦ  
and a maximum of 0.2% organic solvent.  After mixing and waiting 60 
seconds, a single scan was taken.  The cuvette was then cleaned and used 
for the next measurement.  All measurements were taken at ambient 
temperature (21-23 °C), and a single 10 µM hRXRα(D E) stock was used forᵦ  
a maximum of 1 hour or 10 measurements.  For each new 10 µM 
hRXRα(D E) stock, a reference emission scan taken in the absence of ligandᵦ  
was obtained.  In general, measurement sets were designed to provide 
"interlocking" values; for example, one set of measurements included 4, 20, 
and 50 nM, a second set included 8, 30, and 60 nM, and a third set 12, 40, 
and 70 nM.  This approach allows for detection of tryptophan quenching due 
to causes other than ligand binding.
To correct for variation in the raw fluorescence intensities between 
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individual sets (due to small differences in room temperature, lamp intensity, 
dithiothreitol strength, and hRXRα(D E) concentration in stock solutions),ᵦ  
data were converted to % quench at 337 nm using Equation 4.1:
Q=100 1− 0  (4.1)
where Θ is the signal intensity, Θ0 is the signal intensity in the absence of 
ligand, and Q is % quench.  The quench values were then nonlinearly fit to 
Equation 4.8, which is derived by substituting Equations 4.2 and 4.3 into 
Equation 4.5 and solving for [R∗L] (Equation 4.6), then substituting the 
result into Equation 4.7:
[R]=[R free][R∗L ]  (4.2)
[L ]=[L free][R∗L]  (4.3)
R∗L⇌R freeL free  (4.4)
Kd=
[R free ][Lfree ]
[R∗L ]  (4.5)
[R∗L]= [R][L]K d−[R][L]K d
2−4[R ][L]
2
 (4.6)
Q=M [R∗L ][R ]   (4.7)
Q=M  [R][L ]Kd−[R][L]K d2−4 [R][L]2[R]   (4.8)
where [R∗L] is the concentration of receptor-ligand complex; [R] is the total 
receptor concentration; [Rfree] is the concentration of unbound receptor; [L] 
is the total ligand concentration; [Lfree] is the concentration of unbound 
ligand; and M is the maximum quench at saturation of receptor sites.
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4.2.3 Self-Association
Analytical ultracentrifugation (AUC) was performed on a Beckman 
Coulter (Fullerton, CA) XL-A in equilibrium mode using a 6-channel An-50 Ti 
rotor.  Samples were initially prepared as approximately 30 µM stocks by 
exchanging the storage buffer for 100 mM NaCl and 10 mM NaPi (pH 7.0) 
using at least three rounds of exchange in Millipore (Billerica, CA) Microcon 
devices to a minimum 1,000x dilution of storage buffer components.  (In our 
hands, hRXRα(D E) undergoing dialysis tended to precipitate unless theᵦ  
buffer contained approximately 10% or greater glycerol.)  Denaturing runs 
also included 6.0 M guanidinium chloride (GdmCl) in the buffer.  Three 
concentrations where run simultaneously as 1x, 2x, and 4x dilutions. 
Samples were initially run at 3,000 xg and scanned to ensure even 
distribution throughout the cells, then sequentially run to 12,000 xg, 16,000 
xg, and 20,000 xg for 15 hours each, with a minimum of 4 scans at one hour 
intervals to ensure equilibrium at each stage.
Data were analyzed according to the following equations (298):
C1,r=C1,r 0e
M 1−v
2
2RT r
2−r02  (4.9)
Cn ,r=K x ,n C1, rn  (4.10)
=0∑
i=1
x
Ci, r 280bi  (4.11)
where C1,r is the concentration of monomer at radial position r; C1,r0 is the 
concentration of monomer at the reference radial position r0 (arbitrarily 
chosen as the radial position of the first data point being fit); M is the 
molecular mass of the monomer; v is the partial specific volume; ρ is the 
solution density; ω is the rotational velocity in radians sec-1; R is the gas 
constant; T is temperature in Kelvin; Cn,r is the concentration of the 
oligomeric species containing n monomer units; Kx,n is the equilibrium 
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constant for the transition from species x (monomer or dimer) to species n 
(dimer or tetramer); Θ0 is the baseline offset; and b is the path length (1.2 
cm).
A nonlinear algorithm was used to fit Equation 4.11, making use of the 
measured noise for each data point.  The range of data fit for each cell was 
from the first reliable data point after the meniscus (generally 0.015 cm 
later) to 0.01 cm before the bottom of the cell or the first data point with an 
absorbance intensity of > 1.5, whichever came first.  Errors estimates are 1 
standard deviation.
Baseline values for the fits were determined nonlinearly using the 
average absorbances of the 3,000 xg scans, the known ratios of 
concentrations loaded into the cells, and an additional "data point" to 
minimize the total deviation from zero.  Baselines were then held fixed for 
all further analysis.  As others have noted (299), allowing the baseline values 
to float as part of the fit leads to very high correlations in the parameters, 
and occasionally results in physically unrealistic parameters.  Runs were 
analyzed individually and globally as described in Section 4.3.2.  Partial 
specific density of hRXRα(D E) was estimated to be 0.7388 ml mgᵦ -1 (native) 
or 0.7277 ml mg-1 (denatured) using the program SEDNTERP version 1.09 
(300).  Buffer densities were also estimated using SEDNTERP, and 
confirmed to match the theoretical values within experimental error using 
an Anton-Paar (Graz, Austria) DMA-60 densimeter with a DMA-512 remote 
cell.  Density values used were 1.00351 mg mL -1 for native buffer, and 
1.14755 mg mL -1 for denaturing buffer.
4.2.4 Thermal Denaturation
Circular dichroism spectroscopy (CD) was performed on a Jasco 
(Easton, MD) J-810 spectropolarimeter equipped with a peltier temperature 
controller and six-cell changer, using 0.1 cm cuvettes (300 µL volume). 
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Unless otherwise noted, conditions were 10 µM hRXRα(D E) in 100 mMᵦ  
NaCl, 10 mM NaPi, pH 7.0.  Full scans were performed from 250-200 nm at 
5 °C and 250-205 nm at 85 °C using a scan rate of 50 nm min-1, 4 
accumulations, 1 sec response, 1 nm data interval, and 1 nm slit width.  All 
scans were baseline subtracted using a blank scan (containing everything 
except hRXRα(D E)) at 5 °C.  Thermal ramps were performed from 5-85 °Cᵦ  
at 1 °C min-1 unless noted, 222 nm, 5 nm slit width, 1 sec response, and a 
data interval of 1 °C.  Samples containing ligand were kept to a maximum of 
1% organic solvent.  To correct for any solvent effects, scans and ramps 
were also performed for buffers containing 1% organic solvent but no 
ligand, and used as the comparison point for ligand effects.  Although a 
small (< 0.5 °C) decrease in Tm was observed due to solvent alone, the shift 
was not statistically significant.
Data were nonlinearly fit to a simple sigmoidal model allowing for 
sloped upper and lower baselines (Equation 4.16), derived by substituting 
Equations 4.12, 4.13, and 4.14 into Equation 4.15 and rearranging:
N=BNmN T  (4.12)
D=BDmD T  (4.13)
FD=
[D ]
[R]=
1
1emT−T m (4.14)
=D FDN 1−FD   (4.15)
=N
D−N
1emT−Tm
(4.16)
where ΘN and ΘD are the native and denatured signals as a fixed value plus a 
temperature dependence; FD is the fraction of the total receptor 
concentration that is denatured (defined as a sigmoidal curve); Θ is the 
measured signal; T is the temperature in °C; m is essentially the "slope" of 
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the transition and reflects the cooperativity; and Tm is the midpoint of the 
transition.  Fits used at least three normalized replicates; normalized plots 
were used to reduce the dependency of the calculated Tm on the exact values 
for ΘN and ΘD, which significantly decreased error estimates without 
influencing the center value.
Differential scanning calorimetry (DSC) was performed using the 
same scan rate and buffer conditions as in the CD spectroscopy.  However, 
due to the lower sensitivity of the Calorimetry Sciences Corporation (New 
Castle, DE) N-DSCII used, a standard concentration of 30 µM hRXRα(D E)ᵦ  
was used unless noted.  Ramps were run from 5-105 °C, with 10 minute 
equilibration times at each extreme.  A blank cycle was run before each DSC 
scan, and the hRXRα(D E) added during the blank cooling cycle, when theᵦ  
temperature was 20-25 °C.  Tm estimates were taken as the midpoint of the 
most intense peak of the DSC trace after correcting for baseline.
4.2.5 Chemical Denaturation
Chemical denaturation was performed using CD spectroscopy, 
essentially as described in section 4.3.3.  However, scans were taken only at 
25 °C instead of heating, and from 250-212 nm due to guanidinium chloride 
absorbance.  Buffer conditions were identical, except with increasing 
concentrations of GdmCl.  Each measurement was individually baseline 
subtracted, and cuvettes cleaned between measurements.  Measurements 
were performed using both 10 µM and 2.0 µM hRXRα(D E).  Fluorescenceᵦ  
denaturation experiments were performed identically, except that 1.0 cm 
cuvettes were used with a total volume of 1,000 µL and 1.0 µM hRXRα(D E),ᵦ  
using a slit width of 3 nm, 300-380 nm scan range, 1 nm resolution, and 1 
sec integration time.  To show reversibility, GdmCl was removed by repeated 
buffer exchange using Millipore Micron devices, and the final spectrum 
corrected for loss of protein based on absorbance (typically about 10%). 
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Only the 222 nm CD or 334 nm fluorescence data were fit.
Data were fit to a model allowing for tetramer, dimer, monomer, and 
unfolded species, derived following previous approaches (301, 302).  In 
short, given the relationships in Equations 4.17 through 4.22, data were fit 
to Equation 4.23:
[R]=4 [T ]2 [D ][M ][U ]  (4.17)
K D,T=
[T ]
[D]2  (4.18)
K M ,D=
[D]
[M ]2  (4.19)
KU , M=
[M ]
[U ]  (4.20)
K=e
−G
RT =e
−m[Den]−CM 
RT =e
−m[Den]GD , H2O
RT  (4.21)
[]=4 [T ]
[R] T2
[D ]
[R] D
[M ]
[R] M
[U ]
[R ] U  (4.22)
[]=4K D ,T K M ,D2
[M ]4
[R] M2 K M, D
[M ]2
[R] D
[M]
[R] M
[M ]
KU , M[R ]
U  (4.23)
where [R], [T], [D], [M], and [U] are the total concentrations of receptor, 
tetramer, dimer, monomer, and unfolded species, respectively; R is the 
universal gas constant; T is temperature in Kelvin; [Den] is the 
concentration of denaturant; m and GH 2O are the slope and intercept, 
respectively, of a plot of ΔGD versus [Den]; and Cm is the [Den] at which the 
two species have equal concentration.  The implicit assumption that ΔGD is 
linearly dependent on [Den] has been previously validated (303, 304).  Fits 
were performed using a nonlinear algorithm as described below, using CD 
data converted to molar ellipticity (deg cm2 dmol-1) and raw fluorescence 
intensities weighted to provide equal impact on the fit with the CD data. 
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Baselines were fixed at zero based on prior work (269, 305) and lack of 
evidence for any slope in the apparent upper and lower baselines.
4.2.6 Data Analysis
All nonlinear fits used a variation of the Nelder-Mead simplex 
algorithm (306) for least-squares minimization; see Chapter 6 for a more 
detailed presentation.  When replicate data sets were available for global fits 
(AUC, thermal denaturation, and chemical denaturation), a global fit was 
used to increase confidence in, and reduce correlations between, 
parameters (307-310).  Quality of minimization was determined using χ2. 
During global fits, individual data sets were also weighted for the number of 
data points and possibly an arbitrary factor to correct for large differences 
in the magnitude of the data.  χ2 is only a relative measure of a fit, so while 
smaller is better during the fitting process for a particular data set, χ2 values 
for different data sets are not comparable.  In addition, each fit was 
analyzed using a runs test, which is a measure of the randomness in the 
residuals of the fit.  The parameter Z should be close to zero for a random 
distribution; an absolute difference from zero of approximately 2 or greater 
indicates significant trends in the residuals, which in turn suggests the 
model may not be appropriate for the data (311).  Errors were estimated as 
described in Section 6.2.  In short, each parameter was individually 
displaced from the best-fit value and held fixed while a new best fit was 
obtained; when the resulting fit was statistically different from the best fit, 
the displacement was taken as the error.  This method tends to produce 
larger, but more reasonable, error estimates than traditional methods such 
as matrix inversion (308, 312-314).  The reported errors are always ±1 
standard deviation.
Linear fits were performed using standard linear regression.  For 
linear correlations involving lower limit Kd values, a reasonable estimate was 
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set as 1.5-fold greater than the Kd lower limit, with errors set at 33% (i.e., 
the lower limit to twice the lower limit).  This range spans the Kd values 
associated with the entirely physically realistic range of maximum quench 
values, approximately 50-95%, as observed during numerous titrations.
All statistical significant was measured at the p ≤ 0.5 level (two 
standard deviations when comparing values).
4.3 Results
4.3.1 Ligand Binding
Binding constants of hRXRα(D E) for various ligands (see Figure ᵦ 4.1) 
were determined in fluorescence assays.  9cRA is a known activator of 
hRXRα (176), LG335 weakly activates hRXRα (219, 315), and atRA has not 
been shown to activate hRXRα to any measurable extent, as small amounts 
of activation are generally attributed to formation of small amounts of 9cRA 
in the cell (176).  OPBA has been used as a target ligand for engineered 
hRXRα in the Doyle laboratory; it weakly activates hRXRα at concentrations 
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Figure 4.1.  Ligands and peptides.  (A) 9-cis retinoid acid (9cRA).  (B) All-
trans retinoic acid (atRA).  (C) LG335.  (D) γ-oxo-1-pyrenebutyric acid 
(OPBA).  (E) LxxLL peptide (LxxLL motif highlighted), from steroid receptor 
coactivator-1.  (F) nonsense peptide.
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greater than 10 µM (221), beyond the concentration range at which the 
other ligands can be assayed, due to limited solubility.  The binding pocket of 
hRXRα(D E) contains two tryptophan residues, the emissions from which areᵦ  
reduced (quenched) upon ligand binding.  The assays were modified from 
previous work (247, 249) due to signal loss over time, which leads to 
"tryptophan quenching" indistinguishable from that caused by ligand 
binding (see Figures 4.2 and 4.3).  Moreover, the effect was general, as the 
same relative signal loss was observed even when starting with saturated 
receptor.  Our method of individual measurements in clean cuvettes to 
minimize signal loss provided reliable, reproducible data.  Attempts to 
minimize loss using coatings on the cuvettes or alternative buffer conditions 
reduced the signal loss somewhat, but did not eliminate it as a significant 
factor over the course of a titration.  Figure 4.2 and Table 4.3 show the 
quench data, fits, and calculated Kd values for each ligand.  Due to the 
relatively low solubility of OPBA and low affinity for hRXRα(D E), we areᵦ  
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Figure 4.2.  Binding data and fits for 50 nM hRXRα(D E) with ligands.ᵦ  
(Black box, ■) 9cRA.  (Blue diamond, ◆) LG335.  (Green up triangle, ▲) 
OPBA.  (Magenta down triangle, ▼) atRA.  (Red lines, ▬) Best fit curves.  The 
upper limit of data collection is 8000 nM or at least 40×Kd.
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able to only put a lower limit on the Kd by assuming a reasonable maximum 
quench (approximately halfway between the observed maximum quench and 
the lowest maximum quench from the fits for other ligands).  The upper limit 
of data collection for each set was either 8000 nM ligand or at least 40-fold 
greater than the Kd, whichever came first.  The 8000 nM cutoff was used 
because ligands began to precipitate in the assay buffer in the 9-12 µM 
range.  At concentrations greater than 40×Kd, additional data points do not 
significantly influence the fit.
Due to the weak intrinsic fluorescence signal and the rate of signal 
loss, assays with receptor concentrations below 50 nM were unreliable.  As 
the Kd values for the ligands are of comparable affinity (i.e., less than 100-
fold greater), the hRXRα(D E) concentration must be included as an explicitᵦ  
parameter when fitting the data.  However, our analysis of simple models 
suggests that as much as a two-fold error in the hRXRα(D E) concentrationᵦ  
used in the fit does not shift the resulting Kd estimate outside the error 
range.  This concentration tolerance is beneficial, as it eliminates possible 
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Figure 4.3.  Signal loss over time for 50 nM hRXRα(D E).ᵦ   (Black box, ■) 
Receptor alone.  (Blue diamond, ◆) Receptor with 1 µM 9cRA.
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complexities arising from fitting different models, such as dimers with only a 
single active binding site.  On the other hand, we are also unable to 
comment on possible cooperative (positive or negative) behavior during 
binding, as a change in receptor concentration is equivalent to a change in 
the number of ligand binding sites.  Therefore, no information regarding the 
oligomericity hRXRα(D E) can be obtained from binding studies alone.ᵦ
The coactivator LxxLL peptide used is from the steroid receptor 
coactivator-1 with an extra C-terminal cysteine (C-688SRC-1702, see Figure 
4.1), and is similar to that used in previous studies (276, 283, 295).  The 
peptide had no effect on the tryptophan emission up to concentrations of 
100 µM, and so we were unable to obtain a direct binding affinity for the 
peptide using this technique.  However, previous reports suggest the Kd is at 
most 6 µM in the absence of ligand and 2 µM in the presence of 9cRA, and 
possibly 10-fold lower (276, 295).  Therefore, a concentration of 20 µM 
LxxLL peptide should result in at least 90% of the hRXRα(D E) being boundᵦ  
to the peptide.  To observe the effect of the LxxLL peptide on the ligand Kd, 
the ligand binding assays were repeated using a fixed concentration of 20 
µM LxxLL peptide in the buffer.  Figure 4.4 and Table 4.3 show the resulting 
data and Kd values.  No further shift in the Kd values occurred at 
concentrations of LxxLL peptide up to 100 µM, suggesting that hRXRα(D E)ᵦ  
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Table 4.3.  Ligand binding parameters for hRXRα(D E).ᵦ
Ligand alone Ligand + LxxLL peptide
Ligand Kd (nM) Max Quench (%) Kd (nM) Max Quench (%)
9cRA 70 ± 20 84 ± 4 35 ± 14 75 ± 4
LG335 370 ± 100 83 ± 5 110 ± 30 71 ± 3
atRA 900 ± 300 91 ± 5 520 ± 160 87 ± 5
OPBA > 3800 65α > 3800 55α
α Fixed as described in text.
is indeed predominantly bound to the LxxLL peptide at 20 µM.  The use of a 
nonsense peptide did not produce a shift in the observed Kd for 9cRA (70 ± 
20 nM and maximum quench of 83 ± 4%), indicating that the LxxLL peptide 
had a specific effect on the ligand affinity.
4.3.2 Self-Association
To determine the self-association of the natively folded receptors, 
equilibrium analytical ultracentrifugation was performed at three protein 
concentrations and three spin velocities.  During the experiments, the three 
protein concentrations were in separate, stacked cells, so also had different 
radial positions.  Figure 4.5 shows data at 12,000 rpm fit to a single species 
model (floating molecular mass), as well as the expected curves for pure 
monomer, dimer, and tetramer species.  The obvious mismatch between the 
data and the expected single species curves indicates that the samples were 
either a single species with a molecular mass between dimer and tetramer, 
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Figure 4.4.  Binding data and fits for 50 nM hRXRα(DᵦE)with ligands in the 
presence of 20µM LxxLL peptide.  (Black box, ■) 9cRA.  (Blue diamond, ◆) 
LG335.  (Green up triangle, ▲) OPBA.  (Magenta down triangle, ▼) atRA. 
(Red lines, ▬) Best fit curves.  The upper limit of data collection is 8000 nM 
or at least 40×Kd.
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or a mixture of species.  The residuals for the floating molecular mass 
model, shown in Figure 4.6, are clearly not random, as indicated by the 
tendency of the residuals to cluster in positive or negative groups.  These 
trends suggest that a mixture is the more likely explanation for the data. 
Moreover, fits to individual runs and single cells (i.e., single concentration at 
multiple speeds) clearly indicate an increase in molecular mass with 
increasing concentration, suggesting an equilibrium of states.  The 
estimated molecular mass for a single species, 78.3 ± 1.5 kDa, rules out the 
possibility of a monomer-dimer equilibrium, as the monomer expected mass 
is 29.1 kDa; analysis of data for hRXRα(D E) under identical conditionsᵦ  
except for the addition of 6 M GdmCl produces an average molecular mass 
of 32.3 ± 0.6 kDa.  Monomer-tetramer dimer-tetramer non-equilibrium 
(fixed ratio) models are not improvements over the single species model, 
whereas a dimer-tetramer equilibrium model is significantly better.  Finally, 
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Figure 4.5.  Representative hRXRα(D E) AUC data fit to a single speciesᵦ  
model with theoretical curves for monomeric, dimeric, and tetrameric 
species.  (Black box, ■) 12,000 rpm data.  (Red lines, ▬) Best fit curves for 
single species model with floating molecular weight.  (Blue lines, ▬▬) 
Expected curves for pure monomer.  (Green lines, ▬▬) Expected curves for 
pure dimer.  (Magenta lines, ▬▬) Expected curves for pure tetramer.
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as shown in Figure 4.7 and Table 4.4, a monomer-dimer-tetramer model 
produces a greatly improved fit.
Two related problems suggest that additional processes also occurred 
during the ultracentrifugation.  First, the apparent average mass of 
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Figure 4.6.  hRXRα(D E) AUC data fit to a single species model withᵦ  
residuals.  (A) 12,000 rpm.  (B) 16,000 rpm.  (C) 20,000 rpm.  (Red lines, ▬) 
Best fit curves.  Vertical scale changes on residual plots to more clearly 
show trends in the residuals.
5.85 5.95 6.05 6.15 6.25 6.35 6.45 6.55 6.65 6.75 6.85 6.95 7.05 7.15
0
0.3
0.6
0.9
1.2
1.5
■■■■■■■■■
■■■■■■■
■■■■■■■
■■■■■
■■■■■
■■■
■■■
■■■
■■■■
■■■
■
■■■■■■■■■■■■■
■■■■■■■■■■
■■■■■■■
■■■■
■■■■
■■■
■
■■■■■■■■■■■■■■■■■■■■■■■■■■■
■■■■■■■■■
■■■■
A
Radius (cm)
Ab
so
rb
an
ce
5.85 5.95 6.05 6.15 6.25 6.35 6.45 6.55 6.65 6.75 6.85 6.95 7.05 7.15
-0.1
0
0.1
■■
■■■■■■■
■
■■■
■
■■
■■■■■■■■■
■■
■■■■■■
■
■■
■■
■
■■■■■
■■■■■
■■■■■■■■■■
■■■■■■■■
■■■
■
■
■
■■
■■■
■■
■
■■■■
■
■
■■■
■
■■
■■
■
■■■
■■■
■■
■
■■
■■■■■■■■■
■■■■
■■■■■■
■■
■
■■■■■■■■■■
■■■■■■■■■
■■
■■
■■■■
■■■■■
■■■■
■■■■
■■
■■■■
■■■■■■■
■
■■■■■■
■■■■■■■■■■■■■
■■■■■■
■■■■■■
■
■■■
■■■
■■■
■■■■■■■
■■
■■■■■■■■■■■■■■■
■■■■■■
■
■■
■■■■
■■■
■■■■■
■
5.85 5.95 6.05 6.15 6.25 6.35 6.45 6.55 6.65 6.75 6.85 6.95 7.05 7.15
0
0.3
0.6
0.9
1.2
1.5
■■■■■■■■■■■■■
■■■■■■■
■■■■
■■■■■
■■■
■■■
■■■
■■
■■
■■■
■■
■■
■
■■■■■■■■■■■■■■■
■■■■■■■■■
■■■■
■■■
■■■■
■■■
■■■
■■■
■■■■■■■■■■■■■■■■■■■■■■■■■
■■■■■■■■
■■■■■
■■■
B
Radius (cm)
Ab
so
rb
an
ce
5.85 5.95 6.05 6.15 6.25 6.35 6.45 6.55 6.65 6.75 6.85 6.95 7.05 7.15
-0.09
0
0.09
■■■■■■
■■■■■■■■■■■
■
■■■■■■■
■
■■■
■■■■■■
■
■■
■
■■■■■
■■■
■■
■■■
■■
■
■■■■■■
■■
■■■■
■■
■
■
■
■
■■
■
■
■■
■
■
■■■
■■■
■
■
■■
■
■
■
■
■
■
■
■
■■
■
■■
■■■■■
■■■■■
■
■■■■
■■■■
■■■■■
■■
■
■■
■■■■■
■
■■■■■■■■■■
■■
■■■■■■■■■■
■
■■
■
■
■■
■■
■■
■■
■
■
■■■
■■
■■
■
■■
■
■■
■
■■
■
■
■■
■■
■
■■■■■■■■
■■■■■■■
■■■■
■
■
■■■■■■
■■■
■■■■■■■■■
■
■■
■
■■■
■■■
■
■■
■■■
■■
■
■■■■■
■■■■■
■
■■■
■■■
■■■■■■
■■■■
■■
■■■
5.85 5.95 6.05 6.15 6.25 6.35 6.45 6.55 6.65 6.75 6.85 6.95 7.05 7.15
0
0.3
0.6
0.9
1.2
1.5
■■■■■■■■■■■■■■■■
■■■■■■■■
■■■■
■■■
■■■■
■■
■■
■■
■■■
■■
■■■
■■
■■■■■■■■■■■■■■■■■■■
■■■■■■■■■
■■■■
■■■■
■■■
■■■
■■■
■■■
■
■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■
■■■■■
■■■■
■■■
■
C
Radius (cm)
Ab
so
rb
an
ce
5.85 5.95 6.05 6.15 6.25 6.35 6.45 6.55 6.65 6.75 6.85 6.95 7.05 7.15
-0.07
0
0.07
■■■
■■■
■
■■
■■■■
■■■■■
■■■
■■■■■
■
■■■■■
■■■
■
■
■
■
■■■■
■
■■
■■■
■■■■■
■
■■
■
■
■■
■■
■
■
■■
■■
■
■
■
■
■
■
■■
■■
■
■
■
■
■
■■■
■■
■
■
■
■
■■
■
■■■■
■
■
■
■
■■
■■
■
■
■■■■
■
■
■
■■■■■
■■
■
■■
■
■
■■■■■■
■
■■■■
■■■
■
■
■
■■■■■
■■■■■■■
■■■■■■
■■■■
■■■
■
■
■■■■■■
■■
■
■■
■■■
■
■
■
■
■
■
■
■
■■■■
■
■
■
■
■■■
■
■
■
■
■
■■
■
■
■
■■■
■
■
■■■
■■■■■■■
■
■■■■■■■
■
■■■■■■
■■■■■■■
■■
■■
■
■
■■
■
■
■
■■■■■
■
■
■
■
■
■■
■
■■
■
■■■
■■
■■■■■■
■■
■■■■
■■■
■
■
■■
■
■
■■
■
■■■
■
hRXRα(D E) decreases with increasing spin velocity when the nine data setsᵦ  
are analyzed in three sets grouped by spin velocity or individually.  This 
decrease suggests a loss of material and/or non-specific aggregation. 
Second, as can be seen in Figure 4.8, a dimer-tetramer model gives a high 
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Figure 4.7.  hRXRα(D E) AUC data fit to a monomer-dimer-tetramer modelᵦ  
with residuals.  (A) 12,000 rpm.  (B) 16,000 rpm.  (C) 20,000 rpm.  (Red 
lines, ▬) Best fit curves.  Vertical scale changes on residual plots to more 
clearly show trends in the residuals.
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quality fit to the 12,000 rpm velocity data, which is not further improved by 
introduction of a monomeric species (see Table 4.5).  Fits to the 16,000 and 
20,000 rpm data alone are much poorer (data not shown), even after 
introduction of a monomeric species.  The fits are qualitatively similar, but 
fits to the 12,000 rpm data alone have much higher statistically reliability. 
Although the aggregation was apparently greatly reduced in buffer 
containing 6 M GdmCl, some spin velocity dependence is still apparent in 
the fits; using only the 12,000 rpm data produces a superior fit and an 
estimated molecular mass of 29.7 ± 1.2 kDa, which is in good agreement 
with the expected molecular mass (29.1 kDa).  Therefore, we ultimately used 
only the 12,000 rpm data, at all three concentrations, to avoid the influence 
of non-specific effects.  Use of a single spin velocity prevents use of mass 
constraints (299, 316, 317) to further refine the fits, but imposing mass 
constraints is not justified anyway due to an apparent loss of material as a 
function at higher spin velocities (decreased total absorbance).  The total 
absorbance decrease was reversible, as performing a second run on the 
same samples (after halting the ultracentrifuge and mixing) reproduced the 
first runs quite closely.  This behavior suggests that the non-specific 
behavior arose due to the centrifugation, and is not due to degradation of 
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Table 4.4.  Global fit parameters of all AUC data for hRXRα(D E).ᵦ
Fit Qualityα
Modelβ χ2 Z kDa or Kdβ
Single species 48.3 19.5 78.3 ± 1.5 kDa
4M  T⇌ 55.0 13.6 1.6 ± 0.4 µM3
2D  T⇌ 30.4 8.6 35 ± 9 µM
4M  2D  T⇌ ⇌ 27.2 6.5 1.55 ± 0.07 µM (2M  D)⇌
12.9 ± 0.9 µM (2D  T)⇌
α See Chapter 6 for details.
β M = Monomer, D = Dimer, T = Tetramer.
the sample during the long runs.  As the residuals from the 12,000 rpm data 
alone are still not entirely random (Z score of 2.5, slightly higher than the 
target of less than 2), a little non-specific aggregation may have occurred 
even at that spin velocity; this small effect does not significantly impact our 
analysis.
Native polyacrylamide gels produced results with considerable 
ambiguity, and we were unable to reliably determine absolute molecular 
masses.  Moreover, significant aggregation occurred under some conditions. 
Two bands were always observed, with an intensity ratio in approximate 
agreement with the AUC results for the dimer-tetramer model.
Due to limited ligand solubility (approximately 10 µM) and the 
relatively high protein concentrations required for AUC (5-30 µM), attempts 
to determine ligand effects on the oligomerization were unsuccessful.  The 
precipitation of ligands prevented preparation of reference cells containing 
an equimolar concentration of ligand for baseline subtraction; since the 
ligands all have absorbance at 280 nm comparable to hRXRα(D E), theᵦ  
differences between the reference and samples cells would be significant. 
In addition, our observations indicate that the molar absorptivity of 9cRA in 
particular is quite sensitive to environment (e.g., the molar absorptivity in 
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Figure 4.8.  hRXRα(D E) 12,000 rpm AUC data fit to a dimer-tetramerᵦ  
model with residuals.  (Red lines, ▬) Best fit curves.
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■
water is less than half the molar absorptivity in ethanol), and so we would 
have had to introduce the 9cRA molar absorptivity as a floating parameter in 
fits.  Addition of this parameter would introduce large uncertainties into the 
final parameter estimates due to strong cross-correlations.
4.3.3 Thermal Denaturation
To probe the oligomeric and unfolding energetics of hRXRα(D E), weᵦ  
turned to thermal denaturation studies.  However, hRXRα(D E) irreversiblyᵦ  
denatures when heated, so we are unable to extract true thermodynamic 
information from the data.  Shown in Figure 4.9 are CD spectra of the same 
sample at 5 °C, after heating to 85 °C, and after cooling back to 5 °C.  The 5 
°C spectrum indicates the expected predominantly α-helical structure for 
hRXRα(D E) (the two negative peaks at 222 and 208 nm).  The 85 °Cᵦ  
spectrum is suggestive of a predominantly β-sheet structure (a single, broad 
negative peak around 216 nm) rather than an unfolded structure, and the 
spectrum after cooling is not significantly different.  The rate of cooling had 
no effect on the resulting spectrum at 5 °C.  As the small change in the CD 
spectrum upon cooling was linked to a much stronger change in the 
absorbance, it is probably not indicative of a significant change in structure. 
Single wavelength spectra of hRXRα(D E), shown in Figure ᵦ 4.10, have clear 
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Table 4.5.  12,000 rpm AUC global fit parameters for hRXRα(D E).ᵦ
Fit Qualityα
Modelβ χ2 Z Kdβ
4M  T⇌ 14.9 15.4 0.9 ± 0.4 µM3
2D  T⇌ 3.6 2.5 20 ± 2 µM
4M  2D  T⇌ ⇌ 3.7 2.6 0.242 ± 0.001 nM (M  D)⇌
20 ± 3 µM (D  T)⇌
α See Chapter 6 for details.
β M = Monomer, D = Dimer, T = Tetramer.
transitions during heating, but no significant transition during cooling. 
hRXRα(D E) had identical behavior in DSC experiments (Figure ᵦ 4.11), where 
a transition during the first heating was not followed by a transition while 
cooling or upon reheating.  Some DSC runs also had a significant "tail" on 
the DSC transition, which is suggestive of aggregation.  This aggregation is 
visually apparent as a thin film that coated cuvette surfaces.  The protein did 
not precipitate in a traditional manner, and some portion remained in 
solution.  The soluble portion of hRXRα(D E) heated to 55 °C or 85 °C, rapidᵦ  
cooled, and analyzed by AUC.  The soluble fraction had a significantly 
increased average molecular mass (average molecular masses of 109 ± 7 
kDa and 207 ± 7 kDa, respectively).  We performed no further 
characterization of this aggregate, other than to determine complete 
removal of the aggregate from cuvette surfaces required strong detergent 
(> 1%), heating to > 90 °C for at least 15 minutes, and acid washing (> 0.1 
M HCl).
In addition to being irreversible, the transition exhibited scan-rate 
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Figure 4.9.  Far-UV CD spectra of 10 µM hRXRα(DᵦE).  (Black line, ▬) 5 °C. 
(Blue line, ▬) 85 °C.  (Green line, ▬) 5 °C after slowly cooling from 85 °C.
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dependence.  Increasing DSC scan rates caused an increasing apparent Tm, 
for an increase of nearly 3 °C as the scan rate was increased from 0.25 to 
1.5 °C min-1.  Moreover, we did not observe an effect of protein 
concentration on the apparent Tm.  The combination of these effects, the fact 
that even partial heating is irreversible, and that an "unfolded" state was 
never clearly present, indicate that we cannot extract thermodynamic 
information from the data (318, 319).  Therefore, given the basic agreement 
between CD and DSC data, all further experiments were done using fixed 
conditions via CD spectroscopy to minimize material consumption.  Although 
the CD spectrum upon heating is suggestive of two transitions (Figure 4.10), 
and the corresponding DSC trace clearly contains two transitions (Figure 
4.11), all data was fit to a model for a single, irreversible, transition to 
determine the apparent Tm.  We justify this approach on the basis of three 
observations: (i) the relative intensities of the two transitions varied 
considerably between runs and exhibited strong dependence on buffer 
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Figure 4.10.  Temperature-dependent CD spectra of 10 µM hRXRα(DᵦE) at 
222 nm. (Black line, ▬) Heating.  (Blue line, ▬) Cooling.  (Green line, ▬) 
Heating a second sample in the presence of equimolar 9cRA.
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conditions; (ii) because the first transition is much stronger than the second 
in the CD spectra, so the estimated Tm values from single transition fits are 
essentially identical to the lower Tm values from multiple-transition models; 
and (iii) because the dependencies (on other parameter values) in the 
estimated Tm values for two-transition fits are very large, producing great 
uncertainty in the values (large error estimates).
Despite the irreversible nature of the transition, relative Tm values of 
the native structure may still be compared when heated under different 
conditions (e.g., varying ionic strength).  Ionic strength had only a small, 
statistically insignificant, increase on the apparent Tm, throughout a range 0 
to 1 M NaCl (in a constant background of 10 mM NaPi).  A pH range of 5 to 
9 produced no shift in Tm, although a pH of 3 or 11 reduced the Tm to 
approximately 30 °C.  All conditions produce an apparently identical final 
aggregate, except when hRXRα(D E) was completely denatured usingᵦ  
guanidinium chloride (see below) before heating, or when using an acetate 
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Figure 4.11.  DSC traces of 30 µM hRXRα(D E).ᵦ   (Black line, ▬) Initial 
heating trace.  (Blue line, ▬) Cooling trace.  (Green line, ▬) Second heating 
trace.
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buffer, which caused hRXRα(D E) to precipitate rather than form a film.ᵦ
Unlike buffer conditions, ligands at equimolar concentrations had 
considerable effect on the apparent Tm.  As shown in Figure 4.10 for 9cRA 
and Table 4.6 for all ligands, some ligands considerably increased the Tm of 
hRXRα(D E).  The LxxLL peptide also increased the Tᵦ m somewhat.  However, 
the effect of the LxxLL peptide with each ligand was not additive (i.e., the 
effect from the ligand and peptide together was not simply the sum of the 
individual effects); in general, the stronger the effect on Tm of the ligand 
alone, the smaller the additional effect of the LxxLL peptide.  Although the 
limited solubility of the ligands prevented the use of excess concentrations, 
the ligand Kd (see Table 4.3) are low enough that the receptor was near 
saturation at equimolar concentrations.  The LxxLL peptide was used at a 20 
µM concentration to enable comparisons with the binding assays; higher 
concentrations did not cause significantly different results.
Two additional interactions influenced the magnitude of the error 
estimates in Table 4.6: (i) the simultaneous unfolding of the LxxLL peptide 
when the hRXRα(D E) aggregates, which has a significant effect on the CDᵦ  
signal; and (ii) possible binding of OPBA to the aggregated hRXRα(D E),ᵦ  
suggested by exothermic peaks in DSC traces with OPBA present, which 
73
Table 4.6.  Effect of ligands and LxxLL peptide on thermal stability of 
hRXRα(DᵦE).
Ligand Tm (°C) ΔTm (°C)α
+LxxLL
ΔTm (°C)β
None 55.0 ± 0.7 - 3.3 ± 2.3
9cRA - 6.3 ± 0.8 6.8 ± 1.2
LG335 - 3.9 ± 0.7 5.8 ± 1.1
atRA - -0.4 ± 1.1 4.0 ± 1.0
OPBA - -1.2 ± 2.1 1.9 ± 1.3
α ΔTm indicates the change in Tm due to the presence of ligand.
β ΔTm indicates the change in Tm due to the presence of ligand and peptide.
may influence the rate of formation of the aggregate.  Both of these effects 
serve to increase the cross-correlation between m and the apparent Tm, 
which increases the uncertainties in the parameters.
4.3.4 Chemical Denaturation
Guanidinium chloride denatured hRXRα(D E) reversibly, as shown inᵦ  
Figure 4.12.  Despite the effect of pH on Tm noted above, at 25 °C 
hRXRα(D E) was only partially unfolded throughout a pH range of 1.5 toᵦ  
12.5, so only GdmCl was used for chemical denaturation experiments. 
Unfolding by GdmCl and establishment of a new equilibrium apparently 
occurred rapidly, as measurements taken 60 seconds after addition of 
hRXRα(D E) to a solution containing GdmCl were identical to scans takenᵦ  
after more than hour.  Similarly, 0.05% SDS was sufficient to completely 
denature hRXRα(D E) within two minutes even in the absence of heating.ᵦ
Figures 4.13 and 4.14 show the denaturation data in the absence and 
presence of 9cRA.  Due to the oligomeric nature of hRXRα(D E), the CDᵦ  
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Figure 4.12.  Effect of guanidinium chloride on CD spectra of 10 µM 
hRXRα(D E).ᵦ   (Black line, ▬) 0 M GdmCl.  (Blue line, ▬) 6 M GdmCl.  (Green 
line, ▬) Following removal of the 6M GdmCl via repeated buffer exchange.
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spectra contain at least three distinct transitions in the absence of 9cRA. 
These states are not well separated, which leads to high correlations 
between parameters.  To try to reduce the correlations, unfolding was 
measured at three concentrations (1.0, 2.0, and 10 µM), using two 
spectroscopic techniques (CD and fluorescence), and coupled to the dimer-
tetramer equilibrium data available from AUC experiments.  The 
fluorescence intensity decrease correlates with the expected shift in the 
maximum emission from 334 nm to 350 nm (320-322).  However, rigorous 
analysis indicates that the data can be fit by a variety of different but 
statistically equivalent parameter sets; the basic problem is lack of 
resolution for individual states, not insufficient data points.  Quantitative 
conclusions cannot be drawn from the data with additional measurements 
using alternative techniques such as light scattering or analytical 
ultracentrifugation in similar buffers.
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Figure 4.13.  Guanidinium chloride induced unfolding of hRXRα(D E).ᵦ   (A) 
Fluorescence-monitored unfolding (334 nm) using 1 µM receptor.  (B) CD-
monitored unfolding (222 nm), using 10 µM (black box, ■) and 2 µM (blue 
diamond, ◆) receptor.
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4.3.5 Other Techniques
We also attempted binding assays using isothermal titration 
calorimetry, but the mixing energy of the organic solvents necessitated by 
ligand insolubility in water overwhelm the binding signal.  Injection of the 
protein into a solution containing ligand proved irreproducible, possibly due 
to shearing and/or heating effects when injecting a concentrated, viscous 
protein solution.  Attempts to titrate in the LxxLL peptide were 
irreproducible, despite the reported success of a similar experiment (295).
Hanging drop crystallization attempts were unsuccessful, even in 
conditions previously reported to produce crystals (189-192).  We attempted 
to use misincorporation proton-alkyl exchange (MPAX) system and isotope-
coded affinity tag (ICAT) mass spectrometry (323) to probe the structural 
flexibility of hRXRα(D E), but did not obtain reproducible data.ᵦ
To further clarify the oligomeric distribution of hRXRα(D E), gelᵦ  
filtration chromatography and dynamic light scattering were used. 
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Figure 4.14.  Guanidinium chloride induced unfolding of hRXRα(D E) in theᵦ  
presence of equimolar 9cRA.  Monitored using CD spectroscopy at 222 nm. 
(Black box, ■) 10 µM. (Blue diamond, ◆) 2 µM.
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However, the necessary assumptions of size and shape allows for great 
latitude in interpretation of the data.  Although the results are ambiguous, 
the experiments provided no evidence to contradict the basic analysis from 
AUC.
4.4 Discussion
4.4.1 Comparison to Prior Work
RXRα is an oligomeric, multidomain protein that exhibits complex 
behavior.  We have characterized some of the ligand binding, self-
association, thermal denaturation, coactivator interactions, and 
thermodynamic properties of hRXRα(D E).  The use of a standard set ofᵦ  
conditions allows presentation of a more complete, standardized analysis 
than has been available to date and can be used to resolve some of the 
differences between prior reports.
Our measured Kd for 9cra bound to hRXRα(D E) is higher than mostᵦ  
previous measurements (Table 4.2).  Several reasons explain why our value 
is unexpectedly high.
First, the more domains of RXRα used in a binding assay, the lower 
the measured Kd tends to be (Table 4.2): the Kd range for full-length RXRα is 
1.44-13 nM, for RXRα(CDE) 5-41 nM, and for RXRα(DE) and RXRα(E) 1.8-
200 nM.  Although the LBD is essential for binding the ligand, the other 
domains apparently have a role in the ligand affinity, which has been 
suggested by a functional analysis of peroxisome proliferator-activated 
receptor α (PPARα), where replacement of the PPARα DBD by the yeast 
GAL4 DBD resulted in a reduced maximum activity but similar overall profile 
(46).  This trend suggests that our Kd value for hRXRα(D E) is somewhatᵦ  
increased by the absence of the other domains.
Second, many previous reports did not obtain sufficient data points 
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Some prior work used only 4 or 5 data points to calculate the Kd, and in only 
a very few cases have the authors used a maximum ligand concentration 
sufficient to claim "saturation" (a requirement for accuracy in all fitting 
methods (324)).  A simple mathematical analysis of the Kd equation 
demonstrates that even a ligand concentration 10-fold higher than the Kd 
will provide a maximum of 90% bound receptor (assuming the receptor 
concentration is orders of magnitude below the Kd).  Insufficient saturation 
tends to reduce the calculated Kd.
Third, many reports use linearized data during analysis.  The use of 
linearized data violates assumptions required for nonlinear analysis 
(whether linearized or not) (312, 313); see Chapter 6 for a discussion.  The 
Scatchard (325) and Cogan (326) plots used to analyze all of the radioligand 
and some of the fluorescence experiments referenced in Table 4.2 are not 
statistically valid (312, 313, 327).  In addition, a linearized analysis requires 
an extrapolation of several orders of magnitude from the measured data to 
determine the concentration of bound receptor, which is inherently an 
undesirable situation and strongly influences the reported Kd value (324). 
Linearization can have unpredictable effects on the calculated Kd, but tends 
to enhance the effect of insufficient data (i.e., decrease the estimated Kd).
Fourth, the fluorescence assays suffer from the time-dependent 
tryptophan quenching shown in Figure 4.3, which was usually interpreted as 
being ligand-dependent.  Failure to correct for this signal loss results in 
artificially low Kd values.  Several investigators have commented on this 
signal loss (247, 249, 256, 258, 259).  One group used cuvettes coated with 
gelatin to eliminate the loss (249), but no treatment entirely eliminated this 
loss in our hands.  However, it is noteworthy that this report is the only one 
to claim a Kd (for 9cRA and hRXRα(E)) greater than ours (up to 200 nM).  In 
other cases, the loss has been attributed to "inner filtering" (247, 256, 258, 
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259), which is signal loss due to significant absorption of the excitation or 
emission light by the sample.  Inner filtering should not be a time-dependent 
behavior, but rather a constant or concentration-dependent correction for 
signal loss due to self-absorbance or interference in the buffer, both of which 
are generally negligible at the concentrations used for the binding assays. 
Although at low µM concentrations 9cRA does have sufficient absorbance to 
possibly cause inner filtering, time-dependence alone explains the signal 
decrease.  Some prior reports have used higher concentrations of receptor 
(approximately 1 µM), and they tend to have higher reported Kd values (247, 
258, 259, 262, 264); at µM concentrations, the magnitude of signal is greatly 
reduced.  One explanation for the signal loss is adsorption to the cuvette 
surface, as attempts to eliminate the signal loss using surface coatings had a 
greater (often detrimental) effect than changes to the buffer conditions. 
Adsorption implies a concentration change in the cuvette solution over time, 
and so analyses based on a fixed receptor concentration become unreliable. 
Previous attempts to correct for this self-quenching by adjusting the 
magnitude of the signal (247, 256, 258) address only one of the two 
variables in the fit that are changing (signal, not protein concentration). 
This signal loss is probably also a problem in experiments on binding 
kinetics (257, 263).
We minimized signal loss by minimizing cuvette contact time, used 
least-squares analysis to avoid linearization, and obtained measurements to 
a ligand concentration at least 40-fold greater than the Kd were possible. 
When the maximum obtainable data point was less than approximately 10-
fold greater than the Kd, we calculated only a lower limit Kd.  Comparisons of 
analysis methods using different subsets of our data suggest that each of 
these modifications serve to increase the apparent Kd, with the net result 
that our Kd is significantly higher than most previously reported values.  The 
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one-sample-per-cuvette protocol has the unfortunate effect of introducing 
significant noise into the system, which was minimized by obtaining many 
more measurements than typical.  Finally, our error analysis also provides a 
more realistic and larger value for the error estimates than standard 
approaches (324).
In addition to the numerous reports examining binding of hRXRα(D E)ᵦ  
to 9cRA, there is also one report of a Kd for LG335 of 269 ± 52 nM with 
hRXRα(ABCDE), determined via competition with radiolabeled 9cRA (315). 
This value is within error of our value reported for LG335 (370 ± 60 nM). 
Our Kd for atRA, 900 ± 300 nM, is also in agreement with prior reports, 
which indicate the Kd is greater than 200 nM (176, 249, 253, 258, 260). 
Although atRA has been reported to isomerize in cells to form other isomers, 
including 9cRA (176), we do not believe isomerization to be cause of our 
observed binding.  Approximately 10% 9cRA contamination would be 
necessary to generate our results purely from 9cRA, but atRA is more stable 
than 9cRA (328).  Moreover, we detected no significant changes in ligand 
stocks over the course of several months provided they were kept in the 
dark and at -20 °C when not in use.
We are not aware of any other reports of determining ligand binding 
to RXRα via fluorescence quenching using ligands other than 9cRA.  One 
proposed explanation for tryptophan quenching in RXRα is energy transfer 
between the tryptophan residues and 9cRA (247, 259), which is not 
unreasonable in light of the overlap in emission and absorption spectra. 
However, as we have clearly demonstrated, the effect is applicable to many 
ligands, including one (LG335) with no appreciable absorption overlap with 
the tryptophan emission spectrum.  Therefore, the quenching mechanism is 
due simply to having a ligand in the binding pocket, possibly due to either 
tertiary structure rearrangement upon ligand binding and/or direct 
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quenching via means that do not lead to emission, such as energy transfer to 
peptide bonds as they shift or the change in charge distribution when the 
ligand binds (320, 321, 329, 330).
The thermal behavior of nuclear receptors is relatively poorly studied, 
as only a handful of investigators have discussed thermal denaturation (331-
334).  Where reported, all observed irreversible denaturation behavior 
similar to the denaturation of hRXRα(D E).  hRXRα(D E) is apparentlyᵦ ᵦ  
thermally more stable (55 °C) than the estrogen receptors (38-40 °C) (331, 
334) and PPARγ (46 °C) (333), although not necessarily retinoid-related 
orphan receptor α (61 °C with low-affinity ligand) (332).  A few investigators 
have also reported a ligand-dependent increase in the Tm of receptors (331-
333).  ΔTm values range from < 1 °C to 7 °C for PPARγ (333), up to at least 9 
°C for retinoid-related orphan receptor α (332), and up to 5 °C for estrogen 
receptor α (331), which are comparable to our maximum of nearly 7 °C, with 
9cRA (Table 4.6).
The oligomerization of RXRα has been examined in more detail than 
ligand binding (Table 4.1).  We are aware of only two investigations of RXRα 
by AUC; one agrees well with our results despite the use of a slightly 
different construct and different assay conditions (265), while the other 
suggested a predominantly monomeric species (249), in disagreement with 
nearly all later publications.  Only a few quantitative reports for the dimer-
tetramer interaction exist, although they are quite different from ours (20 ± 
2 µM): for hRXRα(CDE), an approximate value of a few hundred micromolar 
has been reported (188), while for mRXRα(CDE) values of 4.4 nM and 2.8 
nM were found using fluorescence anisotropy (21, 257).  The lack of the 
DBD in our construct may explain our much lower affinity, as the DBD alone 
is known to oligomerize (7).  The Kd for the monomer-dimer equilibrium has 
also been reported for mRXRα(CDE): 155 nM (21), 130 nM (258), and 0.38 
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nM (269) in the absence of ligand, and 63 nM in the presence of 9cRA (258). 
The prior monomer-dimer results agree with our upper limit of 200 nM. 
Other differences between our results and prior work may be caused by the 
uniformity of our hRXRα(D E) following expression, which does not showᵦ  
non-equilibrium effects that have previously been reported (192, 201, 256).
The chemical denaturation data presented in Figures 4.13 and 4.14 
appears to be in agreement with the AUC oligomerization results, despite 
the lack of a quantitative analysis.  The difference in the baseline CD signal 
between 2 and 10 µM in the absence of 9cRA is suggestive of a decrease in 
the tetramer concentration in favor of the dimer, as would be expected; the 
lack of such a difference in the presence of 9cRA suggests an unchanged 
state, presumably a pure dimer  (21, 192, 201, 244, 248, 261, 262, 265, 266, 
269, 271, 272, 293, 294).
Prior work examining chemical denaturation of hRXRα(D E) used aᵦ  
model lacking a tetrameric species (269).  Whether by good planning or 
good fortune, our Kd for the dimer-tetramer reaction may justify their choice 
of model, as their concentration used during unfolding was low enough that 
at most a few percent of the receptor would have been tetrameric.  The use 
of an elevated temperature (30 °C) may have further reduced the tetramer 
component.  Our data do not justify eliminating the tetramer species from 
the model, but even a model excluding it does not provide a reliable fit to the 
data.
4.4.2 Correlations
Previous work has suggested a correlation between the affinity of a 
ligand and ΔTm of the receptor (331-333).  In the one case where a direct 
linear correlation has been drawn, using PPARγ, an R2 of 0.95 was found 
(333).  As shown in Figure 4.15A, there is a definite trend of increased ΔTm 
as affinity increases, but it is not a statistically significant correlation (R2 = 
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0.876, p = 0.07).  For the data measured in the presence of the LxxLL 
peptide, the correlation is significantly better (Figure 4.15B, R2 = 0.997, p = 
0.0014).  However, unlike previous work that only examined agonists, we 
find that this trend is true regardless of whether or not the ligand activates 
the receptor.  Only the affinity for the receptor seems to be important in 
determining the magnitude of ΔTm.  The ΔTm may serve as a reasonable 
proxy for affinity in the absence of a direct assay, but not necessarily activity. 
One caveat on this analysis is that the correlation uses only four data points, 
and it is not certain the trends would remain as strong in a larger data set.
Although a good correlation exists between the EC50 values (the 
concentration of ligand at 50% of the maximum activity) for and the Kd 
values for 9cRA, LG335, and OPBA, it is not statistically significant; atRA 
must be excluded because it does not activate RXRα.  The magnitude of the 
effect of the LxxLL peptide on the Kd values does not correspond to how 
effective the ligands are.  The inability to explain receptor activity by 
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Figure 4.15.  Linear correlations of hRXRα(D E) thermal stability andᵦ  
ligand affinity.  (A) Measurements in the absence of LxxLL peptide.  (B) 
Measurements in the presence of LxxLL peptide.  (Red lines, ▬) Linear fits.
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binding affinity could be due to our small sample size or the need to include 
more complex interactions (e.g., oligomerization).
4.4.3 Implications
We have presented an improved protocol for obtaining accurate Kd 
values for RXRα.  In addition, we have shown that fluorescence quenching is 
a general property of ligand binding to RXRα, and therefore can be used in 
place of more expensive assays.  Our results and review of prior work 
suggest that while full-length RXRα may have somewhat greater affinity for 
9cRA than hRXRα(D E), in general prior Kᵦ d estimates have been significantly 
too low.  The observation that the LxxLL peptide reduces the Kd may partly 
explain why assays done from mammalian cell lysates tend to have a lower 
reported Kd, as coactivator proteins will also be present in the lysate.
The chemical denaturation data suggests the monomer of hRXRα(D E)ᵦ  
is not highly stable, as approximately 3.5 M GdmCl is sufficient to yield the 
final unfolded state as measured by CD or fluorescence spectroscopy. 
Addition of 9cRA may eliminate some of the transitions (oligomeric states) 
during the unfolding process, but does not seem to cause an overall increase 
in thermodynamic stability.  Although the final transition in Figure 4.13 
(between 2.5 and 3.5 M GdmCl) may correspond to the monomer-unfolded 
equilibrium, it is also possible that the folded monomer does not exist in 
significant concentration at any time during the unfolding process.  The 
relatively shallow transition slopes (the transitions take place over a nearly 1 
M GdmCl concentration range) suggests that the transitions are not highly 
cooperative.
The correlation between ΔTm and Kd might be interpreted in light of a 
simple model whereby hRXRα(D E) becomes more rigid upon ligand binding,ᵦ  
and therefore less likely to denature.  Indeed, a reduction in flexibility upon 
ligand binding has been proposed as a general model for nuclear receptors 
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(41).  However, several lines of argument suggest something more complex 
may be occurring  First, some reports have examined the flexibility of 
hRXRα(E) in the presence of various ligands using hydrogen-deuterium 
exchange mass spectrometry (268, 272, 273, 275); as a whole, these reports 
have not found a strong correlation between ligand affinity and either the 
amount of exchange protection (i.e., reduction in flexibility) or the particular 
sites protected (near or remote from the binding pocket).  9cRA is still the 
highest affinity ligand known for RXRα, yet it does not cause the greatest 
degree of protection (275).  Second, similar results are observed 
crystallographically, where a comparison of hRXRα(E) bound to 9cRA and 
other ligands shows that lower affinity ligands actually have more receptor 
contacts than 9cRA (192).  Third, in-solution results suggest that the 
receptor retains a great deal of flexibility even when bound to ligand: 
although proteolysis experiments show increased resistance to proteases 
when mRXRα(CDE) is bound to 9cRA (248), NMR structures of hRXRα(E) in 
the presence and absence of 9cRA both show a great deal of flexibility (201). 
The apparent Tm is a value under the control of kinetic processes, so we 
suggest that instead of a global "more rigid" model, it is probable that some 
key process in the aggregation (which may or may not involve "unfolding") 
has a significantly reduced rate when ligand is bound.  This idea is further 
supported by the apparent lack of a thermodynamic stabilization of the 
receptor by 9cRA.
We have also shown unambiguously that hRXRα(D E) exists, at leastᵦ  
at micromolar concentrations, in a dimer-tetramer equilibrium.  Although 
the 20 µM dissociation constant is far higher than what might seem 
necessary to support claims of a physiological role for RXRα tetramers (262, 
271), we can make no observations regarding a (likely) reduction in the Kd 
when the additional domains in RXRα are present and interacting, or of 
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possible in vivo effects due to cellular crowding that may also tend to reduce 
the Kd.
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5CHAPTER 5
CHARACTERIZATION OF hRXRα(DᵦE) VARIANTS
5.1 Introduction
Although much effort has gone into finding new ligands for RXRα and 
understanding the effect of those ligands on the receptor's function, 
relatively little work has been performed from the alternate viewpoint: how 
does changing the receptor affect its function, self-association, and 
interactions with ligands?  This perspective allows us to ask more 
fundamental questions about the protein, such as which residues are critical 
in discriminating between ligands.  Phylogenetic analysis can provide 
somewhat similar information; the most ambitious effort to date has been 
performed using the mineralocorticoid and glucocorticoid receptors, where 
an extensive analysis suggests that the two receptors evolved from a single 
ancestor protein with the ability to bind both mineralocorticoid and 
glucocorticoid receptor ligands, but with mineralocorticoid receptor-like 
function (335).  On a smaller scale, a few studies have examined the 
biophysical effects of specific, naturally occurring mutations in RXRα (216, 
262, 265).
The Doyle laboratory has engineered a large number of hRXRα(E) 
variants, using a variety of techniques, with the goal of creating a variant 
protein that responds to a new ligand (216-221).  While many receptors have 
been found that are activated by the synthetic ligand LG335, and a few that 
are activated by OPBA, it is not immediately obvious why the mutations 
should cause the observed changes in ligand-dependent activation.  The 
simplest explanation is that the binding affinity of the variant receptors for 
the target ligand is higher than the wild-type affinity, but the effects of the 
mutations are not necessarily limited to ligand affinity.  Changes in DNA 
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binding affinity, oligomeric distribution, and coactivator recruitment are 
among the other possible effects.  Examples of these alternative effects have 
been shown most clearly for the androgen receptor.  Specific mutations in 
the androgen receptor have been shown to change the binding kinetics but 
not the overall Kd (336), significantly reduce the in vivo activity of the 
protein at elevated temperatures (337), and cause changes in coactivator 
interactions only for a specific ligand (338).
Therefore, we performed an extensive biophysical characterization on 
nine functional variants of hRXRα(D E) (see Table ᵦ 5.1) to try to understand 
what may be driving the observed changes in activity.  The variants, which 
have a wide range of EC50 and efficacy values (see Table 5.2), were also 
engineered using a variety of methods, including site-directed mutagenesis 
and genetic selection from two large libraries of engineered receptors.  The 
variants chosen have mutations throughout the binding pocket of 
hRXRα(D E) (see Figure ᵦ 5.1).
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Table 5.1. Mutations in hRXRα(D E) variants.ᵦ
Mutated Amino Acids
Variant I268 A272 Q275 I310 F313 L436 F439
AMAT A M A T
ASAF A S A F
VVLM V V L M
VVMSM V V M S M
SVM S V M
TLT T L T
CMI C M I
LMM L M M
IL I L
5.2 Materials and Methods
5.2.1 Materials
Materials were used as described in Section 4.2.1.  Proteins were 
expressed and purified as described in Section 3.2.3.  The mutations in each 
variant are shown in Table 5.1.  Yields were between 40 and 80 mg L-1 with 
> 95% purity for all variants except AMAT, which gave yields of only 10-15 
mg L-1 with purities of approximately 90%.
5.2.2 Ligand Binding
Binding assays were done as described in Section 4.2.2.  LG335 and 
9cRA binding constants were measured for all variants, while OPBA was 
measured only with the variants it is known to activate, SVM and TLT. 
Ligands with an affinity too low to reliably measured are given as a lower 
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Table 5.2.  Activity data for hRXRα(D E) variants in yeast.ᵦ
9cRA LG335 OPBA
Variant Ref.β
EC50
(nM)
Eff.α
(%)
EC50
(nM)
Eff.α
(%)
EC50
(nM)
Eff.α
(%)
WT (219) 100 100 300 10 70,000 20
AMAT (219) > 10,000 0 610 10 N.D.δ N.D.δ
ASAF (219) > 10,000 0 430 50 N.D.δ N.D.δ
VVLM (219) > 10,000 10 40 60 N.D.δ N.D.δ
VVMSM (219) > 10,000 10 680 30 N.D.δ N.D.δ
SVM (221) > 10,000 10 > 10,000 0 2000 100
TLT (221) > 10,000 0 > 10,000 0 3000 80
CMI (220) > 10,000 10 1000 100 N.D.δ N.D.δ
LMM (221) 600 90 20 190 N.D.δ N.D.δ
IL (220) N/Aγ N/Aγ N/Aγ N/Aγ N.D.δ N.D.δ
α Eff. = Efficacy, relative to wild-type hRXRα and 9cRA.
β Ref. = Reference.
γ N/A = Not applicable: receptor is active without ligand (although it is 
further activated by ligands).
δ N.D. = No data.
limit of the Kd, as described in Section 4.3.1.  For a few ligand-receptor 
pairs, the presentation of symmetric errors for Kd values implied inclusion of 
"0 nM" as statistically possible, and so the asymmetric errors are shown for 
these values.  See Sections 6.2 and 6.3.1 for details.
5.2.3 Thermal Denaturation
Thermal denaturation was monitored by CD spectroscopy and DSC as 
described in Section 4.2.4.  The effect of OPBA on the Tm was only measured 
for variants known to be activated by it.
5.2.4 Self-Association
Equilibrium AUC was performed as described in Section 4.2.3.  The 
partial specific densities and molecular masses of the variant are shown in 
Table 5.3.  The limits for monomer-dimer and dimer-tetramer equilibria were 
extracted from the monomer-tetramer fit for a few variants using Equation 
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Figure 5.1.  Residues mutated in at least one hRXRα(D E) variant.ᵦ   9cRA is 
represented as the semi-transparent spheres.  Wild-type amino acids are 
shown.  For clarity, only helices 3, 5, and 11 are visible.  As shown, A272, 
Q275, and L436 are partially or completely behind the ligand.  Image 
constructed from Protein Databank entry 1FBY (190).
F439
L436
I268
A272
Q275
F313
I310
5.1:
K d1,4=K d 1,22 K d 2,4=n2 K d2,43  (5.1)
where Kd1,4 is the monomer-tetramer dissociation constant; Kd1,2 is the 
monomer-dimer dissociation constant; Kd2,4 is the dimer-tetramer 
dissociation constant; and n is the minimum ratio of Kd1,2 to Kd2,4.  For these 
calculations, the error estimates were applied in the most conservation 
fashion, so the Kd2,4 threshold was calculated assuming 1 SD positive error, 
while Kd1,2 was calculated assuming 1 SD negative error, with the result that 
the actual difference in the thresholds is less than n.  We used an n of 100, 
which implies a dimer concentration below the level of reliable detection 
(5%).
5.2.5 Chemical Denaturation
Chemical denaturation was monitored by CD spectroscopy, as 
described in Section 4.2.5.
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Table 5.3.  Physical data for hRXRα(D E) variants.ᵦ
Variant
v α
(ml mg-1)
Molecular Mass
(Da)
AMAT 0.7367 29,034
ASAF 0.7366 29,036
VVLM 0.7389 29,145
VVMSM 0.7374 29,136
SVM 0.7382 29,132
TLT 0.7384 29,130
CMI 0.7387 29,115
LMM 0.7382 29,148
IL 0.7398 29,078
α Partial specific volume.
5.2.6 Data Analysis
Nonlinear and linear data analysis was performed as described in 
Section 4.2.6.
5.2.7 Prediction of Key Residues
Our approach to identifying potentially key residues was modeled 
after prior work (339-341).  In short, we applied a nonlinear least squares 
analysis to Equation 5.2:
G=∑
i=1
n
X ici  (5.2)
where n is the total number of mutations in all variants; Xi is either 0 or 1 to 
indicate the absence or presence, respectively, of mutation i in the current 
variant; and ci is the numerical constant representing the effect of mutation 
i.  The experimental ΔΔG for each variant was calculated according to 
Equation 5.3:
G=RT lnvarwt   (5.3)
where R is the universal gas constant; T is the temperature in Kelvin; Θvar is 
the measured value for the variant; and Θwt is the measured value for wild-
type hRXRα(D E).  Efficacy and ECᵦ 50 data were used for Θ as described in 
Section 5.3.5, and T was set to 303 K, as the yeast cells were grown at 30 
°C.  As discussed in Section 5.3.5, there were more variables (mutations) 
than data points (sequenced variants), so nonlinear least squares produced 
infinite solutions of equal statistical validity.  To produce a single solution, 
we fit the data 50 times starting from random initial guesses and the 10 best 
solutions, as evaluated by χ2 (to eliminate solutions trapped in a non-
equivalent local minima), were kept.  An estimate for each ci was calculated 
by taking the mean and standard deviation of the ten solutions.  A particular 
estimate was considered robust if it met the following criteria: (i) the 
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elimination of various combinations of two or more variants from the fit data 
did not lead to a significantly different prediction; (ii) the sign of the 
parameter was the same for all ten best fit solutions; and (iii) the estimated 
value was at least two standard deviations from zero.
The variants were constructed using standard QuikChange® 
mutagenesis protocols, and the function evaluated in yeast as described 
elsewhere (219, 220).
5.3 Results
5.3.1 Ligand Binding
Fluorescence quenching data to obtain ligand binding constants for 
each receptor-ligand pair are shown in Figure 5.2.  The Kd values for each 
pair are shown in Table 5.4, as are wild-type values for comparison.  All 
variants had reduced affinity for 9cRA compared to wild-type; the largest 
reduction is at least 40-fold.  Four variants, AMAT, VVLM, SVM, and LMM, 
had significantly greater affinity for LG335 than wild-type hRXRα(D E),ᵦ  
while two variants, ASAF and CMI, had significantly reduced affinity. 
Neither variant activated by OPBA had high enough affinity for the Kd to be 
measured confidently; the lower boundaries on the Kd are similar to wild-
type hRXRα(D E).ᵦ
All variants were fit to a single-binding model assuming one binding 
site per monomer independent of the actual oligomeric state, but a few 
variant-ligand pairs do not seem to be adequately fit by this model.  The 
most extreme example is LMM, especially with LG335, where the shape of 
the data are suggestive of two binding events and the fit line is apparently 
missing the higher concentration data completely (see Figures 5.2 and 5.3). 
However, only a small number of variant-ligand pairs have significantly 
improved fits with alternative models, the consistency of results when those 
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Figure 5.2.  Ligand binding data and fits for 50 nM hRXRα(D E) variants.ᵦ  
(Black box, ■) 9cRA.  (Blue diamond, ◆) LG335.  (Green triangle, ▲) OPBA. 
(Red lines, ▬) Best fit curves.  The upper limit of data collection is 8000 nM 
or at least 40*Kd.
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models were applied is poor, and no strong statistical justification exists for 
alternative models (as described in Section 4.3.1).  Therefore, we continued 
to apply only the simplest model.  Without additional information, it is not 
possible to determine whether the deviations in the data are due to an actual 
difference in the binding mode, or instead reflect a more complex tertiary 
structure change upon ligand binding that results in deviations from the 
expected quenching behavior.
The affinity for all ligand-receptor pairs was also measured in the 
presence of a fixed concentration (20 µM) of LxxLL peptide; data are 
presented in Figure 5.3 and Table 5.5.  Unlike the wild-type hRXRα(D E),ᵦ  
most ligand-variant pairs did not have a significant decrease in the Kd in the 
presence of the LxxLL peptide: only ASAF, TLT, and IL had increased affinity 
for LG335, and CMI and IL for 9cRA.  Although the lower limit of the Kd for 
TLT and SVM with OPBA is decreased, it is not possible to conclusively state 
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Table 5.4.  Ligand binding parameters for hRXRα(D E) variants.ᵦ
9cRA LG335 OPBA
Variant Kd (nM)
Max 
Quench 
(%) Kd (nM)
Max 
Quench 
(%) Kd (nM)
Max 
Quench 
(%)
WTα 70 ± 20 84 ± 4 370 ± 100 83 ± 5 > 3800 65
AMAT > 2800β 60 16 ± 7γ 68 ± 3
ASAF 600 ± 200β 69 ± 6 800 ± 300β 73 ± 6
VVLM 160 ± 40β 86 ± 4 80 ± 40γ 71 ± 5
VVMSM 360 ± 70β 89 ± 4 580 ± 170 80 ± 5
SVM 280 ± 80β 85 ± 4 40 ± 30γ 63 ± 5 > 3700 70
TLT 1400 ± 700β 76 ± 10 1100 ± 700 72 ± 12 > 2900 70
CMI 610 ± 150β 86 ± 5 1100 ± 400β 92 ± 8
LMM 130 ± 30β 89 ± 3 60 (+60, -25)γ 67 ± 7
IL 360 ± 80β 87 ± 4 600 ± 400 75 ± 8
α For comparison purposes; see Section 4.3.1.
β Significantly lower affinity than wild-type.
γ Significantly greater affinity than wild-type.
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Figure 5.3.  Binding data and fits for 50 nM hRXRα(D E) variants in theᵦ  
presence of 20 µM LxxLL peptide.  (Black box, ■) 9cRA.  (Blue diamond, ◆) 
LG335.  (Green triangle, ▲) OPBA.  (Red lines, ▬) Best fit curves.  The upper 
limit of data collection is 8000 nM or at least 40*Kd.
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that the Kd has decreased.  As was observed for wild-type hRXRα(D E),ᵦ  
variant-ligand pairs tested with a higher concentration of LxxLL peptide did 
not have significant differences from measurements made with 20 µM 
LxxLL.  Figure 5.4 shows the shift in Kd values due to the LxxLL peptide 
graphically, where ligand-receptor pairs with significantly changed affinity 
(due to the peptide) are below the red line.
5.3.2 Thermal Stability
All variants irreversibly denatured into apparently similar, β-sheet-like 
aggregates upon heating.  The variants span a 20 °C range of apparent Tm 
values (Table 5.6).  Most variants were more stable (higher apparent Tm) 
than wild-type, although ASAF was significantly less stable.
Table 5.6 also shows the ΔTm for each variant-ligand pair.  All variants 
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Table 5.5.  Ligand binding parameters for hRXRα(D E) variants in theᵦ  
presence of 20 µM LxxLL peptide.
9cRA LG335 OPBA
Variant Kd (nM)
Max 
Quench 
(%) Kd (nM)
Max 
Quench 
(%) Kd (nM)
Max 
Quench 
(%)
WTα 35 ± 14β 75 ± 4 110 ± 30β 71 ± 3 > 3800 55
AMAT > 3500 55 9 (+10, -4.4) 69 ± 5 N.D.γ N.D.γ
ASAF 600 ± 300 63 ± 6 110 ± 50β 59 ± 3 N.D.γ N.D.γ
VVLM 240 ± 90 84 ± 5 70 ± 50 68 ± 6 N.D.γ N.D.γ
VVMSM 600 ± 300 81 ± 8 460 ± 120 70 ± 4 N.D.γ N.D.γ
SVM 210 ± 80 78 ± 4 20 ± 14 62 ± 4 > 1900 70
TLT 600 ± 200 69 ± 5 280 ± 110β 72 ± 5 > 2000 55
CMI 270 ± 80β 81 ± 4 600 ± 200 87 ± 7 N.D.γ N.D.γ
LMM 130 ± 60 86 ± 5 40 (+40, -16) 72 ± 6 N.D.γ N.D.γ
IL 70 ± 20β 80 ± 4 26 ± 19β 64 ± 6 N.D.γ N.D.γ
α For comparison purposes; see Section 4.3.1.
β Significantly greater affinity than in the absence of LxxLL peptide.
γ N.D. = No data.
were less stabilized by 9cRA than was wild-type hRXRα(D E).  AMAT wasᵦ  
apparently destabilized by 9cRA, although the immediate cause for this is 
not clear, as experiments performed by neither CD spectroscopy nor DSC 
gave any clear indication of ligand binding to the denatured state.  OPBA did 
not stabilize either SVM or TLT, but, similarly to wild-type hRXRα(D E),ᵦ  
showed evidence of the ligand binding to the aggregate state.  Only one 
variant, TLT, was less stabilized by LG335 than wild-type hRXRα(D E).ᵦ  
AMAT, ASAF, and VVLM were all significantly more stabilized by LG335 than 
wild-type hRXRα(D E).ᵦ
The effect of the LxxLL peptide on variant Tm values was quite diverse 
(see Table 5.7).  Only one variant, VVLM, was significantly stabilized by the 
LxxLL peptide alone.  As with wild-type hRXRα(D E), the certainty in theᵦ  
apparent Tm is relatively poor.  ASAF and IL had an additional increase, 
beyond that of the ligand alone, in the 9cRA ΔTm when the LxxLL peptide 
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Figure 5.4.  Effect of the LxxLL peptide on ligand affinity for hRXRα(D E)ᵦ  
variants.  (Red line, ▬) Visual indicator of region of no significant change. 
(Black boxes, ■) Ligand-receptor pairs that do not have significant 
differences in assays with and without LxxLL peptide.  (Blue diamonds, ◆) 
Ligand-receptor pairs that have significantly higher affinity when the LxxLL 
peptide is present.
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was added.  AMAT had a significant decrease.  The ΔTm with LG335 
significantly decreased for two variants, AMAT and VVLM, in the presence of 
the LxxLL peptide; unlike wild-type hRXRα(D E), none had an increase.ᵦ
5.3.3 Self-Association
The nine variants were each examined by AUC at three concentrations 
and three speeds.  Like the wild-type protein, most of the variants showed 
evidence of significant non-specific aggregation at speeds greater than 
12,000 rpm.  For consistency, the results presented here use only the 12,000 
rpm, although adding the 16,000 and 20,000 rpm data to the fits does not 
change the qualitative results.  Raw data and best fits are shown in Figure 
5.5.  Table 5.8 lists the specific models that were chosen for the variants, 
and the resulting fit parameters.
99
Table 5.6.  Thermal stabilities and effects of ligands for hRXRα(D E)ᵦ  
variants.
+9cRA +LG335 +OPBA
Variant Tm (°C) ΔTm (°C)α ΔTm (°C)α ΔTm (°C)α
WTβ 55.0 ± 0.7 6.3 ± 0.8ε 3.9 ± 0.7ε -1.2 ± 2.1
AMAT 55.8 ± 0.6 -1.1 ± 0.6 6.8 ± 0.7ε N.D.ζ
ASAF 45.7 ± 0.6γ -0.4 ± 0.9 5.4 ± 0.7ε N.D.ζ
VVLM 64.2 ± 1.0δ 2.2 ± 0.9ε 7.3 ± 1.0ε N.D.ζ
VVMSM 54.3 ± 0.3 1.9 ± 1.1 2.4 ± 0.5ε N.D.ζ
SVM 56.4 ± 0.8 1.6 ± 1.0 4.7 ± 1.2ε 0.7 ± 1.1
TLT 58.8 ± 0.6δ -0.3 ± 1.3 0.5 ± 0.9 0.0 ± 1.3
CMI 62.0 ± 1.8δ 2.6 ± 2.9 2.1 ± 2.0 N.D.ζ
LMM 66.0 ± 1.9δ 1.9 ± 1.4 5.5 ± 1.4ε N.D.ζ
IL 59.9 ± 0.8δ 1.6 ± 1.4 5.3 ± 1.4ε N.D.ζ
α ΔTm indicates the change in Tm due to the presence of ligand.
β For comparison purposes; see Section 4.3.3.
γ Stastically significantly lower Tm than wild-type.
δ Stastically significantly greater Tm than wild-type.
ε Stastically significant increase in Tm due to ligand.
ζ N.D. = No data.
Variants were fit to a variety of a models, and the simplest (fewest 
species) model giving a reasonable fit was chosen.  We defined reasonable to 
mean that the quality of the fit was not statistically improved by inclusion of 
additional species in the model.  The results from these fits are consistent 
with qualitative results observed by native PAGE.  For the variants best fit by 
the dimer-tetramer model, the lower limit for reliable measurement of the 
monomer-dimer Kd was approximately 0.2 µM, given the noise in the 
measurements and concentrations used.  0.2 µM is therefore an upper limit 
on the Kd for these variants (SVM and IL), as well as both the dimer-tetramer 
and monomer-dimer constants for VVLM.  The most likely explanation for 
the variants best fit by a monomer-tetramer model is that the dimer forms 
the tetramer more readily than the monomer forms the dimer, and therefore 
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Table 5.7.  Thermal stabilities and effects of ligands for hRXRα(D E)ᵦ  
variants in the presence of 20 µM LxxLL peptide.
+9cRA +LG335 +OPBA
Variant ΔTm (°C)α ΔTm (°C)α ΔTm (°C)α ΔTm (°C)α
WTβ 3.3 ± 2.3 6.8 ± 1.2δ 5.8 ± 1.1δ 1.9 ± 1.3
AMAT 0.0 ± 0.8 -4.6 ± 1.0ε 4.5 ± 0.8δ N.D.ζ
ASAF 2.9 ± 2.1 3.8 ± 1.0δ 4.7 ± 0.7δ N.D.ζ
VVLM 2.7 ± 1.2γ 0.6 ± 1.0 4.7 ± 1.1δ N.D.ζ
VVMSM 0.5 ± 1.5 4.0 ± 0.8δ 2.6 ± 0.6δ N.D.ζ
SVM 3.1 ± 1.8 1.6 ± 0.7δ 4.1 ± 0.7δ 1.4 ± 1.0
TLT 0.8 ± 0.7 0.1 ± 1.1 1.1 ± 1.0 0.9 ± 1.3
CMI 2.7 ± 2.9 2.2 ± 2.6 -0.5 ± 1.9 N.D.ζ
LMM -0.2 ± 2.7 1.5 ± 1.2 3.5 ± 1.6δ N.D.ζ
IL -0.1 ± 1.7 4.4 ± 1.1δ 5.1 ± 1.2δ N.D.ζ
α ΔTm indicates the change in Tm due to the presence of lxxll peptide and 
ligands.
β For comparison purposes; see Section 4.3.3.
γ Stastically significant increase in Tm due to LxxLL peptide.
δ Stastically significant increase in Tm due to ligand and LxxLL peptide.
ε Stastically significant decrease in Tm due to ligand and LxxLL peptide.
ζ N.D. = No data.
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Figure 5.5.  AUC data for hRXRα(D E) variants and fits.ᵦ   (Red lines, ▬) Best 
fits.  See text for specific models.
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Figure 5.5 (continued)
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the dimer is present only in very low concentrations (see Section 5.2.4 for 
details).  The relatively large uncertainty in the best-fit Kd values for CMI 
and LMM arises because the monomer-tetramer Kd includes the 
uncertainties for both the monomer-dimer and dimer-tetramer transitions.
The ASAF variant is best fit by a monomer-tetramer model, but the 
residual patterns and large error estimates for the variant indicate that even 
this model is not entirely adequate.  The poor fit (of any model) is probably 
due to the formation of higher-order aggregates, which are apparent in 
native PAGE experiments (data not shown) and suggested by the residual 
patterns.
The AMAT variant was the only variant to have an average molecular 
mass below that of a dimeric species, due primarily to a greatly reduced 
monomer-dimer affinity.  The much higher fraction of monomer for this 
variant than the others may explain why it is isolated with much lower yield 
and purity.  Monitoring fractions taken during purification of AMAT suggest 
a lower affinity for the metal resin, as significant AMAT was apparent in all 
the wash fractions (data not shown).
5.3.4 Chemical Denaturation
Variants were denatured using GdmCl and the unfolding monitored by 
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Figure 5.5 (continued)
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CD spectroscopy.  Resulting data are shown in Figure 5.6.  As discussed in 
Section 4.3.4, the data cannot be reliably fit to produce unique quantitative 
parameters.  Qualitatively, the data support the basic analysis put forward in 
Section 4.4.2, and are consistent with the AUC results for each variant. 
AMAT, which was predominantly a mixture of monomer and dimer, also had 
the least intense baseline in low GdmCl.  VVLM, which was essentially pure 
tetramer, had the most intense baseline.  However, a direct correlation 
between the the baseline intensity and the species distribution was not 
possible for all variants.  Although the first GdmCl-induced transitions for 
each variant varied considerably, the variants apparently lacking a dimeric 
state (ASAF, CMI, and LMM) had apparent transitions at the lowest 
concentrations of GdmCl.  No variant was apparently more or less 
thermodynamically stable overall than is the wild-type receptor, as all 
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Table 5.8.  Global fit parameters of AUC data for hRXRα(D E) variants.ᵦ
Kdα
Variant
Average 
Molecular 
Mass (kDa) Best Modelα
T  4M⇋
(µM3)
T  2D⇋
(µM)
2D  4M⇋
(µM)
WTβ 80.0 ± 1.1 2D  T⇌ 20 ± 2 < 0.2
AMAT 52.2 ± 1.8 4M  2D  T⇌ ⇌ 13 ± 2γ 40.7 ± 0.4δ
ASAF 103 ± 4 4M  T⇌ 13 ± 12 < 0.14γ > 5δ
VVLM 113 ± 3 T < 0.2γ < 0.2
VVMSM 94.6 ± 1.8 4M  2D  T⇌ ⇌ 1.39 ± 0.01γ 1.32 ± 0.01δ
SVM 67.6 ± 1.8 2D  T⇌ 90 ± 20δ < 0.2
TLT 65.7 ± 1.5 4M  2D  T⇌ ⇌ 70 ± 7δ 0.254 ± 0.005δ
CMI 97 ± 3 4M  T⇌ 49 ± 19 < 0.19γ > 14δ
LMM 100 ± 4 4M  T⇌ 15 ± 12 < 0.14γ > 7δ
IL 77 ± 2 2D  T⇌ 30 ± 6δ < 0.2
α M = Monomer, D = Dimer, T = Tetramer.
β For comparison purposes; see Section 4.3.2.
γ Statistically significant greater tendency to form oligomer than wild-type.
δ Statistically significant smaller tendency to form oligomer than wild-type.
variants were fully unfolded between 3 and 3.5 M GdmCl.
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Figure 5.6.  Guanidinium chloride induced unfolding of 10 µM hRXRα(D E)ᵦ  
variants.  Monitored using CD spectroscopy at 222 nM.
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5.3.5 Prediction and Testing of Key Residues
A great aid to engineering functional variants would be the ability to 
identify individual mutations that are beneficial for the desired effect.  Fox 
and coworkers recently reported on a straightforward approach based on 
linear combinations and partial least squares analysis (339-341).  We applied 
this approach to a selection of variants to determine if the approach was 
useful for our system, with two important caveats: (i) the approach assumes 
the effects of mutations are essentially additive (i.e., independent and 
cumulative), which is reasonable for most proteins at most residues (342, 
343) but has not been verified for nuclear receptors; and (ii) reliable analysis 
requires the ratio of data points (sequenced variants) to observed individual 
mutations should be at least 3.  The ten variants in Table 5.2 (including wild-
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Table 5.9.  Activity data for extra hRXRα(D E) variants in yeast.ᵦ
9cRAα LG335α
Variant
EC50
(nM)
Eff.β
(%)
EC50
(nM)
Eff.β
(%)
I268M; I310V; F313L; L436A > 10,000 0 60 70
I268A; A271S; A272S; I310M; F313L > 10,000 0 100 100
I268V; A271S; I310V; F313V; L436V > 10,000 0 200 80
A271S; A272T; I310S; F313L; L436A > 10,000 0 200 40
I268A; I310A; F313A; L436F > 10,000 0 220 70
I268A; A271S; I310V; F313V; L436V > 10,000 0 300 140
I268V; I310V; F313S > 10,000 0 440 10
I268A; I310S; F313V; L436F > 10,000 10 470 60
I268L; A271V; I310L; F313L > 10,000 0 530 20
I268A; A272V; I310A; F313A; L436F > 10,000 0 530 30
I268L; I310M; F313V > 10,000 20 610 20
I268V; A271V; I310L; F313V > 10,000 0 650 10
I268L; I310V; F313I > 10,000 0 2000 10
α All data from (221).
β Eff. = Efficacy, relative to wild-type hRXRα and 9cRA.
type) contain twenty mutations, for a ratio of 0.5.  To improve the ratio, we 
discarded the CMI and IL variants, which contain several mutations not 
present in other variants, and added the additional variants shown in Table 
5.9, for a total of 20 sequences and 26 mutations (0.77 ratio).  See Section 
5.2.7 for additional details of analysis.
Table 5.10 shows the tested predictions: the I268A and I310L 
mutations, and the variant containing both.  The actual outcomes are also 
shown in Table 5.10, and deviate significantly from the predictions.  The 
I268A variant had reduced 9cRA activity, but less than predicted, while the 
effect on LG335 activity was much stronger than predicted.  The predictions 
for the I310L variant underestimated the actual effect on the 9cRA activity, 
and predicted precisely the opposite effect of the actual observations for 
LG335.  The predictions for the double mutant were also quite different from 
the experimental results.
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Table 5.10.  Predictions and actual effects of individual mutations.
9cRA LG335
Variant Value Type EC50 (nM) Eff.α (%) EC50 (nM) Eff.α (%)
Wild-type Experimental 100 100 300 10
I268A Predicted 1000β 30β 300 10
I268A Experimental 1000 80γ > 10,000γ 0γ
I310L Predicted 100 20β 3β 90β
I310L Experimental > 10,000γ 0γ > 10,000γ 0γ
I268A; I310L Predicted 1000β 10β 3β 90β
I268A; I310L Experimental > 10,000γ 0γ > 10,000γ 0γ
α Eff. = Efficacy.
β Predicted to be a change from wild-type.
γ Experimental result differs from prediction.
5.4 Discussion
5.4.1 Comparison to Prior Work
Relatively few reports on the biophysical characterization of RXRα 
variants exist.  Of the work that has been performed, relatively little 
overlaps with the mutations in our variants.  One prior report examined a 
large number of mutations in the 413-443 region of hRXRα, but only in the 
context of DNA binding (246).  Another report indicated that activation 
function domain 2 is not essential for ligand binding (263).  Many residues 
on the protein surface involved in homo- and heterodimerization have been 
mutated to alanine, with some mutants significantly disrupting self-
association of mRXRα (277).  The IL variant has been reported to have a 
lower limit Kd for 9cRA binding at least three times greater than the wild-
type Kd (216), which agrees well with our observations (70 ± 20 nM for wild-
type, 360 ± 80 nM for IL).
The F313A mutation (which is naturally occurring at the 
corresponding residue 318 in mRXRα), has been reported to reduce 9cRA 
affinity approximately 3-fold, while the F313I mutation has a smaller effect 
(254).  The variants containing any of these mutations show a wide range of 
Kd values for 9cRA.  F313A is also known to impair formation of the tetramer 
(262, 265).  Our variants containing this mutation, AMAT and ASAF, had 
different self-association tendencies: AMAT is impaired in dimer, but not 
tetramer, formation, while ASAF has a tendency to form higher-order 
oligomers.  These results, and the other variation in oligomeric behavior in 
our variants, suggest that oligomerization of hRXRα(D E) is influenced byᵦ  
several binding pocket residues working in a non-additive manner, such that 
the mutations have a combined effect that is not the sum of the individual 
effects.  This non-additivity has been previously observed in the residues 
that are part of the dimer interface: combining multiple alanine mutations 
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that individually disrupted dimer formation resulted in a variant with 
dimerization behavior similar to wild-type (277).  The complete failure of our 
attempt to identify especially critical residues regulating ligand-dependent 
activity also suggests a high degree of non-additivity in binding pocket 
residue effects.  The apparent relative lack of cooperativity in the GdmCl-
induced unfolding also suggests a flexible structure that can adopt a range 
of energetically similar conformations.
Long-range effects of ligand binding have been reported in other 
nuclear receptors, such as ligand-specific effects on DNA and coactivator 
interactions (13, 14, 16, 17, 338, 344-353), oligomerization changes in RXRα 
(21, 201, 258, 265, 266, 294), and an example of binding of a ligand to RXRα 
inducing an active conformation in an unliganded heterodimer partner 
(354).  The flexibility of nuclear receptors is demonstrated by the large 
changes in the ligand binding pocket to accommodate ligands (355-359), and 
is apparent from the NMR structures of hRXRα(E) (201) and peroxisome 
proliferator-activated receptor γ (360).  More than half of the RXRα, RXRβ, 
and USP crystal structures contain large regions of very poor electron 
density (189, 190, 192, 194, 199, 200, 202-208), which indicates significant 
disorder; these are in addition to the first and last few amino acids that are 
not visible in any structures.  Our results highlight that the binding pockets 
of nuclear receptors are complex regulatory mechanisms that trigger 
multiple, long-range allosteric effects upon ligand binding or introduction of 
mutations.  At least two previous reports have attempted to identify the 
specific allosteric sites and "network" of residues allowing for the long-range 
effects (361, 362).
5.4.2 Correlations
As observed for wild-type hRXRα(D E), the ΔTᵦ m of the ligand-receptor 
pairs correlates quite well with the corresponding Kd values.  Figure 5.7 
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shows the correlations, for values measured both in the absence and 
presence of the LxxLL peptide.  The trends are significant: without the 
LxxLL peptide, R2 = 0.600 and p < 0.001; with the peptide, R2 = 0.492 and p 
< 0.001.  These correlations suggest that the ligands serve as important 
structural elements in the receptors.  Some of the scatter in the data is due 
to the comparison of kinetic (thermal denaturation) and thermodynamic 
(ligand binding)data, but the trend is still clear.
A significant correlation between activity of a protein and the binding 
affinity of a ligand has previously been reported (363), although the proteins 
involved were not nuclear receptors and the correlation only held over a 
narrow range of Kd.  Another report demonstrated a strong correlation 
between ligand binding and heterodimerization (as a proxy for function) 
with the ecdysone receptor (364).  A problem when attempting to correlate 
EC50 and Kd is that several receptors do not have a clear EC50 with some 
ligands (e.g., all variants except LMM with 9cRA).  Although we did not 
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Figure 5.7.  Linear correlations of thermal stability and ligand affinity for 
hRXRα(D E) variants.ᵦ   Data includes the wild-type receptor.  (A) 
Measurements in the absence of LxxLL peptide.  (B) Measurements in the 
presence of LxxLL peptide.  (Red lines, ▬) Linear fits.
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explicitly test for it, antagonism of any sort (i.e., a ligand that inhibits the 
receptor) would also be an exception to an EC50 vs. Kd correlation.  An 
additional problem is that although preliminary results suggest that the 
concentration of LG335 in the medium (used to calculate the EC50) is similar 
to that inside the cell (221), OPBA is significantly more soluble in the 
presence of cells than in buffer alone, suggesting absorption into the 
membrane and possibly an increase in intracellular concentration.  Although 
the EC50 does have a statistically significant correlation with Kd when all 
data is included (R2 = 0.26, p = 0.02), the trend is not strong.
An alternative approach is to exclude those ligands which do not have 
a clear EC50 value, which is equivalent to only using those ligands-receptor 
pairs in which the ligand is clearly an agonist.  The correlation of Kd with 
EC50 for this subset is shown in Figure 5.8A (R2 = 0.550, p = 0.006), which 
required discarding nearly half the data.  Binding data obtained in the 
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Figure 5.8.  Linear correlations of EC₅₀ and ligand affinity for hRXRα(D E)ᵦ  
variants.  Data includes the wild-type receptor.  Only ligand-receptor pairs 
where the ligand has clear agonist activity are included.  (A) Ligand affinity 
in the absence of LxxLL peptide.  (B) Ligand affinity in the presence of 
LxxLL peptide.  (Red lines, ▬) Linear fits.
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presence of the LxxLL peptide, which might be expected to better model in 
vivo conditions, is not significantly better than the data in its absence (see 
Figure 5.8B; R2 = 0.594, p = 0.003).  These incomplete correlations suggest 
that additional processes are important in determining activity.
Efficacy does not correlate with Kd values, with or without the LxxLL 
peptide.  The oligomeric distribution of the variants does not correlate well 
with any other property (Kd, Tm, EC50, or efficacy).
Only Kd of only three variants changed in to the presence of the LxxLL 
peptide: CMI, IL, and ASAF.  The lack of effect in most mutations may be 
related to a recent suggestion that ligands for RXRα may shift AF-2 into an 
optimal conformation (202).  The specific mutations in the CMI and IL 
variants (which correspond to the residues present in human retinoic acid 
receptor γ) may be critical for LxxLL interactions.  The mutations in CMI 
and IL are not present in the other variants except for I310M, despite the 
possibility for the F313I mutation in the library-selected variants.  An 
additional indication of a crucial LxxLL interaction is that the IL variant had 
significant background (i.e., activity in the absence of ligand) activity in 
chemical complementation assays, but only when a human coactivator is 
used as part of the genetic selection system (218, 220).  ASAF contains the 
naturally occurring F313A mutation, which has also been shown to trigger 
constitutive activity (254).  Taken together, these results suggest that F313 
may be crucial in ligand-coactivator allostery, and that the behavior is also 
modulated by other binding pocket residues.
The poor correlations between the ligand binding affinities and the 
activity (EC50 or efficacy) of the variants suggests that, in general, ligand 
binding is necessary but not sufficient for hRXRα activation.  A corollary to 
this result is that selections or screens should operate directly on the 
property of interest (generally activity) rather than a proxy (such as ligand 
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affinity), because several properties interact to give rise to activity.
5.4.3 Implications
hRXRα has a highly flexible, dynamic structure. The inability to 
predict the effect of individual mutations, and the clearly non-additive 
behavior of multiple mutations, suggests that studies identifying specific 
mutations as having a particular effect are somewhat limited: a mutation 
may have a particular effect when it is the only mutation, but introducing a 
second mutation may cause radically different behavior from either mutation 
alone.  As this non-additivity occurs through the LBD of hRXRα, all 
assignments of function to particular residues or regions may only be 
appropriate in a particular context (i.e., in the presence of other specific 
residues).
For future design or engineering of hRXRα, and likely nuclear 
receptors in general, the results we have presented are both a reason to be 
optimistic and pessimistic.  On the pessimistic side, it appears that hRXRα is 
nearly the polar opposite of antibodies, which are essentially rigid bodies 
that recognize a ligand based on a relatively fixed shape.  Simply 
"reshaping" the binding pocket of hRXRα to prepare it for a new ligand is 
unlikely to be successful, as the long-range effects of the binding pocket 
mutations will be significant.  Our results also suggest that while the impact 
of individual mutations in a purely wild-type background can be 
characterized, the effects of the mutations will not be additive and the 
outcome of multiple mutations is not easy to predict
On the other hand, our results indicate that hRXRα is relatively 
tolerant of mutations and quite adaptable.  These traits suggest that hRXRα 
can likely to be mutated to bind a wide variety of ligands while retaining 
function.  The challenge will lie in creating an appropriate library to select 
the desired variant from, and in selecting directly for the desired property. 
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We suggest that libraries containing many sites (at least three) 
simultaneously mutated, rather than an incremental approach, is more likely 
to be successful, as mutations that are beneficial early in an iterative 
approach may prove to be detrimental later.  In addition, primarily to 
maintain a reasonable library size, design of libraries should be targeted 
explicitly to the small molecule of interest, and only appropriate mutations 
allowed at each residue, such that the mutations complement the polar and 
hydrophobic regions of the small molecule.
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6CHAPTER 6
NONLINEAR DATA ANALYSIS
6.1 Introduction
Analysis of biochemical data by least-squares analysis is now quite 
common, and manuscripts have been published that detail the procedure 
and when it should be applied (312, 313).  Least-squares provides a 
statistically rigorous method of obtaining a "best" fit to data, provided that 
certain criteria are met.  The general formula for minimization using least-
squares is given by Equation 6.1, which is the weighted sum of residuals 
squared:
2=W∑
i=1
N Y xi−f xi, ai 
2
 (6.1)
where W is a uniform weighting factor; N is the number of data points; Y(xi) 
is the Y value corresponding to the independent value xi; f(xi,a) is the 
function being evaluated at point xi using parameter set a; and σi is the 
standard deviation of the measured value Y(xi).  χ2 is evaluated in an 
iterative process, with the use of an appropriate algorithm to drive the fit 
toward a small value in each iteration.  Alternative methods, such as robust 
parameter estimation (which uses a power other than two, or the absolute 
value, for the residuals), avoid some of the limitations of least-squares 
analysis, but are not as well characterized statistically (327, 365-367).
Perhaps the most commonly ignored criteria for using least-squares 
methods are: (i) the noise in the system must be Gaussian; and (ii) that all 
the uncertainty in measurements must be in the dependent (y) variables. 
Probably the most common technique of data fitting where least-squares is 
implicitly used incorrectly is when nonlinear data are linearized (312, 313, 
324, 327), such as in Scatchard (325) or Cogan (326) plots.  These types of 
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plots violate the principle of Gaussian noise by fitting the inverse of the data, 
which is a problem because a Gaussian distribution does not remain 
Gaussian when the inverse is taken.  In addition, some of these linearizations 
divide the uncertainty in the measurements across both the dependent and 
independent variables.  The net result is that nonlinear data fit by a linear 
method is statistically invalid, and in many cases is both quantitatively and 
qualitatively incorrect.
Numerous algorithms exist for generating a best fit.  The most 
common when applying least-squares is the Gauss-Newton, often with 
variations introduced by Levenberg and Marquardt (313).  This algorithm 
has several advantages: it is generally fast, converges quickly, is relatively 
easy to implement, and gives immediate error estimates using the final 
solution matrix.  However, it has limitations: (i) the algorithm requires that 
the derivatives of the function being fit be calculated during the iterations, 
and (ii) the error estimation matrix generally produces errors that are too 
small (313).  An alternative method, the Nelder-Mead simplex algorithm 
(306), is more general in that it does not require derivatives, but it is also 
somewhat slower.  The Nelder-Mead simplex algorithm does not inherently 
provide any form of error estimation, but can easily be coupled to a rigorous 
method.
Numerous programs now exist for performing least-squares and other 
minimization routines.  Here we present an outline of our approach, which 
makes use of a computer program, still under development, that is built to 
meet specific requirements: (i) perform reliable minimizations (fits); (ii) 
provide automated, rigorous error estimates; (iii) work regardless of the 
complexity of the function being fit (i.e., does not rely on calculation of a 
derivative); (iv) the ability to iteratively apply many models to many data 
sets automatically; (v) fit arbitrary combinations of data to an arbitrary 
116
combination of functions in a global fit (e.g., denaturation data from 
fluorescence and CD spectroscopy simultaneously, which share a similar 
function but with some parameters specific to each data set); and (vi) 
modularity, such that the function being fit, the minimization algorithm (e.g., 
simplex), and the evaluation of the minimization (e.g., least-squares) could 
all be combined in any desired combination.
6.2 Theory and Program Description
Our customized program is coded entirely in Python.  The use of this 
scripting language means that any part of the code may be quickly modified, 
and that the algorithms can be independently verified.  In addition, the use 
of modules means that is simple to replace one algorithm or function for 
another, without rewriting large blocks of code.
As currently written, the program implements a variation of the 
Nelder-Mead simplex algorithm (306).  The basic concept of a simplex is that 
for n parameters, there are n+1 vertices, where the coordinates for each 
vertex are guesses for the best-fit values of each parameter.  In each 
iteration, the vertex containing the worst values (as evaluated by χ2 or 
equivalent) is reflected through the center of all the other simplex points to 
generate a new value.  This new value may be moved further in the same 
direction if it proves to be better than any existing vertex, moved partway 
back toward the center if it is worse than the vertex it originated from, or 
adjusted in several ways to ensure that no parameter is outside specified 
boundaries (e.g., to avoid providing the function with values that generate 
invalid results).  The simplex size (distance between vertices) is dynamic 
during the fit, becoming smaller as the fit converges.  In our case, we 
evaluate a fit as "converged" when the difference (in χ2) between the best 
and worst vertex is below an arbitrary (very low) threshold.  Regardless of 
the outcome of the placement of the new vertex (i.e., it is now the best, 
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worst, or an intermediate guess), the vertex that was second-worst prior to 
moving the worst vertex is now designated the "worst" (to avoid an endless 
loop of reflecting the same vertex).
Our modifications to the basic algorithm are slight.  First, the rule of 
always moving the second-worst vertex following movement of the worst, 
even when the newly placed vertex is still worse than any others, means that 
the algorithm does not converge when there are only two vertices (one 
parameter).  Therefore, we discard this particular rule for the special case of 
a two-vertex simplex.  The second modification only comes into use when 
fitting multiple data sets simultaneously.  Following a "global" simplex using 
all parameters, if groups of parameters exist that are specific to a subset of 
the total data, a "secondary" simplex using only these parameters and data 
sets will be performed while keeping all other parameters fixed.  For 
example, if two data sets are being fit by six parameters, but parameters A 
and B are only relevant for fitting data set 1, then a secondary simplex will 
be used to optimize parameters A and B while fixing all others, and ignoring 
data set 2 (which is irrelevant to the final values of A and B).  This technique 
greatly increases the rate of convergence for large data sets and many 
parameters.
Our default evaluation scheme for minimization is least-squares, but 
that module can be replaced by an alternative method such as robust 
parameter estimation.  In conjunction with an appropriately written 
function, additional algorithms such as numerical integration (368) could 
also be used.
In order to evaluate the quality of any fit, two elements are needed: (i) 
one or more measures of the "goodness" of the fit; and (ii) error estimates 
for the resulting parameters.  Although the use of χ2 in least-squares 
provides one measure of goodness and is useful to guide the fit toward 
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convergence, it does not ensure that the fit is appropriate.  To provide an 
automated measure of appropriateness of the fit, we implemented residual 
analysis (311).  The idea behind residual analysis is to ensure that the 
residuals of the fit are randomly distributed, as systematic deviations (such 
as most of the residuals being positive) can indicate non-random noise in the 
data or the use of an inappropriate model (function) being fit.  In addition, 
statistical measures used to generate error estimates assume that the 
residuals are approximately Gaussian distributed (random).  We have 
implemented the runs test, which is evaluated according to Equations 6.2 
and 6.3:
E=2 N PNP  (6.2)
Z=∣E−R NPR−1 R−2 ∣  (6.3)
where E is the expected number of runs; N is the number of negative 
residuals; P is the number of positive residuals; and Z is the test statistic.  A 
"run" is one or more continuous residuals with the same sign.  Absolute Z 
scores of less than approximately 2 indicate a random distribution, while 
absolute scores of greater than approximately 4 indicate a major deviation. 
The runs test is more general than most alternative methods, but like all 
residual analysis methods it is of limited use when the number of data points 
is less than about 10.
Without a measure of the confidence of the final parameter values 
(error estimates), the fit is worthless.  As with residual analysis, numerous 
methods exist for estimating errors, with a trade-off between reliability and 
calculation time (312).  The fastest, and least reliable, is the use of the 
inverse of the final parameter matrix in Gauss-Newton methods.  Similar 
matrix-based methods have been devised for the simplex algorithm, 
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resulting in essentially identical error estimates (369, 370).  Matrix-based 
methods also assume symmetry in the errors (i.e., the errors for each 
parameter in the positive and negative directions are identical).  Other 
methods rely on shifting parameter values, one at a time, to a fixed value 
away from the best fit, then allowing the new values to converge to a new 
"best fit."  When the deviation in the parameter results in a statistically 
different fit, as evaluated by Fisher (F) and Student (t) statistics (371), the 
difference between the adjusted value and the original best fit value is the 
error estimate.
The most reliable method, and the most time-consuming, is a simple 
grid search, where each parameter is adjusted a small step at a time until a 
significant difference is found.  Intermediate methods include the bootstrap 
(327, 365-367) and Monte Carlo (327, 372), each of which requires refitting 
the data hundreds or thousands of times.  Non-matrix methods allow for 
dependency in the error estimates.  Dependency is common in nonlinear fits, 
and arises when two or more parameters are correlated such that changes 
in one parameter can be somewhat compensated for by changing a second 
parameter (367, 373).  Note that Fisher-based error estimation is only 
appropriate for least-squares based minimization; the bootstrap or Monte 
Carlo methods are more appropriate if using robust parameter estimation.
We have implemented a variation of the the grid scheme which 
provides errors of similar quality to the bootstrap and Monte Carlo methods, 
but generally does so at a smaller computational cost.  In short, initial error 
estimates are found by moving the values for individual parameters in small, 
variable-sized steps until a significant difference is found in the fit, as 
evaluated using Fisher statistics:
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F=
2
2
DF2
1
2
DF1
 (6.4)
where DF is the degrees of freedom (number of data points - number of 
parameters - 1); and 1 and 2 refer to the best fit and adjusted parameter 
values, respectively.  The rapid initial estimate is done with all other 
parameters fixed, so provides an error estimate similar to that generated by 
the matrix-based methods.  In a second round of estimation, each parameter 
is held at the value found in the first pass while the other parameters are 
refit to find the new minimum.  If the new minimum is not statistically 
different from the the best minimum, the error estimate is increased by an 
amount proportional to the difference between the calculated F-value for the 
new minimum and the desired F-value for significance.  This process is 
iterated until the new minimum is statistically different from the best fit, 
usually at a level of two standard deviations (p=0.05).  The entire process, 
from initial estimate to final, is performed independently for both the 
negative and positive direction.  Generally, the larger of the two resulting 
values is presented as the final error estimate (reduced to one standard 
deviation), although when this implied physically unrealistic results the 
asymmetric error is kept.
If parameters are not highly dependent, the error estimation process 
is rapid and generally only requires a few rounds; in the case of parameters 
with very high dependencies, our approach can take as long as a Monte 
Carlo or bootstrap method, and frequently results in asymmetrical errors. 
The difference between the initial and final error estimates gives the 
dependency:
D=1−E1E2
 (6.5)
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where D is the dependency; E1 is the initial error estimate; and E2 is the final 
error estimate.  A dependency of less than 0.5 (i.e., less than two-fold 
difference between the two error estimates) is excellent, while dependencies 
of greater than approximately 0.9 (i.e., greater than ten-fold difference 
between the two error estimates) suggest that the number of parameters 
should be reduced or that additional data may be needed to generate a 
reliable fit (367, 373).
A critical issue in all nonlinear fits is whether the true minimum has 
been found.  One advantage to non-matrix based error estimates is that the 
local space around the best fit value is thoroughly investigated; if during the 
course of the error estimation a fit is found that is superior to the previously 
calculated best fit, the new fit is taken as the starting point and the entire 
process is restarted.  For complex functions, this reoptimization is useful to 
ensure the global minimum is found.  In addition, multiple fits should be 
performed using different starting guesses; different initial guesses leading 
to the same final fit is suggestive of a global minimum.  Our code automates 
the process of starting from a variety of random initial guesses, and stores 
the desired number of resulting fits to perform thorough error estimates on 
all of them.  For simple functions, the entire procedure is not necessary, but 
is very rapid if performed anyway.
As shown in Equation 6.1, weighting can be used in two ways during a 
least-squares fit; its use in other methods may be similar but is not as 
statistically sound (327).  The first method is to weight each residual by the 
uncertainty in the measurement (σi), which propagates the uncertainty of 
measurements into the fit and gives more reliable parameter estimates 
(374).  The second method is to weight all data points by a fixed value (W), 
which is equivalent to multiplying the final χ2 by a fixed value.  Fixed value 
weighting is useful in two ways when performing global fits: (i) a scalar can 
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be used to correct for large differences in the magnitudes of the dependent 
variables to avoid domination of χ2 by a single data set; and (ii) to correct for 
the number of data points, as larger data sets tend to dominate χ2.  The 
dependence of χ2 on the number of data points is usually desired, but in 
cases where equal weighting of data sets is desired, Equation 6.6 can be 
used:
W= 1
N2  (6.6)
where N is the number of data points.  All weighting methods are easily 
automated.
The program allows for complete control over the fitting behavior, 
including details such as the convergence threshold, maximum number of 
iterations, and weighting.  In addition, the algorithm allows for two types of 
constraints: (i) absolute constraints, which the parameter value may never 
exceed (useful to avoid providing an unacceptable value to a function); and 
(ii) partial constraints, which are used to constrain the initial random 
guesses and guide the fit, but which may be exceeded to estimate errors and 
at other specific times.
6.3 Applications
All applications are taken from actual analysis in Chapters 4 and 5. 
Therefore, only the theoretical justification and relevant program details are 
provided here.
6.3.1 Ligand Binding Data
The ligand binding data presented in Sections 4.3.1 and 5.3.1 do not 
meet the least-squares criteria of having Gaussian noise, because the 
division of two Gaussian distributions does not produce a Gaussian 
distribution.  Therefore, the data were fit using both least-squares and 
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robust parameter estimation (using the absolute value of the residual 
instead of its square).  However, no significance difference was found in the 
outcome of the fits, so we ultimately used exclusively the least-squares 
algorithm.  The lack of a significant difference probably occurs because the 
noise in the binding model is approximately Gaussian.
The use of the simplex algorithm produced identical best-fit values as 
the use of the Levenberg-Marquardt algorithm, but not identical error 
estimates and dependencies.  The magnitude of the differences vary 
somewhat with individual data sets, but matrix methods produced errors 
similar to or somewhat smaller than the simplex initial error estimates. 
Matrix methods also overestimated the dependencies, with values of 0.6-0.8, 
while the Fisher-statistics method resulted in dependencies of 0.3-0.5.  The 
Kd errors are asymmetric, with the error in the positive direction being 
approximately 2.5-fold larger than the error in the negative direction.
6.3.2 Thermal Denaturation Data
The thermal denaturation data presented in Sections 4.3.3 and 5.3.2 
was globally fit to a single function and set of parameters.  The function did 
not always converge directly to the global minimum, so many initially 
guesses were used.  Approximately half the initial guesses led to a best fit, 
so the best fit from ten initial guesses gave a reproducible set of final 
parameter values.  The parameters have dependencies of up to 0.9, so error 
estimates are a much better measure of the true uncertainty in the 
parameter values than from matrix methods.
6.3.3 Analytical Ultracentrifugation Data
The analytical ultracentrifugation data presented in Sections 4.3.2 and 
5.3.3 were fit using a single function and several data sets.  One or more 
parameters was only relevant to a single data set, and so secondary simplex 
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optimization helped the fit converge to a global minimum.  Several initial 
guesses and full error fitting of two or more "best fits" was necessary to 
verify the global minimum.  The parameters are highly correlated, usually 
with dependencies greater than 0.9.
Prior work has demonstrated that the noise in AUC is not Gaussian 
(365-367), and therefore least-squares analysis is not appropriate.  However, 
for our data, alternative analyses based on robust parameter estimation did 
not produce quantitatively different results.
Several programs exist that are dedicated to the fitting of analytical 
ultracentrifugation data, including Sedfit/Sedphat (317), UltraScan II (375), 
and SedAnal (http://sedanal.bbri.org/).  However, the programs are limited 
by the inability to automatically generate reliable errors, and/or the inability 
to automate application of multiple models to many different data sets.  As 
some models took hours to fit (in our program and others) automatically 
fitting the data from multiple experiments to multiple models overnight was 
extremely useful.  On the other hand, our program currently lacks a nifty 
graphical interface.
6.3.4 Chemical Denaturation Data
The denaturation data described in Sections 4.3.4 and 5.3.4, makes 
use of functions that cannot be written without the use of a programming 
language, and cannot be fit using algorithms requiring a derivative (e.g., 
Levenberg-Marquardt).  A derivative for quartic Equation 4.23 cannot be 
computed, as the dependent variable cannot be isolated.  "If" statements and 
other programming controls are necessary to avoid errors arising from 
rounding in floating point values.  Equations 4.22 and 4.23 assume that all 
four possible species contribute significantly to the signal; when the fit 
parameters were evaluated for a particular data point and a species was 
found to represent less than 0.001% of the total concentration, the 
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appropriate term was dropped and the data point re-evaluated repeated 
using the resulting simpler model.
The use of rigorous statistical analysis led us to conclude that the 
range of statistically equivalent fits for this data was too large to present a 
reliable set of parameters.  Matrix-based approaches error estimates did not 
indicate the great uncertainty.  Despite numerous attempts to eliminate 
(keep fixed) parameters during the fits, especially slopes and intercepts for 
the individual species baselines, nothing was sufficient to yield statistically 
valid, unique parameter sets.
6.4 Discussion
In summary, our approach to, and program for, nonlinear analysis 
provides reliable error estimates, the ability to fit any function using a 
variety of minimization functions and algorithms, automation, and complete 
control over the fitting process.  At the time of this writing, the program is 
not yet in a state ready for distribution to and use by the general scientific 
community, but a general cleanup and effort to make it user-friendly is in 
progress; when this process is complete, it will be made freely available.
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7CHAPTER 7
CONCLUSION AND FUTURE WORK
7.1 Conclusion
In this work, we have addressed several aspects of engineering 
nuclear receptors, from how to identify a unique genomic DNA target 
sequence and  construct the appropriate DNA binding domain, to rigorous 
analysis of variants and possible mechanisms of nuclear receptors function. 
hRXRα is a slightly flexible cavity that lock onto ligands, but rather a truly 
dynamic protein with numerous long-range, allosteric sites, capable of 
significant structural change in response to slight stimuli and of exquisite 
ligand discrimination.  The functional diversity of hRXRα (and nuclear 
receptors in general) can't easily be explained by a relatively static 
structure.
Our sample size of variants is far too small to provide true guidelines 
as to how to select residues for mutation in hRXRα.  However, our results do 
illustrate that explicit protein design of hRXRα will most likely fail, given our 
current level of ignorance: the high degree of interaction between residues 
and the diverse long-range effects defy simple predictions.  Studying single 
amino acid mutations one at a time may be misleading when trying to 
identify the function of specific residues, as a second mutation may well 
offset the effect of the first.  On the other hand, the hRXRα is clearly quite 
adaptable, and apparently tolerates diverse multiple mutations.  This 
behavior suggests that, given an appropriate library, an hRXRα variant can 
be identified to bind and be activated by an arbitrary small molecule. 
However, our data also suggest that selection should be performed directly 
on the property of interest, as hRXRα may be able to adapt to a proxy 
property without having any affect on the property of interest.
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7.2 Future Work
Certainly the most requested experiments, and those with the greatest 
unknown as a time investment, are those involving more structural 
characterization.  The most ambitious goal would be crystallization of the 
variants described above, with and without ligands and the LxxLL peptide, 
to try to correlate changes in the variants' properties with changes in their 
structure.  However, crystallization of nuclear receptors is not trivial; 
despite thousands of trials, we were unable to replicate existing reports by 
crystallizing wild-type hRXRα(D E).  Moreover, our data suggests thatᵦ  
crystal structures may not be as informative as generally assumed due to 
their inherently static nature.  NMR studies would potentially be more 
useful, as the measurements include solution dynamics, but the fact that 
very few nuclear receptors have been studied by this technique suggests the 
difficulty.  We were unable to prepare samples containing sufficiently 
concentrated hRXRα(D E) for NMR experiments without using very high saltᵦ  
concentrations or other interfering additives.  Computational analysis of the 
variants using known structures as models may also provide additional 
insights.
Other structural techniques that lack atomic-level detail might also be 
useful.  Although we are unable to probe the effects of ligand binding on 
oligomerization via analytical ultracentrifugation, and techniques such as 
dynamic light scattering and gel filtration chromatography require 
assumptions of size and shape, other techniques can avoid these problems 
and assumptions.  Atomic force microscopy, small angle x-ray scattering, and 
neutron scattering can provide direct measurements of oligomer 
dimensions, which would be useful for eliminating assumptions of size and 
shape.  These techniques might also be applicable to full-length receptors, 
which are apparently not amenable to crystallization.
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Experiments that could provide comparable information to the 
structural studies are those probing the dynamics and kinetics of hRXRα. 
We have not examined the kinetics of ligand binding to variants or wild-type 
hRXRα(D E) at all, although such studies might provide insight into theᵦ  
weak correlation between binding and activation.  Probing the dynamics of 
the variants, via techniques such as hydrogen-deuterium exchange or ICAT 
labeling of MPAX-prepared (323) variants, might also provide key insights 
into both structural and dynamic information related to ligand binding.  We 
have generated hRXRα variants with three of the four cysteine residues 
removed to allow MPAX-based labeling, and verified that they express well, 
but were unable to successfully label and analyze them using the MPAX-ICAT 
system.  Two residues were mutated to consensus amino acids (C369L and 
C404A), and a third with a mutation that has previously been shown not to 
affect function (C432G).  The final cysteine, C269, was never visible by mass 
spectrometry analysis, and so we did not replace it, although in retrospect 
its presence may still be causing experimental difficulties (by consuming 
labeling reagent and occupying most of the affinity sites during ICAT post-
labeling cleanup).
To possibly resolve the difficulties with analyzing the GdmCl-induced 
unfolding data collected by CD spectroscopy, AUC experiments using buffers 
containing increasing amounts of guanidinium chloride could be performed 
and the data globally analyzed with existing CD data.  Although we 
performed preliminary experiments on the effects of salt and pH on the 
apparent Tm, we have by no means exhausted such studies.  The use of more 
realistic salt and buffer conditions (in intracellular terms), in combination 
with conditions mimicking cellular crowding such as high concentrations of 
glycerol or bovine serum albumin, may provide insight to the actual 
oligomerization and aggregation behavior of hRXRα within cells.  Similar 
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experiments could be performed to examine the effects of such conditions on 
the ligand binding.  The effect of temperature on the ligand binding and 
oligomerization might provide further insight into the thermodynamics of 
both processes.
A more ambitious project would be examine the effects of the known, 
and possible, post-translation modifications of RXRα on the protein's 
behavior.  A different (possibly larger) coactivator fragment could be used to 
see if the effect on ligand affinity is common to all motifs, and/or to include a 
fluorescence amino acid or label to enable direct measures on coactivator 
affinity; similar experiments could be done with corepressor motifs.
The obvious future work is to simply repeat all the described 
experiments on more variants, of which many exist.  However, one crucial 
open question is the cause of non-activation in non-functional variants. 
Quite possibly many simply do not express or fold well, but it would be 
interesting to characterize a handful of variants that appear to express and 
fold but remain inactive.  While we hope that our results begin to provide an 
explanation for why variants behave as they do, it may be that the non-
functional variants show a similar range of behavior, and the real cause of 
the changes in function have to do with properties that have not yet been 
measured.
The additional wild-type hRXRα constructs (described in Chapter 3) 
would be interesting to follow up on and data to compare to hRXRα(D E).ᵦ  
Nuclear receptors are treated as modular, but a systemic study of ligand 
binding, oligomerization, thermal stability, and thermodynamic stability for 
hRXRα(D E), hRXRα(CDE), hRXRα(ABCDE), and GBDhRXRα(DE) would beᵦ  
an excellent test of the limits of modularity.  The GBDhRXRα(DE) construct 
might be purified in E. coli with relatively little effort, by a creative use of 
affinity tags or other purification techniques to get around the protease 
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cleavage problem.  hRXRα(CDE) may behave better with the C195A 
mutation introduced in the studies studying hRXRα(C) (212-214, 255); 
personal communications also suggest that the zinc concentration needs to 
be kept low and tightly controlled.  It is likely that hRXRα(ABCDE), as well 
as hRXRα(ABCDα), will need to be expressed using a somewhat different 
system: either a large tag such as maltose binding protein, an intein 
expression system, or in some eukaryotic organism.  Any constructs 
containing the DBD also introduce the possibility of performing experiments 
in the presence and absence of DNA.
Probably the two most ambitious future projects also involve the 
greatest payoff if they are successful.  A systematic generation of mutations 
in all binding pocket residues in RXRα, and characterization of those 
variants, would allow generation of a complete picture of the long-range 
interactions involving the binding pocket and the coupling between residues. 
Although such a complete replacement throughout the binding pocket of 
even the single amino acid mutations would require several thousand 
variants, such a study need not be quite so exhaustive to provide useful 
information.  However, lacking high-throughput techniques for purification 
and characterization, such a project is likely too ambitious for the present. 
A more focused and manageable project might be to test the predictions of 
networks of interacting residues or other previously reported "key" 
positions, not only to determine if the ideas are valid but also to examine 
how well such a set of interacting positions holds up when multiple 
mutations are made.
A second high payoff project would be to replicate comparable studies 
using a different nuclear receptor.  As different nuclear receptors will 
probably require re-optimization of every step of the work detailed above, 
such a project is not lightly undertaken.  Moreover, RXRα is convenient 
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because it contains two tryptophan residues in the binding pocket, enabling 
the fluorescence assay for ligand binding; a tryptophan may not be so 
readily available in other nuclear receptors.  Although challenging, 
expression of multiple nuclear receptors not only opens doors for studies on 
new receptors, but also on interactions between receptors.  A somewhat 
easier, yet still valuable, project would be to examine hRXRβ and hRXRγ, 
which are orthologs of hRXRα and so might provide additional insights.
One of the primary goals of the work described here is to guide future 
protein engineering on RXRα, with the goal of enabling the applications 
discussed in Chapter 1.  To that end, the long-range work that still needs to 
be accomplished is to design not only a functional ligand binding domain, 
but also to couple it to an experimentally validated arbitrary DNA binding 
domain, as described in Chapter 2.  We have provided a guide to designing 
and analyzing rigorous characterization, designing the necessary DNA 
binding domain to target the variant as necessary, and suggestions for 
designing libraries that will yield variants with the desired function.
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A APPENDIX A
ESPSEARCH CODE
# ESPSearch.py, version 1.01
""" Searches DNA sequence for binding sites and analyzes for patterns.
    Copyright (C) 2004-2005 Terry J. Watt and Donald F. Doyle
    This program is free software; you can redistribute it and/or
    modify it under the terms of the GNU General Public License
    as published by the Free Software Foundation; either version 2
    of the License, or (at your option) any later version.
    This program is distributed in the hope that it will be useful,
    but WITHOUT ANY WARRANTY; without even the implied warranty of
    MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE.  See the
    GNU General Public License for more details.
    You should have received a copy of the GNU General Public License
    along with this program; if not, write to the Free Software
    Foundation, Inc., 59 Temple Place - Suite 330, Boston, MA  02111-1307, USA.
    You may contact Dr. Donald Doyle at:
    donald.doyle@chemistry.gatech.edu
    School of Chemistry & Biochemistry
    Atlanta, GA 30332-0400
    See espsearch.html for instructions on using this script and for the GPL.
    If publishing any results obtained with this program, please cite:
    Watt, T. J. and Doyle, D. F.  ESPSearch: A Program for Finding Exact
        Sequences and Patterns in DNA, RNA, or Protein.  Biotechniques, 2005,
        38, 109-115.
    See http://web.chemistry.gatech.edu/~doyle/espsearch/ for more information.
"""
#---------------------------------------------------------------------------
def AbortProgram(ExitString):
    """Ends the program, printing any necessary messages.
    """
    import sys # to enable forced exit
    print ExitString # exit message
    ExitVar = raw_input('Press <ENTER> to exit.') # wait for input before exit
    sys.exit() # force program exit
#---------------------------------------------------------------------------
def DefinePattern(PatternToMatch, ShortestTarget, LongestTarget, Mode, DatabaseFrag):
    """Generates lists that represent the user-specified patterns.
    This routine cycles through the user-entered pattern(s) to create a
    list of rules and other useful information for each pattern.  Everything
    is ultimately stored in PatternRestrictions and returned.
    PatternRestriction is arranged as follows:
    [x][0] = Whether or not this pattern contains any unique positions
    [x][1] = Pattern as entered by user
    [x][2] = Output file name associated with the pattern
    [x][3] = Pattern in segments for generating header info in output file
    [x][4] = All Pattern information, by position (letter or gap)
    for non-gap positions:
    [x][4][y][0] = # of nearest previous position that is identical (-1 if none)
    [x][4][y][1] = Strand (1 if complement (<), -1 if primary (>), 0 if either (|)); 
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always -1 for proteins
    [x][4][y][2] = Indicator of unique position if 1 (!)
    for gap positions:
    [x][4][y][0] = Low end of gap range
    [x][4][y][1] = High end of gap range
    """
    # first determine if any patterns even exist to parse
    if len(PatternToMatch) == 0: return [], LongestTarget # the minimum information for 
the rest of the routines to function smoothly
    PatternChars = 'ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz' # allowed chars 
for pattern
    Digits = '-0123456789' # allowed values for gaps
    PatternRestrictions = []
    MinPatternBuffer = LongestTarget # for determining how many positions need to be 
remembered in buffer
    MultPatterns = PatternToMatch.split(',') # break into as many patterns as exist
    CurPatNumber = 0 # for generating file names
    for EachPattern in MultPatterns: # for each pattern
        CurPatNumber = CurPatNumber + 1
        NumLetters = 0 # number of non-gap positions in pattern
        AnyUnique = 0 # if any positions are unique, will get tagged to -1
        EachPattern=EachPattern.strip() # remove whitespace
        PatternFile = '%sp%s' % (DatabaseFrag, CurPatNumber) # for 
PatternRestrictions[x][2]
        PatternList = [] # for PatternRestrictions[x][4]
        HeaderList = [] # for PatternRestrictions[x][3]
        MaxGapLength = 0 # for determining buffer length
        PatPos = 0 # position in pattern while parsing
        CurStrand = -1 # var to interpret >, <, and | in pattern, default is >
        Uniqueness = 0 # var to interpret unique position, ! in pattern
        if EachPattern[-1] == ']': # if pattern ends with gap, exit
            AbortProgram('Error: terminal gap found in pattern.')
        if EachPattern[0] == '[': # if pattern begins with gap, exit
            AbortProgram('Error: pattern begins with a gap.')
        while PatPos < len(EachPattern): # not for loop b/c "step" is variable
            if EachPattern[PatPos] == '[': # if position indicates the beginning of a gap
                PatternFile = PatternFile + '_' # indicate gap in file name
                # now search forward for end of gap (])
                for GapEnd in range(PatPos+1, len(EachPattern)):
                    if EachPattern[GapEnd] == ']':
                        break
                    elif EachPattern[GapEnd] in PatternChars: # if found letter before ], 
exit
                        AbortProgram('Error: missing closing ] on gap in pattern.')
                CutStr = EachPattern[PatPos+1:GapEnd] # the isolated gap w/o brackets
                RangeVars = CutStr.split(':') # now split into #s
                if len(RangeVars) != 2: # if contains more or less than 1 ":"
                    AbortProgram('Error: pattern gaps must be in the format [X:Y], where 
X & Y are integers.')
                else:
                    for RangeEntry in RangeVars: # determine if any value is empty or 
invalid
                        if len(RangeEntry) == 0 or RangeEntry.strip(Digits) != '':
                            AbortProgram('Error: pattern gaps must be in the format 
[X:Y], where X & Y are integers.')
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                if min(int(RangeVars[0]), int(RangeVars[1])) < -ShortestTarget: # 
determine if negative value is too negative
                    AbortProgram('Error: magnitude of negative number in gap is larger 
than shortest possible target.')
                PatternAppend = [min(int(RangeVars[0]), int(RangeVars[1])), 
max(int(RangeVars[0]), int(RangeVars[1]))] # put smaller value first, larger second
                MaxGapLength = MaxGapLength + PatternAppend[1] # increase cummulative 
maximum gap length
                HeaderList.append(EachPattern[PatPos:GapEnd+1]) # store gap info for file 
header
                PatPos = GapEnd # move position to end of gap
                PatternList.append(PatternAppend) # add new info
            elif EachPattern[PatPos] == '>': # following positions are on primary strand
                CurStrand = -1
            elif EachPattern[PatPos] == '<': # following positions are on complement 
strand
                CurStrand = 1
            elif EachPattern[PatPos] == '|': # following positions could be on either 
strand
                CurStrand = 0
            elif EachPattern[PatPos] == '!': # following position is unique
                Uniqueness = 1
                AnyUnique = -1
            elif EachPattern[PatPos] not in PatternChars: # invalid character, exit
                AbortProgram('Error: invalid character (' + str(EachPattern[PatPos]) + ') 
in pattern.')
            else: # a letter
                NumLetters = NumLetters + 1
                # adjust header output appropriately for strand & store
                if Mode == 1:
                    PatternAppend = [-1, CurStrand, Uniqueness] # rules for this position
                    if CurStrand == 1:
                        HeaderList.append('<' + EachPattern[PatPos])
                    elif CurStrand == 0:
                        HeaderList.append('|' + EachPattern[PatPos])
                    else:
                        HeaderList.append('>' + EachPattern[PatPos])
                else:
                    PatternAppend = [-1, -1, Uniqueness] # rules for this position
                    HeaderList.append(EachPattern[PatPos])
                PatternFile = PatternFile + EachPattern[PatPos] # update file name
                if Uniqueness == 0: # if not a unique position, identify previous 
position that is same (if any)
                    for ListPos in range(len(PatternList)-1, -1, -1):
                        if EachPattern[PatPos] == PatternFile[ListPos]: # found position 
of same type, mark current position to point to it
                            PatternAppend[0] = ListPos
                            break # only want closest position, so stop now
                Uniqueness = 0 # now reset Uniqueness indicator to default
                PatternList.append(PatternAppend) # add new info
            PatPos = PatPos + 1 # move to next position
        # now append pattern information to master list & determine buffer needs
        PatternRestrictions.append([AnyUnique, EachPattern, PatternFile, HeaderList, 
PatternList])
        LenPattern = NumLetters*LongestTarget + MaxGapLength
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        MinPatternBuffer = max(MinPatternBuffer, LenPattern)
    # add .txt extension to all file names
    for EachPattern in range(len(PatternRestrictions)):
        PatternRestrictions[EachPattern][2] = PatternRestrictions[EachPattern][2] + 
'.txt'
    return PatternRestrictions, MinPatternBuffer
#---------------------------------------------------------------------------
def DoOSOperations(InputFiles, OutputDirectory):
    """Creates directories & tests write ability.
    If successfully writes to assigned output directory, creates new
    directories to store output.  New directories are named after the input
    file, to allow multiple source files in a single run of this script.
    """
    import os # necessary to delete files and create directories
    # test to see that can write to output directory, if not then exit
    TestWriteFile = OutputDirectory + 'espstemp.txt'
    try:
        TestFile = open(TestWriteFile, 'w')
    except IOError:
        AbortProgram('Error: output directory does not exist or cannot be written to.')
    TestFile.close()
    os.remove(TestWriteFile) # delete temporary file
    # now know that output directory exists and is writeable, so create directories
    NewDirectories = []
    # name directories after input file, w/o extensions
    for FileNum in range(len(InputFiles)):
        InputFrag = InputFiles[FileNum][:]
        for SlashPos in range(len(InputFrag)-1, -1, -1):
            if InputFrag[SlashPos] == '/':
                InputFrag = InputFrag[SlashPos+1:] # remove / and everything before
                break # because only looking for last one
        for DotPos in range(len(InputFrag)-1, -1, -1):
            if InputFrag[DotPos] == '.':
                InputFrag = InputFrag[:DotPos] # remove . and everything after
                break # because only looking for last one
        NewDirectories.append(OutputDirectory + InputFrag + '/')
        # allow for possibility that the "new" directory already exists
        try:
            os.mkdir(NewDirectories[FileNum])
        except OSError:
            # hopefully just means already exists
            pass
    return NewDirectories
#---------------------------------------------------------------------------
def FindSequences(SeqMatches, InputFileName, OutputDirectory, TargetLength, 
MaxMismatches, FileNameArray, PatternRestrictions, OutputType, PatternType, BufferSize, 
MinTarget, MinBufferLen, PatternQueueLen, ComplementKeys, Mode):
    """Searches a source sequence for the desired sequences & outputs results.
    First prepares all the output files and initializes a bunch of variables.
    Does a bunch of processing to handle header info in files and loading of
    buffers.  Reads in a buffer of positions from source file to optimize
    performance elsewhere; not using a buffer of reasonable length (500+)
    means that the time spent on things besides searching becomes significant.
    To identify target sequences, looks at a "window" (determined by shortest
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    end segment in database) in buffer; if that sequence exists in SeqMatches,
    then one or more targets match it.  For output type 2, this immediately
    leads to output, because only 1 segment in each target.  For others,
    need to determine 1) if any hits at this position are the first in a target,
    2) if any "extra" positions (if segment is longer than shortest) match
    the nex ones in buffer, 3) and find other segments for this hit by
    reading ahead in buffer the appropriate distances (defined by gaps) to see
    if the sequences match.  When output is generated, hits are stored in
    CompleteHitQueue for later processing by patterns.
    Patterns are identified in a similar fashion, but a longer buffer is needed,
    so patterns keep a second buffer current, updated by the main buffer.
    In principle they work the same way as a target with multiple segments,
    but it is a little more complicated because it can't be assumed that each
    segment of a pattern is separated by a gap, patterns can cross strands,
    and patterns can have unique positions.  Gaps are handled by treating them
    explicitly (not implicitly as in targets), and cross strand behavior by
    creative use of multiplication.  Unique ones are handled immediately before
    output.  Patterns do have it easier in that everything stored in CHQ is a
    hit, so processing can actually be faster for searches involving gaps than
    with target sequences.  Accessing information in CHQ is also much faster
    than SeqMatches, because it is typically a much smaller dictionary.
    Though certain aspects of this code may not look optimized, the majority of
    time is usually spent on dictionary lookups (mostly generating the hash
    values), which is a more or less fixed cost somewhat influenced by
    dictionary size.    
    """
    # CHQ[x] = all hits for given position value (x based on output position value)
    # CHQ[x][y][0] = sequence (for +)
    #          [1] = strand for hit
    #          [2] = hit name
    #HitList[x] = data for part or all of successful hit
    #       [x][0] = Start of sequence (point to buffer position)
    #       [x][1] = minimum distance of current gap dealing with
    #       [x][2] = maximum distance
    #       [x][3] = Current mismatch count
    #       [x][4] = list of gap values used to create this hit
    #       [x][5] = length of next segment
    # Patternhits[x] = partial (until complete) pattern
    #            [x][0] = next position in CHQ to examine
    #            [x][1] = list of dictionaries/lists of hits/gaps (1 for each pattern 
entry)
    #            [x][2] = list of sequences for pattern positions (for sequence-level 
patterns)
    NumberPatterns = len(PatternRestrictions)
    InputFile = open(InputFileName, 'r') # open the input file
    # generate appropriate output files for given output type
    OutputFile = []
    for FileNum, FileName in enumerate(FileNameArray):
        OutFile = OutputDirectory + FileName
        try:
            OutputFile.append(open(OutFile, 'w'))
        except IOError:
            if FileNum == 0: # if failed on first file
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                AbortProgram('Error: output directory does not exist or could not be 
written to.')
            else: # failed because too many open files
                for EachFile in OutputFile:
                    EachFile.close()
                AbortProgram('Error: too many files generated for operating system. 
Change output format or reduce number of target names.')
    PatternFile = {} # for quickly accessing which file to write to for patterns
    # open any files necessary to write out pattern results
    for EachPattern in PatternRestrictions:
        PatFile = OutputDirectory + EachPattern[2]
        try:
            PatternFile[EachPattern[1]] = open(PatFile, 'w')
        except IOError:
            # most likely b/c too many open files
            AbortProgram('Error: failed to create pattern file, possibly because too many 
files are open.  Change output format or reduce number of target names.')
    if OutputType != 2:
        # output header information into all files
        if Mode == 1:
            OutputString = '%sPosition\tSequence\tStrand\tMismatches%s\n' % 
('Target\t'*OutputType, '\tGaps')
            for PatNum in range(NumberPatterns):
                PatternFile[PatternRestrictions[PatNum][1]].write('Position\tSequence\tSt
rand%s\n' % (''.join([('\t' + PatHeader) for PatHeader in 
PatternRestrictions[PatNum][3]])))
        else:
            OutputString = '%sPosition\tSequence\tMismatches%s\n' % 
('Target\t'*OutputType, '\tGaps')
            for PatNum in range(NumberPatterns):
                PatternFile[PatternRestrictions[PatNum][1]].write('Position\tSequence%s\n
' % (''.join([('\t' + PatHeader) for PatHeader in PatternRestrictions[PatNum][3]])))
        for FileNum in range(len(FileNameArray)):
            OutputFile[FileNum].write(OutputString)
    else: # OutputType = 2
        # adjust headers for Target size and output
        if Mode == 1:
            OutputString = 'Position\tBase%s' % (''.join([('\tFrame' + str(FrameNum+1)) 
for FrameNum in range(MinBufferLen)]))
            OutputFile[0].write(OutputString)
            OutputFile[1].write(OutputString)
        else:
            OutputFile[0].write('Position\tAmino Acid')
        # output header information into pattern files
        for PatNum in range(NumberPatterns):
            PatternFile[PatternRestrictions[PatNum][1]].write('Position\tSequence\tStrand
%s\n' % (''.join([('\t' + PatHeader) for PatHeader in PatternRestrictions[PatNum][3]])))
    # ensure buffer is long enough to hold info for longest possible target & pattern
    if BufferSize < MinBufferLen:
        BufferSize = MinBufferLen + BufferSize
    if BufferSize < PatternQueueLen:
        BufferSize = PatternQueueLen + BufferSize
    # Initialize all the variables necessary to keep track of search
    SequenceInfo = '' # for separating sequences in output
    NewSequenceInfo = '' # for storing the next sequence header when reach end of a 
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sequence
    StripChars = '0123456789 \n\t' # for removing whitespace & line numbers
    MinListLen = 1-MinBufferLen # for shifting buffer
    MinQueueLen = 1-PatternQueueLen # for shifting pattern buffer
    Sequence = '' # will hold the current "window" being examined
    Buffer = '' # holds the current set of positions being scanned
    CurrentLine = '' # for processing each line as read in
    CurrentInLine = '' # for processing each line as read in
    BeginSeq = 1 # for triggering behavior needed at beginning of sequences
    OutputFirstBases = 1 # for triggering initial output needed for Output Type 2
    FirstSeq = 1 # for triggering special behavior for the very first sequence
    EOF = 0 # for knowing when file is done being read
    FirstHitRef = [1 for FileNum in range(len(FileNameArray))] # for regenerating list of 
whether output sequence info into files
    FirstPatHitRef = [1 for PatNum in range(NumberPatterns)] # for regenerating list of 
whether output sequence info into pattern files
    # find hits
    while EOF == 0: # until eof
        # do processing for beginning of sequence
        if BeginSeq == 1:
            FirstHit = FirstHitRef[:]
            FirstPatHit = FirstPatHitRef[:]
            if OutputType == 2: # output last few positions to sense strand/protein 
sequence
                if Buffer != '': # max in next line used in case sequence is extremely 
short
                    OutputFile[0].write(''.join(['\n%s\t%s' % ((LowCounter+BufferPos+1), 
Buffer[BufferPos]) for BufferPos in range(max(len(Buffer)+MinListLen, 0), len(Buffer))]))
                OutputFirstBases = 1
            Adjustment = MinListLen # for knowing how much of buffer to save between 
loads
            PatternAdjustment = MinQueueLen # for knowing how much of pattern buffer to 
save
            BeginSeq = 0 # no longer the beginning of a sequence
            MaxCounter = 0 # reset all counters (specialized counters are based on this 
one)
            CompleteHitQueue = {} # reset remembered hits for patterns
            CHQBuffer = ' '*(PatternQueueLen) # reset pattern buffer
            Buffer = '' # reset buffer
            if FirstSeq == 1: # need to skip over any header information
                FirstSeq = 0
                while CurrentLine == '': # until find a real line
                    CurrentLine = InputFile.readline().strip()
                # test for support file formats
                if CurrentLine[0:3].strip() == 'ID' or CurrentLine[0:6].strip() == 
'LOCUS':
                    # EMBL or GenBank formats, skip over headers
                    SequenceInfo = '>%s\n' % (CurrentLine)
                    while True:
                        CurrentLine = InputFile.readline()
                        if CurrentLine == '' or CurrentLine[0:6] == 'ORIGIN' or 
CurrentLine[0:2] == 'SQ': break
                elif CurrentLine[0] == '>':
                    # FASTA format, ready to go now
                    SequenceInfo = '%s\n' % (CurrentLine)
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                else:
                    # assume plain format, reset file
                    InputFile.close()
                    InputFile = open(InputFileName, 'r') # open the input file
        # Load Buffer
        NewLine = '' # holds new positions being read in
        while len(NewLine) < BufferSize: # until enough data is present
            CurrentInLine = InputFile.readline()
            if CurrentInLine == '': # end of file, search the positions normally "saved" 
between loads to ensure search last few
                EOF = 1
                Adjustment = 1 - TargetLength
                PatternAdjustment = 0
                break
            else:
                CurrentLine = CurrentInLine.strip(StripChars) # remove whitespace & 
numbers
                if CurrentLine != '': # i.e., isn't just white space
                    if CurrentLine[0] == '>' or CurrentLine[0:2] == '//': # end of 
sequence marker
                        if CurrentLine[0:2] == '//': # end of EMBL or GenBank seq
                            # now read until reach next beginning or end of file
                            while CurrentLine[0:3].strip() != 'ID' and 
CurrentLine[0:6].strip() != 'LOCUS' and CurrentLine != '':
                                CurrentLine = InputFile.readline()
                            NewSequenceInfo = '>%s\n' % (CurrentLine.strip())
                            while True:
                                CurrentLine = InputFile.readline() # remove whitespace
                                if CurrentLine == '' or CurrentLine[0:6] == 'ORIGIN' or 
CurrentLine[0:2] == 'SQ': break
                            if CurrentLine == '':
                                EOF = 1
                            else:
                                BeginSeq = 1
                        else:
                            # otherwise just assume FASTA and therefore line is cleared
                            NewSequenceInfo = '%s\n' % (CurrentInLine.strip('\n')) # uses 
CurrentInLine rather than current line to fix missing #s on end of line, if any
                            BeginSeq = 1
                        Adjustment = 1 - TargetLength # search end of sequence
                        PatternAdjustment = 0
                        break # to avoid loading any more into buffer
                    else: # extend buffer
                        CurrentLine = ''.join(CurrentLine.split()) # remove internal 
whitespace
                        NewLine = '%s%s' % (NewLine, CurrentLine.upper())
        Buffer = '%s%s' % (Buffer[MinListLen:], NewLine) # update buffer, saving end 
positions that were not previously searched
        CHQBuffer = '%s%s' % (CHQBuffer[MinQueueLen:MinListLen], Buffer) # same with 
pattern buffer
        MaxCounter = MaxCounter + len(NewLine) # update master counter
        LowCounter = MaxCounter - len(Buffer) # update counter for presenting position #s 
in target hits
        PatCounter = MaxCounter - len(CHQBuffer) # update counter for presenting position 
#s in pattern hits
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        # split outputtype = 2 from others here b/c quite different, so more efficient 
(lines of code & speed) to do so
        if OutputType != 2:
            if len(Buffer) >= MinBufferLen: # if long enough to actually run
                for BufferPos in range(len(Buffer)+Adjustment): # for each position in 
buffer to be examined on this run
                    Sequence = Buffer[BufferPos:BufferPos + TargetLength] # current 
"window"
                    if Sequence in SeqMatches: # if this is a target sequence
                        TempQueue = [] # for storing data for patterns
                        for EachTarget in SeqMatches[Sequence]: # for each match for that 
sequence
                            if EachTarget[1] < 0 and EachTarget[7] == 
Buffer[BufferPos+TargetLength:BufferPos+TargetLength+len(EachTarget[7])]: # first hit in 
series, ensure any "extra" positions also match
                                BlankGaps = ['']*(-EachTarget[1]-1) # empty list with 
enough space for gap values
                                HitList = [[BufferPos+TargetLength+len(EachTarget[7]), 
EachTarget[3], EachTarget[4], EachTarget[2], BlankGaps, EachTarget[8]]] # initialize list 
for tracking hits
                                for EachSeg in range(1, -EachTarget[1]): # for remaining 
segments
                                    NewHitList = [] # for updating partial hits
                                    for EachHit in HitList: # for each partial hit so far
                                        for NextPos in range(EachHit[0] + EachHit[1], 
EachHit[0] + EachHit[2]): # for all positions at right gap distance from the hit
                                            NewSequence = 
Buffer[NextPos:NextPos+EachHit[5]] # determine sequence at this position
                                            if NewSequence in SeqMatches: # if new 
sequence matches something
                                                for NextTarget in 
SeqMatches[NewSequence]: # for each match at that position
                                                    if NextTarget[0] == EachTarget[0] and 
NextTarget[1] == EachSeg: # if same series and next position
                                                        NewMismatches = EachHit[3] + 
NextTarget[2] # increase mismatches for this hit
                                                        if NewMismatches <= 
MaxMismatches: # if mismatch threshold is not exceeded, update hit information
                                                            NewHitList.append([NextPos+Ea
chHit[5], NextTarget[3], NextTarget[4], NewMismatches, EachHit[4], NextTarget[8]])
                                                            NewHitList[-1][4][EachSeg-1] 
= '%s ' % (NextPos - EachHit[0])
                                    HitList = NewHitList # update master hit information
                                if HitList != []: # if a full hit was found
                                    if NumberPatterns > 0: # used to prevent slow 
increase in memory usage that otherwise occurs
                                        for EachFullHit in HitList: # output & store info 
for each
                                        # Target name has last character dropped to lose 
"marker" for multiple sequences with same name
                                            if FirstHit[EachTarget[5]] == 1:
                                                FirstHit[EachTarget[5]] = 0
                                                OutputFile[EachTarget[5]].write(SequenceI
nfo)
                                            if EachTarget[6] == 0: # + strand
                                                OutputFile[EachTarget[5]].write('%s%s%s\t
%s%s\t%s\t%s\n' % (EachTarget[0][:-1]*OutputType, '\t'*OutputType, 
LowCounter+BufferPos+1, Buffer[BufferPos:EachFullHit[0]], '\t+'*Mode, EachFullHit[3], 
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''.join(EachFullHit[4])))
                                                TempQueue.append([Buffer[BufferPos:EachFu
llHit[0]], 1, EachTarget[0][:-1]])
                                            else: # - strand
                                                OutputFile[EachTarget[5]].write('%s%s%s\t
%s\t-\t%s\t%s\n' % (EachTarget[0][:-1]*OutputType, '\t'*OutputType, 
LowCounter+EachFullHit[0], ''.join([ComplementKeys[Char] for Char in 
Buffer[BufferPos:EachFullHit[0]][::-1]]), EachFullHit[3], ''.join(EachFullHit[4][::-1])))
                                                TempQueue.append([Buffer[BufferPos:EachFu
llHit[0]], -1, EachTarget[0][:-1]])
                                    else:
                                        for EachFullHit in HitList: # output & store info 
for each
                                            if FirstHit[EachTarget[5]] == 1:
                                                FirstHit[EachTarget[5]] = 0
                                                OutputFile[EachTarget[5]].write(SequenceI
nfo)
                                            if EachTarget[6] == 0: # + strand
                                                OutputFile[EachTarget[5]].write('%s%s%s\t
%s%s\t%s\t%s\n' % (EachTarget[0][:-1]*OutputType, '\t'*OutputType, 
LowCounter+BufferPos+1, Buffer[BufferPos:EachFullHit[0]], '\t+'*Mode, EachFullHit[3], 
''.join(EachFullHit[4])))
                                            else: # - strand
                                                OutputFile[EachTarget[5]].write('%s%s%s\t
%s\t-\t%s\t%s\n' % (EachTarget[0][:-1]*OutputType, '\t'*OutputType, 
LowCounter+EachFullHit[0], ''.join([ComplementKeys[Char] for Char in 
Buffer[BufferPos:EachFullHit[0]][::-1]]), EachFullHit[3], ''.join(EachFullHit[4][::-1])))
                        if TempQueue != []: # if hits were found, remember their info 
long term
                            CompleteHitQueue[LowCounter+BufferPos] = TempQueue
        else: # outputtype = 2
            if Mode == 1: # nucleic acid style output
                if OutputFirstBases == 1:
                    # write divider lines
                    OutputFile[0].write('\n%s' % (SequenceInfo[:-1]))
                    OutputFile[1].write('\n%s' % (SequenceInfo[:-1]))
                    # output first few bases to antisense
                    OutputFile[1].write(''.join(['\n%s\t%s' % ((LowCounter+BufferPos+1), 
ComplementKeys[Buffer[BufferPos]]) for BufferPos in range(min(len(Buffer), MinBufferLen-
1))]))
                    OutputFirstBases = 0
                LastPos = 0
                if len(Buffer) >= MinBufferLen: # if long enough to actually run
                    for BufferPos in range(len(Buffer)+Adjustment): # for each position 
in buffer to be examined on this run
                        Sequence = Buffer[BufferPos:BufferPos + TargetLength] # current 
"window"
                        if Sequence in SeqMatches: # if this is a target sequence
                            if LastPos <= BufferPos: # flush bases w/o hit & shift into 
appropriate frame
                                OutputFile[0].write(''.join(['\n%s\t%s' % 
((LowCounter+CurPos+1), Buffer[CurPos]) for CurPos in range(LastPos, BufferPos+1)]))
                                OutputFile[1].write(''.join(['\n%s\t%s' % 
((LowCounter+CurPos+TargetLength), ComplementKeys[Buffer[CurPos+TargetLength-1]]) for 
CurPos in range(LastPos, BufferPos+1)]))
                                LastPos = BufferPos+1
                                OutputFile[0].write('\t'*((LowCounter+BufferPos)%TargetLe
ngth+1))
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                                OutputFile[1].write('\t'*((LowCounter+BufferPos)%TargetLe
ngth+1))
                            if NumberPatterns > 0: # used to prevent slow memory 
consumption
                                TempQueue = []
                                for EachTarget in SeqMatches[Sequence]: # for each match 
at that address
                                    # output each target name (w/o last character) 
matching this sequence & store in CHQ
                                    OutputFile[EachTarget[6]].write('%s ' % 
(EachTarget[0][:-1]))
                                    if EachTarget[6] == 0: # + strand
                                        TempQueue.append([Buffer[BufferPos:BufferPos+Targ
etLength], 1, EachTarget[0][:-1]])
                                    else:
                                        TempQueue.append([Buffer[BufferPos:BufferPos+Targ
etLength], -1, EachTarget[0][:-1]])
                                CompleteHitQueue[LowCounter+BufferPos] = TempQueue
                            else:
                                for EachTarget in SeqMatches[Sequence]: # for each match 
at that address
                                    # output each target name (w/o last character) 
matching this sequence & store in CHQ
                                    OutputFile[EachTarget[6]].write('%s ' % 
(EachTarget[0][:-1]))
                    # flush any remaining bases that did not have a hit
                    OutputFile[0].write(''.join(['\n%s\t%s' % ((LowCounter+CurPos+1), 
Buffer[CurPos]) for CurPos in range(LastPos, BufferPos+1)]))
                    OutputFile[1].write(''.join(['\n%s\t%s' % 
((LowCounter+CurPos+TargetLength), ComplementKeys[Buffer[CurPos+TargetLength-1]]) for 
CurPos in range(LastPos, BufferPos+1)]))
            else: # protein style output
                LastPos = 0
                if len(Buffer) >= MinBufferLen: # if long enough to actually run
                    for BufferPos in range(len(Buffer)+Adjustment): # for each position 
in buffer to be examined on this run
                        Sequence = Buffer[BufferPos:BufferPos + TargetLength] # current 
"window"
                        if Sequence in SeqMatches: # if this is a target sequence
                            if LastPos <= BufferPos: # flush bases w/o hit & shift into 
appropriate frame
                                OutputFile[0].write(''.join(['\n%s\t%s' % 
((LowCounter+CurPos+1), Buffer[CurPos]) for CurPos in range(LastPos, BufferPos+1)]))
                                OutputFile[0].write('\t')
                                LastPos = BufferPos+1
                            if NumberPatterns > 0: # used to prevent slow memory 
consumption
                                TempQueue = []
                                for EachTarget in SeqMatches[Sequence]: # for each match 
at that address
                                    # output each target name (w/o last character) 
matching this sequence & store in CHQ
                                    OutputFile[0].write('%s ' % (EachTarget[0][:-1]))
                                    TempQueue.append([Buffer[BufferPos:BufferPos+TargetLe
ngth], 1, EachTarget[0][:-1]])
                                CompleteHitQueue[LowCounter+BufferPos] = TempQueue
                            else:
                                for EachTarget in SeqMatches[Sequence]: # for each match 
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at that address
                                    # output each target name (w/o last character) 
matching this sequence & store in CHQ
                                    OutputFile[EachTarget[6]].write('%s ' % 
(EachTarget[0][:-1]))
                    # flush any remaining bases that did not have a hit
                    OutputFile[0].write(''.join(['\n%s\t%s' % ((LowCounter+CurPos+1), 
Buffer[CurPos]) for CurPos in range(LastPos, BufferPos+1)]))
                
        # pattern matching
        if NumberPatterns > 0 and len(Buffer) >= MinBufferLen: # if patterns exist & 
buffer is long enough to search
            KeyList=CompleteHitQueue.keys() # get position #s that have hits
            KeyList.sort() # sort position #s; often out of order otherwise, which will 
cause pattern hits to be missed
            for HitPos in KeyList: # all positions with data in them
                if HitPos >= MaxCounter + PatternAdjustment: break # if saving for next 
round
                PatNum = -1 # used for determining if should output sequence info
                for Pattern in PatternRestrictions: # for each pattern
                    PatNum = PatNum + 1
                    PatternHits = [] # for storing hits as they develop
                    for Firsts in CompleteHitQueue[HitPos]: # for each target sequence at 
this position
                        # store name in proper place (with others of the same total 
length so far)
                        for Partial in PatternHits:
                            if Partial[0] == HitPos + len(Firsts[0]) and Firsts[1] == 
Partial[3]: # if start of next position is same
                                Partial[1][0][Firsts[2]] = Firsts[2] # add name to list 
at that distance
                                break
                        else:
                            PatternHits.append([HitPos + len(Firsts[0]), 
[{Firsts[2]:Firsts[2]}], [Firsts[0]], Firsts[1]])
                    for Entry in Pattern[4][1:]: # for each pattern entry
                        NewPatternHits = [] # for updating PatternHits
                        if len(Entry) == 2: # if a gap
                            for Partial in PatternHits: # for each partial pattern so far
                                for NextPos in range(Partial[0]+Entry[0], 
Partial[0]+Entry[1]+1):
                                    if NextPos in CompleteHitQueue: # if hits exist at 
this position, create a new partial hit
                                        NewPatternHits.append([NextPos, Partial[1][:], 
Partial[2][:], Partial[3]])
                                        NewPatternHits[-1][1].append([str(NextPos-
Partial[0])])
                                        NewPatternHits[-1][2].append('') # placeholder
                        else: # a "real" position
                            for Partial in PatternHits: # for each partial pattern so far
                                NewNewPatternHits = [] # for extending NewPatternHits
                                if Partial[0] in CompleteHitQueue: # if a hit here
                                    for EachHit in CompleteHitQueue[Partial[0]]: # each 
hit at next position
                                        if Entry[1] != EachHit[1]*Partial[3] and 
(Entry[0] == -1 or (Entry[0] > -1 and EachHit[2] in Partial[1][Entry[0]])): # if on 
appropriate strand and name exists in previous position, if relevant
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                                            # store name in proper place (with others of 
the same total length so far)
                                            for NewPartial in NewNewPatternHits:
                                                if NewPartial[0] == Partial[0] + 
len(EachHit[0]): # if start of next position is same
                                                    NewPartial[1][-1][EachHit[2]] = 
EachHit[2] # add name to list at that distance
                                                    break
                                            else:
                                                if PatternType == 1 and Entry[0] > -1: # 
if matching based on sequence, make sure they do or don't add this
                                                    if (Entry[1] == -1 and EachHit[0] != 
Partial[2][Entry[0]]) or (Entry[1] == 1 and EachHit[0] != ''.join([ComplementKeys[Char] 
for Char in Partial[2][Entry[0]][::-1]])): break
                                                NewNewPatternHits.append([Partial[0] + 
len(EachHit[0]), Partial[1][:], Partial[2][:], Partial[3]])
                                                NewNewPatternHits[-
1][1].append({EachHit[2]:EachHit[2]})
                                                NewNewPatternHits[-
1][2].append(EachHit[0])
                                NewPatternHits = NewPatternHits + NewNewPatternHits # 
remember these new hits
                            for Partial in NewPatternHits: # update old positions for 
cases where must be same as current one
                                Partial[1][Entry[0]] = Partial[1][-1] # self=self if no 
positions need be the same
                        PatternHits = NewPatternHits # update master list
                        if PatternHits == []: break # stop cycling through pattern if no 
partial hits remaining
                    for FullHit in PatternHits: # for each finished hit
                        # ensure unique positions actually are
                        if Pattern[0] == -1: # if any unique positions exist
                            for EntryNum in range(len(Pattern[4])): # length of pattern
                                if len(Pattern[4][EntryNum]) > 2 and 
Pattern[4][EntryNum][2] == 1: # if a unique position
                                    # use OldPos & NewPos to avoid copy.deepcopy() 
elsewhere when not really needed
                                    OldPos = FullHit[1][EntryNum].copy()
                                    for EachMatch in FullHit[1][EntryNum].keys(): # check 
each entry for this position
                                        DelPos = 0 # to know if should delete this entry 
at current position
                                        for OtherEntryNum in range(len(Pattern[4])): # 
check all other positions
                                            if OtherEntryNum != EntryNum and 
len(Pattern[4][OtherEntryNum]) > 2 and EachMatch in FullHit[1][OtherEntryNum]: # don't 
check gaps or self
                                                CurPos = FullHit[1][OtherEntryNum].copy()
                                                DelPos = 1 # note need to remove from 
position EntryNum
                                                del CurPos[EachMatch] # remove this entry 
from this position
                                                FullHit[1][OtherEntryNum] = CurPos
                                        if DelPos == 1: # if matches were found with this 
entry
                                            del OldPos[EachMatch] # delete this entry
                                    FullHit[1][EntryNum] = OldPos
                            NoOutput = 0
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                            for EachPos in FullHit[1]: # make sure all positions in this 
hit still have entries
                                if len(EachPos) == 0:
                                    NoOutput = 1
                                    break
                            if NoOutput == 1: continue # skip output if a position was 
found to be empty now
                        # convert dictionaries to lists for output & determine longest
                        for EntryNum in range(len(Pattern[4])): # length of pattern
                            if len(Pattern[4][EntryNum]) > 2: # only do this on list of 
hits, not gaps
                                FullHit[1][EntryNum] = FullHit[1][EntryNum].values()
                                FullHit[1][EntryNum].sort() # for consistency, otherwise 
arrangement varies, but not required
                        if FirstPatHit[PatNum] == 1:
                            FirstPatHit[PatNum] = 0
                            PatternFile[Pattern[1]].write(SequenceInfo)
                        if FullHit[3] == 1: # + strand
                            PatternFile[Pattern[1]].write('%s\t%s%s%s' % (HitPos+1, 
CHQBuffer[HitPos-PatCounter:FullHit[0]-PatCounter], '\t+'*Mode, ''.join(['\t' + 
''.join([EachMatch + ' ' for EachMatch in EachPos]) for EachPos in FullHit[1]])))
                        else: # - strand
                            FullHit[1].reverse() # flip it to match headers in file
                            PatternFile[Pattern[1]].write('%s\t%s\t-%s' % (FullHit[0], 
''.join([ComplementKeys[Char] for Char in CHQBuffer[HitPos-PatCounter:FullHit[0]-
PatCounter][::-1]]), ''.join(['\t' + ''.join([EachMatch + ' ' for EachMatch in EachPos]) 
for EachPos in FullHit[1]])))
                        PatternFile[Pattern[1]].write('\n')
                del CompleteHitQueue[HitPos] # finished with this position, so remove it
        if NewSequenceInfo != '': # copy new header into active header position
            SequenceInfo = NewSequenceInfo
            NewSequenceInfo = ''
    if OutputType == 2:
        # done, output remaining few bases/residues to sense strand/protein chain
        OutputFile[0].write(''.join(['\n%s\t%s' % ((LowCounter+BufferPos+1), 
Buffer[BufferPos]) for BufferPos in range(max(len(Buffer)+MinListLen, 0), len(Buffer))]))
    # close all files
    InputFile.close()
    for File in OutputFile:
        File.close()
    for File in PatternFile.values():
        File.close()
#---------------------------------------------------------------------------
def GenerateMismatches(SplitTargets, Before, After, NumMis, Pos, MaxMis, MismatchKeys):
    """Recursively generates all possible mismatches for a given sequence by
        iterating through sequence 1 position at a time, keeping the info
        associated with the sequence the same as the master sequence.
    """
    if len(After) >= NumMis: # if not done with current cycle
        for CharPos in range(len(After)): # for each character not yet done
            if MismatchKeys[After[0]] != '': # For ones that do not have mismatches 
(e.g., N & X)
                if NumMis == 1: # if current mismatch is done, store it
                    SplitTargets.append([Before + MismatchKeys[After[0]] + After[1:], 
SplitTargets[Pos][1][:]]) # send a copy
                    SplitTargets[len(SplitTargets)-1][1][2] = MaxMis
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                else: # move on to the next position to change to a mismatch
                    SplitTargets = GenerateMismatches(SplitTargets, Before + 
MismatchKeys[After[0]], After[1:], NumMis-1, Pos, MaxMis, MismatchKeys)
            Before = Before + After[0] # shift to the sequence left to do
            After = After[1:]
    return SplitTargets
#---------------------------------------------------------------------------
def GetKeys(KeyFile):
    """Reads rules file for what each character encountered will mean.
    ComplementKeys determines what the complements to a base are.  This also
        sets Protein or Nucleic Acid Mode.  If anything is present here, then
        Nucleic Acid mode is assumed; if this area is blank, then Protein.
    MismatchKeys determines what letter means not the same as another letter.
    WildcardKeys determines what wildcard letters correspond to, as a list.
        To match wildcards in source sequence, must include themselves in list.
    MasterKeys is the same as ComplementKeys, with all other ASCII characters
        added as a precaution against crashes; they all act as 'undefined'
        positions if encountered in a source sequence.  It replaces
        ComplementKeys in the FindSequences routine.  For Protein Mode, this
        is just a list of all characters as a precaution against crashes.
    """
    TestFileExist(KeyFile) # see if file exists
    InputFile = open(KeyFile, 'r')
    WhichDic = 0 # for indicating which dictionary is being built
    Mode = 0
    ComplementKeys = {}
    MismatchKeys = {}
    WildcardKeys = {}
    for EachLine in InputFile:
        EachLine = EachLine.strip() # remove white space
        if EachLine.lower() == 'complements:':
            WhichDic = 1
        elif EachLine.lower() == 'mismatches:':
            WhichDic = 2
        elif EachLine.lower() == 'wildcards:':
            WhichDic = 3
        elif len(EachLine) > 0 and EachLine[0] != '#': # if not blank line
            Pairs = EachLine.split(',') # split into key/value pairs
            for EachEntry in Pairs:
                if EachEntry != '': # in case line break after comma
                    KeyVal = EachEntry.split('=') # split key/value apart
                    if WhichDic == 1:
                        ComplementKeys[KeyVal[0].strip()] = KeyVal[1].strip()
                    elif WhichDic == 2:
                        MismatchKeys[KeyVal[0].strip()] = KeyVal[1].strip()
                    elif WhichDic == 3:
                        WildcardKeys[KeyVal[0].strip()] = list(KeyVal[1].strip())
                    else:
                        AbortProgram('Error: rules file is missing header line.')
    # following segment adds all other characters to return themselves in case 
encountered in source
    if ComplementKeys != {}:
        MasterKeys = ComplementKeys.copy()
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        Mode = 1 # nucleic acid
    else:
        for EachKey in MismatchKeys.keys():
            ComplementKeys[EachKey] = EachKey
        Mode = 0
        MasterKeys = {}
    TempList = [chr(AsciiChar) for AsciiChar in range(0, 256)]
    for Char in TempList:
        if Char not in MasterKeys: # don't replace "real" keys
            MasterKeys[Char] = Char
    return Mode, ComplementKeys, MismatchKeys, WildcardKeys, MasterKeys
#---------------------------------------------------------------------------
def Initialization(IniFile):
    """Reads IniFile to determine search paramaters and options.
    Reads in all user settings, determines that essential information is there.
    If something critical is missing, it will exit the program.  All
    non-essential information is checked; if missing or invalid, a warning is
    issued and the default value is used.
    """
    TestFileExist(IniFile) # see if file exists
    InputFile = open(IniFile, 'r')
    Digits = '-0123456789'
    # initial parameters so can trap if they don't get set
    # ones that cause critical errors
    InputFiles = []
    DatabaseFile = ''
    KeyFile = ''
    # ones that cause warnings to be issued; if not set will get put to a default
    OutputDirectory = ' ' # default is current dir = ''
    InputDir = ' ' # default is current dir = ''
    PatternToMatch = ' ' # default is ''
    MaxMismatches = -1 # default is 0
    Mismatches = -1 # default is 0
    CreateDir = -1 # default is 0
    OutputType = -1 # default is 1
    StandardizeNames = -1 # default is 0
    PatternType = -1 # default is 0, meaning matches patterns by name
    Buffer = -1 # default is 1000
    RAMWarning = -1 # default is 50
    # parse ini file read into variables & search strings
    for EachLine in InputFile:
        ProcessArray = EachLine.split('=', 1) # get parameter & value
        CurIniEntry = ProcessArray[0].lower().strip() # remove white space & make 
lowercase
        if len(ProcessArray) == 2: # if it had an = sign in entry
            CurIniValue = ProcessArray[1].strip()
            if CurIniEntry == 'pattern':
                PatternToMatch = CurIniValue
            elif CurIniEntry == 'database':
                DatabaseFile = CurIniValue
            elif CurIniEntry == 'source directory':
                InputDir = CurIniValue.replace('\\', '/')
                if len(InputDir) > 0 and InputDir[-1] != '/':
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                    InputDir = InputDir + '/' # ensure ends with a final /
            elif CurIniEntry == 'output directory':
                OutputDirectory = CurIniValue.replace('\\', '/')
                if len(OutputDirectory) > 0 and OutputDirectory[-1] != '/':
                    OutputDirectory = OutputDirectory + '/' # ensure ends with a final /
            elif CurIniEntry == 'rules file':
                KeyFile = CurIniValue
            elif len(CurIniValue) > 0: # following assume non blank entry
                if CurIniEntry == 'source file':
                    InputFiles = [FileName.strip() for FileName in 
ProcessArray[1].split(',')]
                elif CurIniValue.strip(Digits) == '': # following must contain only 
numerals
                    if CurIniEntry == 'maximum mismatches per segment':
                        Mismatches = int(CurIniValue)
                    elif CurIniEntry == 'maximum total mismatches':
                        MaxMismatches = int(CurIniValue)
                    elif CurIniEntry == 'create directories':
                        CreateDir = int(CurIniValue)
                    elif CurIniEntry == 'output format':
                        OutputType = int(CurIniValue)
                    elif CurIniEntry == 'standardize name length':
                        StandardizeNames = int(CurIniValue)
                    elif CurIniEntry == 'exact sequence pattern match':
                        PatternType = int(CurIniValue)
                    elif CurIniEntry == 'buffer':
                        Buffer = int(CurIniValue)
                    elif CurIniEntry == 'ram warning level':
                        RAMWarning = int(CurIniValue)
            # ignore anything else
    InputFile.close()
    # error handling
    if InputFiles == []:
        AbortProgram('Error: "Source File=" line not found or is blank in initialization 
file.')
    if DatabaseFile == '':
        AbortProgram('Error: "Database=" line not found or is blank in initialization 
file.')
    else:
        # Get "name" of database, w/o extension or directory
        DatabaseFrag = DatabaseFile[:]
        for SlashPos in range(len(DatabaseFrag)-1, -1, -1):
            if DatabaseFrag[SlashPos] == '/':
                DatabaseFrag = DatabaseFrag[SlashPos+1:] # remove / and everything before
                break # because only looking for last one
        for DotPos in range(len(DatabaseFrag)-1, -1, -1):
            if DatabaseFrag[DotPos] == '.':
                DatabaseFrag = DatabaseFrag[:DotPos] + '_' # remove . and everything 
after
                break # because only looking for last one
    if KeyFile == '':
        AbortProgram('Error: "Rules File=" line not found or is blank in initialization 
file.')
    # "warning" handling: non-critical problems in .ini information
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    if InputDir == ' ':
        print 'Warning: "Source Directory=" line not found in initialization file.'
        print '  Assuming current directory for source.'
        InputDir = ''
    if OutputDirectory == ' ':
        print 'Warning: "Output Directory=" line not found in initialization file.'
        print '  Assuming current directory for output.'
        OutputDirectory = ''
    if PatternToMatch == ' ':
        print 'Warning: "Pattern=" line not found in initialization file.'
        print '  Running program with no pattern.'
        PatternToMatch = ''
    elif PatternType != 1 and PatternType != 0:
        print 'Warning: "Exact Sequence Pattern Match=" line not found or has invalid 
value (not 0 or 1) in initialization file.'
        print '  Running program with default value of 0.'
        PatternType = 0
    if MaxMismatches < 0:
        print 'Warning: "Maximum Total Mismatches=" line not found or has invalid value 
in initialization file.'
        print '  Running program with no mismatches.'
        MaxMismatches = 0
    elif Mismatches < 0:
        print 'Warning: "Maximum Mismatches per Segment=" line not found or has invalid 
value in initialization file.'
        print '  Running program with no mismatches.'
        Mismatches = 0
        MaxMismatches = 0
    elif MaxMismatches < Mismatches:
        print 'Warning: Maximum Total Mismatches < Mismatches per Segment.'
        print '  Increasing Maximum Total Mismatches to equal Mismatches per Segment.'
        MaxMismatches = Mismatches
    if CreateDir != 1 and CreateDir != 0:
        print 'Warning: "Create Directories=" line not found or has invalid value (not 0 
or 1) in initialization file.'
        print '  Running program without directory creation.'
        CreateDir = 0
    if OutputType not in range(0, 3): # not 0, 1, or 2
        print 'Warning: "Output Format=" line not found or has invalid value (not 0, 1, 
or 2) in initialization file.'
        print '  Running program with in default output mode (1).'
        OutputType = 1
    if StandardizeNames != 1 and StandardizeNames != 0:
        print 'Warning: "Standardize Name Length=" line not found or has invalid value 
(not 0 or 1) in initialization file.'
        print '  Running program without standardizing lengths.'
        StandardizeNames = 0
    if Buffer <= 0:
        print 'Warning: "Buffer=" line not found or has invalid value (not a positive 
integer) in initialization file.'
        print '  Running program with default buffer size of 1000.'
        Buffer = 1000
    if RAMWarning <= 0:
        print 'Warning: "RAM Warning Level=" line not found or has invalid value (not a 
positive integer) in initialization file.'
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        print '  Running program with default warning level of 50.'
        RAMWarning = 50
    # check for file names that are too similar (for directory creation) and/or identical 
(would just be wasteful to run)
    # too similar is defined as identical source file names if extension and 
capitalization is removed
    for FileNum in range(len(InputFiles)):
        LastDot1 = len(InputFiles[FileNum])
        for DotPos in range(LastDot1-1, -1, -1):
            if InputFiles[FileNum][DotPos] == '.': LastDot1 = DotPos
            break # found last . in file name
        for NextNum in range(FileNum+1, len(InputFiles)): # search all files after this 
one
            LastDot2 = len(InputFiles[NextNum])
            for DotPos in range(LastDot2 - 1, -1, -1):
                if InputFiles[NextNum][DotPos] == '.': LastDot2 = DotPos
                break # found last .
            if InputFiles[FileNum][:LastDot1] == InputFiles[NextNum][:LastDot2]:
                AbortProgram('Error: identical or nearly identical (only extension 
different) source files found.')
                
    # combine source directory with all source files
    InputFileName = [InputDir + FileName.strip() for FileName in InputFiles]
    return InputFileName, OutputDirectory, PatternToMatch, DatabaseFile, Mismatches, 
MaxMismatches, CreateDir, OutputType, PatternType, DatabaseFrag, Buffer, RAMWarning, 
KeyFile, StandardizeNames
#---------------------------------------------------------------------------
def LoadDatabase(DatabaseFile, Mismatches, OutputType, RAMThreshold, ComplementKeys, 
MismatchKeys, WildcardKeys, Mode, DatabaseFrag, StandardizeNames):
    """Loads all target sequences to be searched for and parses them.
    Reads in all target sequences, breaks them up as appropriate,
    generates reverse complements, generates all mismatch sequences if needed,
    expands wildcards into multiple sequences, and stores result into
    SegMatches.  Also returns a variety of other relevant information for
    speeding things along later.
    The limiting factor in this routine is creation of SeqMatches; generally
    over 50% of the total processing time is the assignment statement
    (mostly generation of the hash value & memory creation).
    SeqMatches is dictionary with key = sequence, value = list of:
    [y] = all information about targets matching that sequence
    [y][0] = Names of target (with unique marker char appended)
    [y][1] = # this segment is in order (1=2nd, 2=3rd, etc.)
             if 1st position, then is -NumSegs for that sequence
    [y][2] = # of mismatches for this target at this sequence
    [y][3] = minimum gap length following this segment
    [y][4] = maximum gap length following this segment
    [y][5] = index in FileNameArray containing the relevant output file
    [y][6] = Strand (0 = sense, 1 = antisense)
    [y][7] = '' unless 1st in series & 1st segment is longer than TL,
                in which case it contains the extra positions
    [y][8] = Length of following segment
    """
    RAMThreshold = RAMThreshold*10000 # roughly 10K sequences per MB RAM
    TestFileExist(DatabaseFile) # see if database file exists
    InputFile = open(DatabaseFile, 'r')
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    Digits = '0123456789' # negative values not allowed for gaps
    TargetList = [] # for storing targets
    TargetLength = 10**10
    MultSeqsForTarget = 0 # if target has multiple sequences associated with it, need to 
do some extra error checking
    for EachLine in InputFile:
        ProcessArray = EachLine.split('=', 1) # split into names and sequences
        if len(ProcessArray) == 2: # only if this line contains an =
            MultArray = ProcessArray[1].split(',') # split sequences into separate parts 
(if more than 1)
            for EachSeq in MultArray:
                TargetList.append([ProcessArray[0].strip(), EachSeq.strip().upper()]) # 
remove white space, store name/seq pair
    InputFile.close()
    # ensure at least one target identified before proceeding
    if len(TargetList) == 0:
        AbortProgram('Error: no valid target sequences found in database.')
    if StandardizeNames == 1: # make all names same length
        LongestName = 0
        for EachEntry in TargetList: # determine longest name length
            if len(EachEntry[0]) > LongestName:
                LongestName = len(EachEntry[0]) # store longest name length
        for Pos in range(len(TargetList)): # adjust name lengths
            if len(TargetList[Pos][0]) < LongestName:
                TargetList[Pos][0] = TargetList[Pos][0] + ' '*(LongestName - 
len(TargetList[Pos][0])) # append spaces to make all same length
    # generate list of names for files; all targets with same name must refer to same 
file
    if OutputType == 0: # generate names based on 
        FileNameArray = [] # stores file names
        for EachTarget in TargetList: # for each entry
            for PrevTarget in range(len(FileNameArray)): # for all previous file names 
established
                if EachTarget[0].lower() == FileNameArray[PrevTarget].lower(): # if same 
name
                    EachTarget.append(PrevTarget) # make this entry refer to this file
                    MultSeqsForTarget = 1 # and note that multiple sequences for single 
target
                    break
            else: # need to create new file reference
                EachTarget.append(len(FileNameArray))
                FileNameArray.append(DatabaseFrag + EachTarget[0])
    else:
        # check for multiple entries for single target by removing duplicates & comparing 
length
        TempDic = {}
        for EachTarget in TargetList:
            EachTarget.append(0)
            TempDic[EachTarget[0].lower()] = EachTarget[0]
        if len(TempDic) < len(TargetList):
            MultSeqsForTarget = 1
        if OutputType == 1: # single file output
            FileNameArray = [DatabaseFrag + 'output']
        else: # full annotated output
            if Mode == 1:
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                FileNameArray = [DatabaseFrag + 'sense', DatabaseFrag + 'antisense']
            else:
                FileNameArray = [DatabaseFrag + 'sequence']
    # now append .txt to all file names
    for FileNum in range(len(FileNameArray)):
        FileNameArray[FileNum] = FileNameArray[FileNum] + '.txt'
    # now make each entry (even if same target name) unique to avoid "crossing over" of 
multiple target sequences with gaps
    NameTracker = {}
    for TargetNum in range(len(TargetList)):
        if TargetList[TargetNum][0] in NameTracker:
            NameTracker[TargetList[TargetNum][0]] = 
NameTracker[TargetList[TargetNum][0]]+2
            if NameTracker[TargetList[TargetNum][0]] > 128:
                AbortProgram('Error: too many listed sequences associated with a single 
target name.')
        else:
            NameTracker[TargetList[TargetNum][0]] = 0
        TargetList[TargetNum][0] = TargetList[TargetNum][0] + 
chr(127+NameTracker[TargetList[TargetNum][0]])
    SplitTargets = [] # for storing segments
    LongestTarget = 0
    ShortestTarget = 10**10 # presumably nobody will run a target longer than 10 billion
    for EachTarget in TargetList:
        # split each entry into segments
        SeqSegs = [] # sequence segments for this target
        GapSegs = [] # gap segments for this target
        # check for easy problems to catch
        if EachTarget[1][-1] == ']': # terminal gap
            AbortProgram('Error: terminal gap found in target sequence.')
        if EachTarget[1][0] == '[': # opening gap
            AbortProgram('Error: target sequence begins with gap.')
        if EachTarget[1].count('[') != EachTarget[1].count(']'): # unbalanced gap markers
            AbortProgram('Error: target sequence is missing opening or closing gap marker 
([ or ]).')
        Portions = EachTarget[1].split('[') # Portions[0] = first sequence part, [x] = 
[x-1 gap, x seq part]
        NumSegs = len(Portions) # Number of segments for this target
        # first segment does not have gap region attached, so just add it
        SeqSegs.append(Portions[0])
        # others need to have gap regions removed before adding to list
        for Remaining in range(1, len(Portions)):
            Portions[Remaining] = Portions[Remaining].split(']')
            SeqSegs.append(Portions[Remaining][1])
            GapSegs.append(Portions[Remaining][0].split(':'))
            if len(GapSegs[-1]) != 2: # if gap did not contain exactly 1 ":"
                AbortProgram('Error: target gaps must be in the format [X:Y], where X & Y 
are non-negative integers.')
            else:
                for EachPart in GapSegs[-1]: # determine that all values are valid
                    if len(EachPart) == 0 or EachPart.strip(Digits) != '':
                        AbortProgram('Error: target gaps must be in the format [X:Y], 
where X & Y are non-negative integers.')
        # SeqSegs is now list of all segments, GapSegs is list of [first, second] of gap 
elements
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        for EachSeg in SeqSegs:
            if len(EachSeg) == 0: # if 0 length segment
                AbortProgram('Error: target contains 2 gaps without sequence between 
them.')
            else: # ensure all characters exist in dictionaries
                for Char in EachSeg:
                    if Char not in ComplementKeys:
                        AbortProgram('Error: target sequence contains a character (' + 
str(Char) + ') not in complement rule set.')
                    elif Char not in MismatchKeys:
                        AbortProgram('Error: target sequence contains a character (' + 
str(Char) + ') not in mismatch rule set.')
        # determine low & high values for each gap region, maximum value
        MinRegion = []
        MaxRegion = []
        for GapNum in range(len(GapSegs)): # for each gap segment, determine max and min, 
determine longest overall
            MinRegion.append(min(int(GapSegs[GapNum][0]), int(GapSegs[GapNum][1])))
            MaxRegion.append(max(int(GapSegs[GapNum][0]), int(GapSegs[GapNum][1]))+1) # 
+1 to include this value when calculating ranges
        # append all information for each segment
        for SegNum in range(NumSegs-1):
            SplitTargets.append([SeqSegs[SegNum], [EachTarget[0], SegNum, 0, 
MinRegion[SegNum], MaxRegion[SegNum], EachTarget[2], 0, '', len(SeqSegs[SegNum+1])]])
        SplitTargets.append([SeqSegs[NumSegs-1], [EachTarget[0], NumSegs-1, 0, 0, 0, 
EachTarget[2], 0, '', 0]])
        SplitTargets[-NumSegs][1][1] = -NumSegs
        # generate reverse complements to each segment
        if Mode == 1: # nucleic acid style
            comparray = []
            for SegNum in range(NumSegs): # for each sequence Segment, get rc & append
                compstr = ''.join([ComplementKeys[Char] for Char in SeqSegs[SegNum][::-
1]])
                comparray.append(compstr)
            comparray.reverse()
            MaxRegion.reverse()
            MinRegion.reverse()
            RCName = EachTarget[0][:-1] + chr(ord(EachTarget[0][-1])+1)
            for SegNum in range(NumSegs-1):
                SplitTargets.append([comparray[SegNum], [RCName, SegNum, 0, 
MinRegion[SegNum], MaxRegion[SegNum], EachTarget[2], 1, '', len(comparray[SegNum+1])]])
            SplitTargets.append([comparray[NumSegs-1], [RCName, NumSegs-1, 0, 0, 0, 
EachTarget[2], 1, '', 0]])
            SplitTargets[-NumSegs][1][1] = -NumSegs
            TargetLength = min(TargetLength, len(SeqSegs[0]), len(SeqSegs[-1]))
        else:
            TargetLength = min(TargetLength, len(SeqSegs[0]))
        # determine longest & shortest possible Target
        CurMinLength = sum([len(EachSeg) for EachSeg in SeqSegs]) + sum(MinRegion)
        CurMaxLength = sum([len(EachSeg) for EachSeg in SeqSegs]) + sum(MaxRegion)
        LongestTarget = max(LongestTarget, CurMaxLength)
        ShortestTarget = min(ShortestTarget, CurMinLength)
        # if user requested output format 2 with variable target size, switch output type
        if OutputType == 2 and (ShortestTarget != LongestTarget or NumSegs > 1):
            print 'Warning: output format 2 only works when all target sequences are the 
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same length and do not contain gaps.'
            print '  Changing output format to default (type 1).'
            FileNameArray = [DatabaseFrag + 'output.txt']
            OutputType = 1
    # generate all possible mismatches
    splitlen = len(SplitTargets)
    for MismatchNum in range(1, Mismatches+1):
        for TargetNum in range(splitlen):
            SplitTargets = GenerateMismatches(SplitTargets, '', 
SplitTargets[TargetNum][0], MismatchNum, TargetNum, MismatchNum, MismatchKeys)
    # now calculate how many sequences are going to be generated & ensure all chars are 
in wildcards dictionary
    Hits = 0
    for EachTarget in SplitTargets:
        TempHits = 1
        for Char in EachTarget[0]:
            if Char in WildcardKeys:
                TempHits = TempHits*len(WildcardKeys[Char])
            else:
                AbortProgram('Error: generated sequence contains a character (' + 
str(Char) + ') not in wildcard rule set.')
        Hits = Hits + TempHits
    if Hits > RAMThreshold: # if RAM usage is likely to be excessive
        ExcessFactor = str(int(100.0*(Hits-RAMThreshold)/RAMThreshold)) + '%'
        MessageStr = 'Warning: estimated RAM usage is ' + ExcessFactor + ' higher than 
warning level.  Continue? '
        InputStr = ''
        while InputStr != 'y' and InputStr != 'n':
            InputFromUser = raw_input(MessageStr)
            InputStr = InputFromUser[0:1].lower()
        if InputStr == 'n':
            AbortProgram('Exiting.')
    # now need to expand all forms into single matches & store in master array
    SeqMatches = {}
    for EachTarget in SplitTargets: # for each segment
        TempList = [''] # reset
        for Char in EachTarget[0]: # for each character in segment sequences
            curlen = len(WildcardKeys[Char]) # number of characters corresponding to that 
letter
            # duplicate list to allow for new entries
            TempList = TempList * curlen
            for NewCharNum in range(curlen): # for each conversion necessary, run through 
a fraction of the list and replace the letter
                ListStart = NewCharNum * len(TempList)/curlen
                ListStop = (NewCharNum + 1) * len(TempList)/curlen
                for ListPos in range(ListStart, ListStop):
                    TempList[ListPos] = TempList[ListPos] + 
WildcardKeys[Char][NewCharNum]
        # store all permutations from a SplitTargets entry in SeqMatches
        if EachTarget[1][1] < 0 and len(EachTarget[0]) > TargetLength:
            NeedCopy = 1 # all 1st sequences must be represented by consistent length, so 
allow for moving excess into data array
        else:
            NeedCopy = 0
            TargetData = EachTarget[1]
155
        for NewTarget in TempList:
            if NeedCopy == 1: # duplicate to allow storage of excess sequence info
                TargetStr = NewTarget[:TargetLength]
                TargetData = EachTarget[1][:]
                TargetData[7] = NewTarget[TargetLength:]
            else:
                TargetStr = NewTarget
            if TargetStr in SeqMatches:
                PrevMatch = SeqMatches[TargetStr]
                if MultSeqsForTarget == 1: # possibility for single target/sequence pair 
to generate same sequence w/ different mismatch levels, so find lowest
                    for MatchNum in range(len(PrevMatch)):
                        # if same name/series/strand, same position, and same extension
                        if PrevMatch[MatchNum][0] == TargetData[0] and 
PrevMatch[MatchNum][7] == TargetData[7] and PrevMatch[MatchNum][1] == TargetData[1]:
                            if PrevMatch[MatchNum][2] > TargetData[2]: # replace existing 
if newer has fewer mismatches
                                PrevMatch[MatchNum] = TargetData
                            # else don't need to add this one, skip it
                            break
                    else:
                        PrevMatch.append(TargetData) # otherwise just add it as a new 
match for this sequence
                else:
                    PrevMatch.append(TargetData) # No need to worry about mismatch levels
            else:
                SeqMatches[TargetStr] = [TargetData] # create entry
    return TargetLength, SeqMatches, FileNameArray, OutputType, ShortestTarget, 
LongestTarget
#---------------------------------------------------------------------------
def TestFileExist(FileName):
    """Determines if FileName exists, aborts script if not found.
    """
    try:
        TestFile = open(FileName, 'r')
    except IOError:
        AbortProgram('Error: ' + FileName +  ' not found.\n')
    TestFile.close()
#---------------------------------------------------------------------------
def TestFileOverWrite(OutputDirs, OutputType, FileNameArray, PatternRestrictions):
    """Determines if FileName exists, and confirms overwrite if so.
    """
    for OutDir in OutputDirs:
        FileList = []
        for FileName in FileNameArray:
            FileList.append(FileName)
        for PatNum in range(len(PatternRestrictions)):
            FileList.append(PatternRestrictions[PatNum][2])
        for FileName in FileList: # For each file to be created in this directory
            TestFileName = OutDir + FileName
            try:
                TestFile = open(TestFileName, 'r')
            except IOError:
                pass # file does not exist, so do nothing
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            else: # does exist, so confirm overwrite
                MessageStr = 'Do you wish to overwrite existing files? '
                InputStr = ''
                while InputStr != 'y' and InputStr != 'n':
                    InputFromUser = raw_input(MessageStr)
                    InputStr = InputFromUser[0:1].lower()
                if InputStr == 'n':
                    AbortProgram('Exiting: provide a new output directory or move 
exisiting files to avoid overwrites.')
                TestFile.close()
                return # so only prompts user once even if more files exist
#---------------------------------------------------------------------------
# Main program, mostly just calls routines.
# Routines allow psyco to accelerate code if available & ease finding of code
try: # try to load psyco, expecting that it may not be installed
    import psyco
except:
    pass # just don't load it
else:
    psyco.full()
SettingsFile = 'espsearch.ini' # the basic user settings file
print 'Initializing...'
# get initial variables from user
InputFileName, OutputDirectory, PatternToMatch, DatabaseFile, Mismatches, MaxMismatches, 
CreateDir, OutputType, PatternType, DatabaseFrag, BufferSize, IssueRAMWarning, KeyFile, 
StandardizeNames = Initialization(SettingsFile)
# get rules from user
Mode, ComplementKeys, MismatchKeys, WildcardKeys, MasterKeys = GetKeys(KeyFile)
# load target sequence database and parse it
TargetLength, SeqMatches, FileNameArray, OutputType, ShortestTarget, LongestTarget = 
LoadDatabase(DatabaseFile, Mismatches, OutputType, IssueRAMWarning, ComplementKeys, 
MismatchKeys, WildcardKeys, Mode, DatabaseFrag, StandardizeNames)
# parse patterns specified by user
PatternRestrictions, MinPatternBuffer = DefinePattern(PatternToMatch, ShortestTarget, 
LongestTarget, Mode, DatabaseFrag)
# create directories if necessary, test for existence of source file(s)
if CreateDir == 0:
    # avoid creating directories, so no looping over multiple source files
    if len(InputFileName) > 1:
        print 'Warning: not creating directories, so will only process first source 
file.'
    OutputDirs = [OutputDirectory]
    InputFileName = [InputFileName[0]]
    # test to ensure that the input file actually exists; if not, then exit
    TestFileExist(InputFileName[0])
else:
    # test to ensure that the input file(s) actually exist; if not, then exit
    for FileName in InputFileName:
        TestFileExist(FileName)
    # Tests for ability to write files and creates directories
    OutputDirs = DoOSOperations(InputFileName, OutputDirectory)
print 'Done.'
# test for overwrites
TestFileOverWrite(OutputDirs, OutputType, FileNameArray, PatternRestrictions)
# run through all source files
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for FileNum in range(len(InputFileName)):
    print '  Searching', InputFileName[FileNum]
    FindSequences(SeqMatches, InputFileName[FileNum], OutputDirs[FileNum], TargetLength, 
MaxMismatches, FileNameArray, PatternRestrictions, OutputType, PatternType, BufferSize, 
ShortestTarget, LongestTarget, MinPatternBuffer, MasterKeys, Mode)
AbortProgram('Analysis complete.')
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B APPENDIX B
ESPSEARCHGUI CODE
# ESPSearchGUI.py, version 1.01
""" Graphical user interface for ESPSearch.
    Copyright (C) 2005 Terry J. Watt
    This program is free software; you can redistribute it and/or
    modify it under the terms of the GNU General Public License
    as published by the Free Software Foundation; either version 2
    of the License, or (at your option) any later version.
    This program is distributed in the hope that it will be useful,
    but WITHOUT ANY WARRANTY; without even the implied warranty of
    MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE.  See the
    GNU General Public License for more details.
    You should have received a copy of the GNU General Public License
    along with this program; if not, write to the Free Software
    Foundation, Inc., 59 Temple Place - Suite 330, Boston, MA  02111-1307, USA.
    You may contact Terry Watt at:
    terry.watt@chemistry.gatech.edu
    School of Chemistry & Biochemistry
    Atlanta, GA 30332-0400
    See espsearchgui.html for instructions on using this script and for the GPL.
    See http://web.chemistry.gatech.edu/~doyle/espsearch/ for more information.
"""
#---------------------------------------------------------------------------
def ChooseDir(Key, Fields):
    """Opens dialog to choose directory & sets the corresponding field.
    """
    Diag = tkFileDialog
    dirname = Diag.askdirectory()
    if dirname != None:
        Fields[Key].delete(0, Tkinter.END)
        Fields[Key].insert(0, dirname)
#---------------------------------------------------------------------------
def ChooseFile(Key, Fields):
    """Opens dialog to choose file & sets the corresponding field.
    """
    Diag = tkFileDialog
    filename = Diag.askopenfile(title='Select File')
    if filename != None:
        filename.close()
        InsertText = str(filename).split('\'')
        Fields[Key].delete(0, Tkinter.END)
        Fields[Key].insert(0, InsertText[1])
#---------------------------------------------------------------------------
def ChooseFiles(Key, DirKey, Fields):
    """Opens dialog to choose multiple files, and sets list & directory separately.
    """
    Diag = tkFileDialog
    filenames = Diag.askopenfiles(title='Select File(s)')
    if filenames != '':
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        InsertText = ''
        for EachName in filenames:
            EachName.close()
            Name = str(EachName).split('\'')
            RealName = Name[1].split('/')
            InsertText = InsertText + ', ' + RealName[-1]
        Fields[Key].delete(0, Tkinter.END)
        Fields[Key].insert(0, InsertText[2:])
        DirText = Name[1][:-len(RealName[-1])]
        Fields[DirKey].config(state=Tkinter.NORMAL)
        Fields[DirKey].delete(0, Tkinter.END)
        Fields[DirKey].insert(0, DirText)
        Fields[DirKey].config(state=Tkinter.DISABLED)
#---------------------------------------------------------------------------
def DrawEverything(root, SettingsFile):
    """Draws GUI, returning widgets that need to be manipulated.
    Note: command=Func(1,2,3,...) triggers call, and links command to the return value
        instead use: command=lambda A=1, B=2, C=3, ... : Func(A,B,C,...)
    """
    # Parameter labels
    TitleFont = ('Helvetica', 9, 'bold')
    MainFont = ('Helvetica', 8)
    HiddenFont = ('Helvetica', 4)
    LabelA = Tkinter.Label(text='File Locations', font=TitleFont)
    LabelA.grid(row=0, column=0, columnspan=5)
    Label1 = Tkinter.Label(text='Database', font=MainFont)
    Label1.grid(row=1, column=0, sticky=Tkinter.E)
    Label2 = Tkinter.Label(text='Output Directory', font=MainFont)
    Label2.grid(row=2, column=0, sticky=Tkinter.E)
    Label3 = Tkinter.Label(text='Rules File', font=MainFont)
    Label3.grid(row=3, column=0, sticky=Tkinter.E)
    Label4 = Tkinter.Label(text='Source Directory', font=MainFont)
    Label4.grid(row=4, column=0, sticky=Tkinter.E)
    Label5 = Tkinter.Label(text='Source File(s)', font=MainFont)
    Label5.grid(row=5, column=0, sticky=Tkinter.E)
    LabelAA = Tkinter.Label(text='', font=HiddenFont)
    LabelAA.grid(row=6, column=0, columnspan=5)
    LabelB = Tkinter.Label(text='General Options', font=TitleFont)
    LabelB.grid(row=10, column=0, columnspan=5)
    Label6 = Tkinter.Label(text='Create Directories', font=MainFont)
    Label6.grid(row=11, column=0, sticky=Tkinter.E)
    Label7 = Tkinter.Label(text='Output Format', font=MainFont)
    Label7.grid(row=12, column=0, sticky=Tkinter.E)
    Label8 = Tkinter.Label(text='Standarize Name Length', font=MainFont)
    Label8.grid(row=13, column=0, sticky=Tkinter.E)
    LabelBB = Tkinter.Label(text='', font=HiddenFont)
    LabelBB.grid(row=14, column=0, columnspan=5)
    LabelC = Tkinter.Label(text='Target Sequence Options', font=TitleFont)
    LabelC.grid(row=20, column=0, columnspan=5)
    Label9 = Tkinter.Label(text='Maximum Mismatches per Segment', font=MainFont)
    Label9.grid(row=21, column=0, sticky=Tkinter.E)
    Label10 = Tkinter.Label(text='Maximum Total Mismatches', font=MainFont)
    Label10.grid(row=22, column=0, sticky=Tkinter.E)
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    LabelCC = Tkinter.Label(text='', font=HiddenFont)
    LabelCC.grid(row=23, column=0, columnspan=5)
    LabelD = Tkinter.Label(text='Pattern Options', font=TitleFont)
    LabelD.grid(row=30, column=0, columnspan=5)
    Label11 = Tkinter.Label(text='Exact Sequence Pattern Match', font=MainFont)
    Label11.grid(row=31, column=0, sticky=Tkinter.E)
    Label12 = Tkinter.Label(text='Pattern(s)', font=MainFont)
    Label12.grid(row=32, column=0, sticky=Tkinter.E)
    LabelDD = Tkinter.Label(text='', font=HiddenFont)
    LabelDD.grid(row=33, column=0, columnspan=5)
    LabelE = Tkinter.Label(text='Performance Options', font=TitleFont)
    LabelE.grid(row=40, column=0, columnspan=5)
    Label13 = Tkinter.Label(text='Buffer', font=MainFont)
    Label13.grid(row=41, column=0, sticky=Tkinter.E)
    Label14 = Tkinter.Label(text='RAM Warning Level', font=MainFont)
    Label14.grid(row=42, column=0, sticky=Tkinter.E)
    LabelEE = Tkinter.Label(text='', font=HiddenFont)
    LabelEE.grid(row=43, column=0, columnspan=5)
    # Entry fields
    Fields = {}
    Fields['Database'] = Tkinter.Entry(width=40)
    Fields['Database'].grid(row=1, column=1, padx=5, columnspan=3)
    DBButton = Tkinter.Button(text="Choose...", command=lambda A = 'Database', B = 
Fields: ChooseFile(A, B))
    DBButton.grid(row=1, column=4)
    Fields['Output Directory'] = Tkinter.Entry(width=40)
    Fields['Output Directory'].grid(row=2, column=1, padx=5, columnspan=3)
    ODButton = Tkinter.Button(text="Choose...", command=lambda A = 'Output Directory', B 
= Fields: ChooseDir(A, B))
    ODButton.grid(row=2, column=4)
    Fields['Rules File'] = Tkinter.Entry(width=40)
    Fields['Rules File'].grid(row=3, column=1, padx=5, columnspan=3)
    RFButton = Tkinter.Button(text="Choose...", command=lambda A = 'Rules File', B = 
Fields: ChooseFile(A, B))
    RFButton.grid(row=3, column=4)
    Fields['Source Directory'] = Tkinter.Entry(width=40, state=Tkinter.DISABLED)
    Fields['Source Directory'].grid(row=4, column=1, padx=5, columnspan=3)
    Fields['Source File'] = Tkinter.Entry(width=40)
    Fields['Source File'].grid(row=5, column=1, padx=5, columnspan=3)
    SDButton = Tkinter.Button(text="Choose...", command=lambda A = 'Source File', B = 
'Source Directory', C = Fields: ChooseFiles(A, B, C))
    SDButton.grid(row=5, column=4)
    Fields['Create Directories Var'] = Tkinter.IntVar()
    Fields['Create Directories'] = Tkinter.Checkbutton(variable=Fields['Create 
Directories Var'])
    Fields['Create Directories'].grid(row=11, column=1, padx=5, sticky=Tkinter.W)
    Fields['Output Format Var'] = Tkinter.IntVar()
    Fields['Output Format 1'] = Tkinter.Radiobutton(text='Many Files', 
variable=Fields['Output Format Var'], value=0, anchor=Tkinter.W)
    Fields['Output Format 1'].grid(row=12, column=1, padx=5, sticky=Tkinter.W)
    Fields['Output Format 2'] = Tkinter.Radiobutton(text='Single File', 
variable=Fields['Output Format Var'], value=1, anchor=Tkinter.W)
    Fields['Output Format 2'].grid(row=12, column=2, padx=5, sticky=Tkinter.W)
    Fields['Output Format 3'] = Tkinter.Radiobutton(text='Strands', 
variable=Fields['Output Format Var'], value=2, anchor=Tkinter.W)
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    Fields['Output Format 3'].grid(row=12, column=3, padx=5, sticky=Tkinter.W)
    Fields['Output Format Var'].set(1)
    Fields['Name Length Var'] = Tkinter.IntVar()
    Fields['Standardize Name Length'] = Tkinter.Checkbutton(variable=Fields['Name Length 
Var'])
    Fields['Standardize Name Length'].grid(row=13, column=1, padx=5, sticky=Tkinter.W)
    Fields['Maximum Mismatches per Segment'] = Tkinter.Entry(state=Tkinter.NORMAL, 
width=5)
    Fields['Maximum Mismatches per Segment'].grid(row=21, column=1, padx=5, 
sticky=Tkinter.W)
    Fields['Maximum Mismatches per Segment'].insert(0, '0')
    Fields['Maximum Total Mismatches'] = Tkinter.Entry(state=Tkinter.NORMAL, width=5)
    Fields['Maximum Total Mismatches'].grid(row=22, column=1, padx=5, sticky=Tkinter.W)
    Fields['Maximum Total Mismatches'].insert(0, '0')
    Fields['Pattern Var'] = Tkinter.IntVar()
    Fields['Exact Sequence Pattern Match'] = Tkinter.Checkbutton(variable=Fields['Pattern 
Var'])
    Fields['Exact Sequence Pattern Match'].grid(row=31, column=1, padx=5, 
sticky=Tkinter.W)
    Fields['Pattern'] = Tkinter.Entry(state=Tkinter.NORMAL, width=40)
    Fields['Pattern'].grid(row=32, column=1, padx=5, columnspan=3)
    Fields['Buffer'] = Tkinter.Entry(state=Tkinter.NORMAL, width=5)
    Fields['Buffer'].grid(row=41, column=1, padx=5, sticky=Tkinter.W)
    Fields['Buffer'].insert(0, '1000')
    Fields['RAM Warning Level'] = Tkinter.Entry(state=Tkinter.NORMAL, width=5)
    Fields['RAM Warning Level'].grid(row=42, column=1, padx=5, sticky=Tkinter.W)
    Fields['RAM Warning Level'].insert(0, '50')
    # command buttons
    FrameA = Tkinter.Frame(borderwidth=2, relief=Tkinter.RIDGE)
    FrameA.grid(row=50, column=0, columnspan=5)
    LoadButton = Tkinter.Button(FrameA, text='Load Settings', height=2, width=15, 
command=lambda A = Fields : LoadSettings(A))
    LoadButton.grid(row=50, column=0, padx=10, pady=5)
    SaveButton = Tkinter.Button(FrameA, text='Save Settings', height=2, width=15, 
command=lambda A = Fields : SaveSettings(A))
    SaveButton.grid(row=50, column=1, padx=10, pady=5)
    RunButton = Tkinter.Button(FrameA, text='Run Search', height=2, width=15, 
command=lambda A = SettingsFile, B = Fields, C = root : RunSearch(A, B, C))
    RunButton.grid(row=50, column=2, padx=10, pady=5)
    QuitButton = Tkinter.Button(FrameA, text='Quit', height=2, width=15, 
command=root.quit)
    QuitButton.grid(row=50, column=3, padx=10, pady=5)
    return Fields
#---------------------------------------------------------------------------
def LoadSettings(Fields):
    """Loads ini file & dumps into appropriate fields.
    No error checking is performed, ESPSearch handles all.
    For check/radio button values, unrecognized values are treated as default.
    For all, missing values are treated as default.
    """
    # prompt user for file name
    Diag = tkFileDialog
    InputFile = Diag.askopenfile(filetypes = [('Settings Files', '*.ini'), ('All Files', 
'*')])
    # don't try to load if they didn't select a file
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    if InputFile == None: return
    # clear/reset all fields to defaults
    Fields['Database'].delete(0, Tkinter.END)
    Fields['Output Directory'].delete(0, Tkinter.END)
    Fields['Rules File'].delete(0, Tkinter.END)
    Fields['Source Directory'].config(state=Tkinter.NORMAL) # active for editing
    Fields['Source Directory'].delete(0, Tkinter.END)
    Fields['Source File'].delete(0, Tkinter.END)
    Fields['Create Directories Var'].set(0)
    Fields['Output Format Var'].set(1)
    Fields['Name Length Var'].set(0)
    Fields['Maximum Mismatches per Segment'].delete(0, Tkinter.END)
    Fields['Maximum Mismatches per Segment'].insert(0, '0')
    Fields['Maximum Total Mismatches'].delete(0, Tkinter.END)
    Fields['Maximum Total Mismatches'].insert(0, '0')
    Fields['Pattern Var'].set(0)
    Fields['Pattern'].delete(0, Tkinter.END)
    Fields['Buffer'].delete(0, Tkinter.END)
    Fields['Buffer'].insert(0, '1000')
    Fields['RAM Warning Level'].delete(0, Tkinter.END)
    Fields['RAM Warning Level'].insert(0, '50')
    # load parameters & set fields
    for EachLine in InputFile:
        ProcessArray = EachLine.split('=', 1) # get parameter & value
        CurIniEntry = ProcessArray[0].lower().strip() # remove white space & make 
lowercase
        if len(ProcessArray) == 2: # if it had an = sign in entry
            CurIniValue = ProcessArray[1].strip()
            if CurIniEntry == 'pattern':
                Fields['Pattern'].insert(0, CurIniValue)
            elif CurIniEntry == 'database':
                Fields['Database'].insert(0, CurIniValue)
            elif CurIniEntry == 'source directory':
                Fields['Source Directory'].insert(0, CurIniValue)
            elif CurIniEntry == 'output directory':
                Fields['Output Directory'].insert(0, CurIniValue)
            elif CurIniEntry == 'rules file':
                Fields['Rules File'].insert(0, CurIniValue)
            elif CurIniEntry == 'source file':
                Fields['Source File'].insert(0, CurIniValue)
            elif CurIniEntry == 'maximum mismatches per segment':
                Fields['Maximum Mismatches per Segment'].delete(0, Tkinter.END)
                Fields['Maximum Mismatches per Segment'].insert(0, CurIniValue)
            elif CurIniEntry == 'maximum total mismatches':
                Fields['Maximum Total Mismatches'].delete(0, Tkinter.END)
                Fields['Maximum Total Mismatches'].insert(0, CurIniValue)
            elif CurIniEntry == 'buffer':
                Fields['Buffer'].delete(0, Tkinter.END)
                Fields['Buffer'].insert(0, CurIniValue)
            elif CurIniEntry == 'ram warning level':
                Fields['RAM Warning Level'].delete(0, Tkinter.END)
                Fields['RAM Warning Level'].insert(0, CurIniValue)
            # next four actually require some processing
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            elif CurIniEntry == 'create directories':
                if CurIniValue == '1':
                    Fields['Create Directories Var'].set(1)
            elif CurIniEntry == 'output format':
                if CurIniValue == '0':
                    Fields['Output Format Var'].set(0)
                elif CurIniValue == '2':
                    Fields['Output Format Var'].set(2)
            elif CurIniEntry == 'standardize name length':
                if CurIniValue == '1':
                    Fields['Name Length Var'].set(1)
            elif CurIniEntry == 'exact sequence pattern match':
                if CurIniValue == '1':
                    Fields['Pattern Var'].set(1)
            # ignore anything else
    InputFile.close()
    Fields['Source Directory'].config(state=Tkinter.DISABLED) # turn this off again
#---------------------------------------------------------------------------
def RunSearch(SettingsFile, Fields, root):
    """Runs main search, locking access to gui in meantime.
    Using redefined stdin & stdout, traps ESPSearch output & displays in a log
    window, and prompts the user for input when needed.  The log window will
    close (and allow access to main window) when user closes, following
    ESPSearch completion (whether successful or not).
    """
    SaveSettings(Fields, SettingsFile)
    class StdoutRedirect: # writes to a text box instead of Python display
        def __init__(self):
            self.last = '' # used by prompts in StdinRedirect
        def write(self, stuff):
            StatusDisplay.config(state=Tkinter.NORMAL)
            StatusDisplay.insert(Tkinter.END, stuff)
            StatusDisplay.yview(Tkinter.END)
            StatusDisplay.config(state=Tkinter.DISABLED)
            self.last = stuff
    class StdinRedirect: # pops up an input dialog box whenever readline called 
(raw_input by ESPSearch)
        def readline(self):
            Prompt = StdoutDisplay.last
            Response = tkSimpleDialog.askstring('ESPSearch requires input', Prompt, 
parent=DialogWindow)
            Response = Response + '\n'
            print '\n', Response[:-1]
            return Response
            
    def CloseWindow(): # used to return control to main window
        if ButtonState == Tkinter.NORMAL: # only if ESPSearch has finished
            DialogWindow.withdraw() # release control
            DialogWindow.update_idletasks() # update background
            root.focus_set() # return focus to main window
            DialogWindow.destroy() # remove this window 
            
    # create dialog box
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    DialogWindow = Tkinter.Toplevel() # define new main window
    DialogWindow.title('ESPSearch Status')
    DialogWindow.transient(root) # make not appear in taskbar & link max/min to main 
window
    DialogWindow.grab_set() # make modal
    DialogWindow.initial_focus = DialogWindow # set focus to this window
    DialogWindow.protocol('WM_DELETE_WINDOW', lambda : CloseWindow()) # tie to OK button
    DialogWindow.geometry('+%d+%d' % (root.winfo_rootx()+50, root.winfo_rooty()+50)) # 
position window 50 right & down from main window (upper right corners)
    
    # create a log for ESPSearch output & associate a scrollbar
    StatusDisplayScrollbar = Tkinter.Scrollbar(master=DialogWindow)
    StatusDisplayScrollbar.grid(row=0, column=1, 
sticky=Tkinter.W+Tkinter.N+Tkinter.S+Tkinter.E)
    StatusDisplay = Tkinter.Text(master=DialogWindow, height=10, state=Tkinter.DISABLED, 
yscrollcommand=StatusDisplayScrollbar.set, wrap=Tkinter.WORD, width=80)
    StatusDisplay.grid(row=0, column=0, sticky=Tkinter.W)
    StatusDisplayScrollbar.config(command=StatusDisplay.yview)
    ButtonState = Tkinter.DISABLED
    OKButton = Tkinter.Button(master=DialogWindow, text='Close Window', 
state=ButtonState, default=Tkinter.ACTIVE, command=lambda : CloseWindow())
    OKButton.grid(row=10, column=0, columnspan=2)
    # redirect stdin & stdout
    import sys
    OldStdout = sys.stdout
    StdoutDisplay = StdoutRedirect()
    sys.stdout = StdoutDisplay
    OldStdin = sys.stdin
    StdinSource = StdinRedirect()
    sys.stdin = StdinSource
         
    # run ESPSearch, trapping the exit from it
    try:
        import espsearch
    except SystemExit:
        ButtonState = Tkinter.NORMAL
        OKButton.config(state=ButtonState)
    # restore stdin & stdout
    sys.stdout = OldStdout
    sys.stdin = OldStdin
#---------------------------------------------------------------------------
def SaveSettings(Fields, SettingsFile=''):
    """Writes espsearch.ini.
    No error checking is performed to validate settings.
    """
    if SettingsFile == '':
        # prompt user for file name
        Diag = tkFileDialog
        OutputFile = Diag.asksaveasfile(filetypes = [('Settings Files', '*.ini'), ('All 
Files', '*')], defaultextension='.ini', title='Save Settings')
        # don't try to save if they didn't select a file
        if OutputFile == None: return
    else:
        OutputFile = open(SettingsFile, 'w')
    # write out all fields, including comments for standard espsearch ini file
    OutputFile.write('# See espsearch.html for information on these settings\n')
    OutputFile.write('# File Locations\n')
    OutputFile.write('Database=' + Fields['Database'].get() + '\n')
    OutputFile.write('Output Directory=' + Fields['Output Directory'].get() + '\n')
    OutputFile.write('Rules File=' + Fields['Rules File'].get() + '\n')
    Fields['Source Directory'].config(state=Tkinter.NORMAL) # active for editing
    OutputFile.write('Source Directory=' + Fields['Source Directory'].get() + '\n')
    Fields['Source Directory'].config(state=Tkinter.DISABLED) # turn this off again
    OutputFile.write('Source File=' + Fields['Source File'].get() + '\n')
    OutputFile.write('\n')
    OutputFile.write('# General Options\n')
    OutputFile.write('Create Directories=' + str(Fields['Create Directories Var'].get()) 
+ '\n')
    OutputFile.write('Output Format=' + str(Fields['Output Format Var'].get()) + '\n')
    OutputFile.write('Standardize Name Length=' + str(Fields['Name Length Var'].get()) + 
'\n')
    OutputFile.write('\n')
    OutputFile.write('# Target Sequence Options\n')
    OutputFile.write('Maximum Mismatches per Segment=' + Fields['Maximum Mismatches per 
Segment'].get() + '\n')
    OutputFile.write('Maximum Total Mismatches=' + Fields['Maximum Total 
Mismatches'].get() + '\n')
    OutputFile.write('\n')
    OutputFile.write('# Pattern Options\n')
    OutputFile.write('Exact Sequence Pattern Match=' + str(Fields['Pattern Var'].get()) + 
'\n')
    OutputFile.write('Pattern=' + Fields['Pattern'].get() + '\n')
    OutputFile.write('\n')
    OutputFile.write('# Performance Options\n')
    OutputFile.write('Buffer=' + Fields['Buffer'].get() + '\n')
    OutputFile.write('RAM Warning Level=' + Fields['RAM Warning Level'].get() + '\n')
    OutputFile.close()
#---------------------------------------------------------------------------
# MAIN
import Tkinter # Load Tkinter GUI module
import tkFileDialog # Tkinter FileDialog
import tkSimpleDialog # for prompt dialogs
SettingsFile = 'espsearch.ini' # the basic user settings file
root = Tkinter.Tk() # define master window
root.title('ESPSearchGUI')
Fields = DrawEverything(root, SettingsFile)
# load espearch.ini & fill fields
root.wm_resizable(0,0) # prevent resizing of window
root.mainloop() # trigger display of window & event handling
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C APPENDIX C
ESPSEARCH SAMPLE FILES
C.1 espsearch.ini
# See espsearch.html for information on these settings
# File Locations
Database=humanzif.txt
Output Directory=
Rules File=dna.txt
Source Directory=
Source File=source.txt
# General Options
Create Directories=0
Output Format=1
Standardize Name Lengths=0
# Target Sequence Options
Maximum Mismatches per Segment=0
Maximum Total Mismatches=0
# Pattern Options
Exact Sequence Pattern Match=0
Pattern=ABC
# Performance Options
Buffer=1000
RAM Warning Level=50
C.2 humanzif.txt
CSNR1=GAA,GAC,GAG
CSNR2=GAA,GAC,GAG
DSAR=ATC,GTC
DSCR=GCC
HSNK=AAC,GAC
HSSR=GTT
ISNR=GAA,GAT
ISNV=AAT
KSNR=GAG
QAHR=GGA
QFNR=GAG
QGNR=GAA
QSHR1=AGA,GGA
QSHR2=GGA
QSHR3=AGA,GGA
QSHR4=GGA
QSHR5=AGA,CGA,GGA,GAA
QSHT=AGA,CGA,TGA
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QSHV=AGA,CGA,TGA
QSNI=AAA,CAA
QSNR1=GAA
QSNR2=GAA
QSNR3=GAA
QSNR4=GAA
QSNK=AAA,GAA,TAA
QSNT=AAA
QSNV1=AAA,CAA
QSNV2=AAA,CAA,GAA,TAA
QSNV3=AAA,CAA
QSNV4=AAA,CAA
QSSR1=GCA,GTA
QSSR2=GCA,GTA
QSSR3=GCA,GTA
QSTR=GCA,GTA
QSTV=GAA,GAC,GAG
QTHQ=AGA,CGA,TGA
QTHR1=AGA,CGA,GGA,GAA
QTHR2=GGA
RDER1=GAG,GCG,GTG
RDER2=GCG
RDER3=GCG
RDER4=GCG
RDER5=GCG
RDER6=GCG
RDHR1=GGG
RDHR2=GGG
RDHT=AGG,CGG,GGG,TGG
RDKI=GGG
RDKR=AGG,GGG
RSHR=GGG
RSNR=GAG
SSNR=GAG
VSNV=AAT
VSSR=GCA,GCG,GCT,GTA,GTG,GTT
VSTR=GCA,GCT
WSNR=GGA,GGT
C.3 baxsirna.txt
A = gcggcggtgatggacgggtcc
B = atggggggggaggcacccgag
C = aggatgattgccgccgtggac
D = agcaaactggtgctcaaggcc
E = tgggtgagactcctcaagcct
F = tggtgccctctccccatcttc
C.4 lxxll.txt
class1 = SRLXXLL
class2 = HPLLXXLL
class3 = UJLXXLL
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general1 = LXXLL
C.5 dna.txt
# matches standard IUPAC DNA base codes & wildcards, will not match wildcards in source
Complements:
A=T, C=G, G=C, T=A, M=K, K=M, R=Y, W=W, S=S, Y=R, B=V, V=B, D=H, H=D, N=N
Mismatches:
A=B, C=D, G=H, T=V, M=K, K=M, R=Y, W=S, S=W, Y=R, B=A, D=C, H=G, V=T, N=
Wildcards:
A=A, C=C, G=G, T=T, M=AC, R=AG, W=AT, K=GT, S=CG, Y=CT, B=CGT, D=AGT, H=ACT, V=ACG, 
N=ACGT
C.6 dna2.txt
# matches standard IUPAC DNA base codes & wildcards, will match wildcards in source
Complements:
A=T, C=G, G=C, T=A, M=K, K=M, R=Y, W=W, S=S, Y=R, B=V, V=B, D=H, H=D, N=N
Mismatches:
A=B, C=D, G=H, T=V, M=K, K=M, R=Y, W=S, S=W, Y=R, B=A, D=C, H=G, V=T, N=
Wildcards:
A=A, C=C, G=G, T=T, M=ACM, R=AGR, W=ATW, K=GTK, S=CGS, Y=CTY, B=CGTB, D=AGTD, H=ACTH, 
V=ACGV, N=ACGTNMKRYWSBDHV
C.7 rna.txt
# matches standard IUPAC RNA base codes & wildcards, will not match wildcards in source
Complements:
A=U, C=G, G=C, U=A, M=K, K=M, R=Y, W=W, S=S, Y=R, B=V, V=B, D=H, H=D, N=N
Mismatches:
A=B, C=D, G=H, U=V, M=K, K=M, R=Y, W=S, S=W, Y=R, B=A, D=C, H=G, V=U, N=
Wildcards:
A=A, C=C, G=G, U=U, M=AC, R=AG, W=AU, K=GU, S=CG, Y=CU, B=CGU, D=AGU, H=ACU, V=ACG, 
N=ACGU
C.8 rna2.txt
# matches sUandard IUPAC RNA base codes & wildcards, will match wildcards in source
Complements:
A=U, C=G, G=C, U=A, M=K, K=M, R=Y, W=W, S=S, Y=R, B=V, V=B, D=H, H=D, N=N
Mismatches:
A=B, C=D, G=H, U=V, M=K, K=M, R=Y, W=S, S=W, Y=R, B=A, D=C, H=G, V=U, N=
Wildcards:
A=A, C=C, G=G, U=U, M=ACM, R=AGR, W=AUW, K=GUK, S=CGS, Y=CUY, B=CGUB, D=AGUD, H=ACUH, 
V=ACGV, N=ACGUNMKRYWSBDHV
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C.9 protein.txt
# matches standard IUPAC amino acid codes & wildcards, will not match wildcards in source
Complements:
Mismatches:
A=a, B=b, C=c, D=d, E=e, F=f, G=g, H=h, I=i, K=k, L=l, M=m, N=n, P=p, Q=q, R=r, S=s, T=t, 
V=v, W=w, X=, Y=y, Z=z
Wildcards:
A=A, B=DN, C=C, D=D, E=E, F=F, G=G, H=H, I=I, K=K, L=L, M=M, N=N, P=P, Q=Q, R=R, S=S, 
T=T, V=V, W=W, Y=Y, Z=EQ,
X=ACDEFGHIKLMNPQRSTVWY, a=CDEFGHIKLMNPQRSTVWY, c=ADEFGHIKLMNPQRSTVWY, 
d=ACEFGHIKLMNPQRSTVWY, e=ACDFGHIKLMNPQRSTVWY,
f=ACDEGHIKLMNPQRSTVWY, g=ACDEFHIKLMNPQRSTVWY, h=ACDEFGIKLMNPQRSTVWY, 
i=ACDEFGHKLMNPQRSTVWY, k=ACDEFGHILMNPQRSTVWY,
l=ACDEFGHIKMNPQRSTVWY, m=ACDEFGHIKLNPQRSTVWY, n=ACDEFGHIKLMPQRSTVWY, 
p=ACDEFGHIKLMNQRSTVWY, q=ACDEFGHIKLMNPRSTVWY,
r=ACDEFGHIKLMNPQSTVWY, s=ACDEFGHIKLMNPQRTVWY, t=ACDEFGHIKLMNPQRSVWY, 
v=ACDEFGHIKLMNPQRSTWY, w=ACDEFGHIKLMNPQRSTVY,
y=ACDEFGHIKLMNPQRSTVW
C.10 protein2.txt
# matches standard IUPAC amino acid codes & wildcards, will match wildcards in source
Complements:
Mismatches:
A=a, B=b, C=c, D=d, E=e, F=f, G=g, H=h, I=i, K=k, L=l, M=m, N=n, P=p, Q=q, R=r, S=s, T=t, 
V=v, W=w, X=, Y=y, Z=z
Wildcards:
A=A, B=DNB, C=C, D=D, E=E, F=F, G=G, H=H, I=I, K=K, L=L, M=M, N=N, P=P, Q=Q, R=R, S=S, 
T=T, V=V, W=W, Y=Y, Z=EQZ,
X=ACDEFGHIKLMNPQRSTVWYXBZ, a=CDEFGHIKLMNPQRSTVWY, c=ADEFGHIKLMNPQRSTVWY, 
d=ACEFGHIKLMNPQRSTVWY, e=ACDFGHIKLMNPQRSTVWY,
f=ACDEGHIKLMNPQRSTVWY, g=ACDEFHIKLMNPQRSTVWY, h=ACDEFGIKLMNPQRSTVWY, 
i=ACDEFGHKLMNPQRSTVWY, k=ACDEFGHILMNPQRSTVWY,
l=ACDEFGHIKMNPQRSTVWY, m=ACDEFGHIKLNPQRSTVWY, n=ACDEFGHIKLMPQRSTVWY, 
p=ACDEFGHIKLMNQRSTVWY, q=ACDEFGHIKLMNPRSTVWY,
r=ACDEFGHIKLMNPQSTVWY, s=ACDEFGHIKLMNPQRTVWY, t=ACDEFGHIKLMNPQRSVWY, 
v=ACDEFGHIKLMNPQRSTWY, w=ACDEFGHIKLMNPQRSTVY,
y=ACDEFGHIKLMNPQRSTVW
C.11 protein_ex.txt
# matches standard IUPAC amino acid codes & wildcards, will not match wildcards in source
# adds custom wildcards J & U
Complements:
Mismatches:
A=a, B=b, C=c, D=d, E=e, F=f, G=g, H=h, I=i, K=k, L=l, M=m, N=n, P=p, Q=q, R=r, S=s, T=t, 
V=v, W=w, X=, Y=y, Z=z, J=j, U=u
Wildcards:
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A=A, B=DN, C=C, D=D, E=E, F=F, G=G, H=H, I=I, K=K, L=L, M=M, N=N, P=P, Q=Q, R=R, S=S, 
T=T, V=V, W=W, Y=Y, Z=EQ,
X=ACDEFGHIKLMNPQRSTVWY, a=CDEFGHIKLMNPQRSTVWY, c=ADEFGHIKLMNPQRSTVWY, 
d=ACEFGHIKLMNPQRSTVWY, e=ACDFGHIKLMNPQRSTVWY,
f=ACDEGHIKLMNPQRSTVWY, g=ACDEFHIKLMNPQRSTVWY, h=ACDEFGIKLMNPQRSTVWY, 
i=ACDEFGHKLMNPQRSTVWY, k=ACDEFGHILMNPQRSTVWY,
l=ACDEFGHIKMNPQRSTVWY, m=ACDEFGHIKLNPQRSTVWY, n=ACDEFGHIKLMPQRSTVWY, 
p=ACDEFGHIKLMNQRSTVWY, q=ACDEFGHIKLMNPRSTVWY,
r=ACDEFGHIKLMNPQSTVWY, s=ACDEFGHIKLMNPQRTVWY, t=ACDEFGHIKLMNPQRSVWY, 
v=ACDEFGHIKLMNPQRSTWY, w=ACDEFGHIKLMNPQRSTVY,
y=ACDEFGHIKLMNPQRSTVW, J=ILV, j=ACDEFGHKMNPQRSTWY, U=ST, u=ACDEFGHIKLMNPQRVWY
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D APPENDIX D
ESPSEARCH MANUAL
D.1 Introduction
D.1.1 What is ESPSearch?
ESPSearch, which stands for Exact Sequence and Pattern Search, 
searches a DNA, RNA, or protein sequence for specific target sequences, 
such as the 3 base triplets recognized by specific zinc fingers. An unlimited 
number of target sequences can be searched for simultaneously. Pattern 
matching can also be performed, to look for patterns of hits, such as 
identifying direct repeats or other long stretches that are recognized by zinc 
fingers.
ESPSearch is written in Python (http://www.python.org). Python is a 
scripting language, so the program is source code rather than a compiled 
program; this means you are free to edit the code if you desire (see Section 
D.4.3). Because Python can run on essentially any platform, ESPSearch 
should work on essentially any computer.
If you publish results obtained using ESPSearch, please cite:
Watt, T. J. and Doyle, D. F. (2005) ESPSearch: A Program for Finding Exact 
Sequences and Patterns in DNA, RNA, or Protein. Biotechniques, 38, 109-
115.
ESPSearch and related files may be downloaded from 
http://web.chemistry.gatech.edu/~doyle/espsearch/.
D.1.2 What ESPSearch is Designed to Do
ESPSearch is designed to identify essentially any target sequence 
within any source sequence to find the exact desired sequence(s). Moreover, 
it does so using a simple interface that is fast and easy to configure, works 
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with nearly any operating system, and can be modified if the need arises for 
additional functionality. Specific abilities include:
 Search arbitrary source sequences for many, possibly complex, 
target sequences simultaneously. ESPSearch can search for 1 or 
1000 target sequences simultaneously with little or no difference in 
speed, and is unique in its ability to do so with arbitrarily complex 
sequences.
 Identify complex target sequences that may be difficult or 
impossible to identify with other tools (e.g., BLAST) due to length 
restrictions, wildcard constraints, variable regions, or specific 
mismatch levels. ESPSearch has no length restrictions, and a great 
deal of complexity may be specified for target sequences.
 Analyze target hits for specific patterns. ESPSearch is unique in its 
ability to analyze the relationship of target hits according to user-
specified patterns constructed from target sequence hits. Patterns 
can be simple or complex as needed.
 Provide detailed output, including hit locations, mismatches, and 
size of variable regions. ESPSearch can provide an annotated 
sequence indicating where, and in which frame, all target 
sequences are found, or generate a separate file for each target 
sequence listing hits.
 Allow customization of search parameters at all levels. For example, 
it is possible to search for non-standard DNA bases, arbitrary 
groups (e.g., hydrophobic amino acids), or use non-standard 
complements (see Section D.2.4). 
D.1.3 How ESPSearch is Different
ESPSearch is a general tool for identifying any target within any 
source sequence with complete control over all aspects of the search, but 
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may not be the best choice for specific applications where specialized tools 
exist for the search.
 ESPSearch is not a general alignment tool such as BLAST. BLAST is 
generally faster and more efficient for aligning most sequences than 
ESPSearch. However, ESPSearch will locate sequences that BLAST 
cannot find, such as very short sequences and sequences containing 
many wildcards or gaps.
 ESPSearch can, like many other tools in existence (such as the 
TRANSFAC tools), identify a specific class of binding site (e.g., 
transcription factors). However, ESPSearch is not limited to a 
particular data set or scanning a particular DNA sequence. On the 
other hand, these other specialized tools may be faster for certain 
specific applications that take advantage of their specialization.
 ESPSearch differs from most software that search "patterns" (such 
as TRANSFAC's "Patch" program) in that the "patterns" searched by 
ESPSearch are combinations of specified target sequences, 
determined entirely by you. Most other programs are highly 
restrictive in their "patterns." Moreover, complex pattern searches 
in ESPSearch are very straightforward through the use of specific 
sequences in a database and one or more patterns that arrange 
them as necessary.
D.1.4 Running ESPSearch
First download and install Python (http://www.python.org), version 2.3 
or greater (ESPSearch makes use of commands not available in prior 
versions). Follow the instructions provided on the website for installation; 
Windows users should find a convenient installation file which will also set 
up Python scripts (including ESPSearch) to be run by double-clicking the file 
icon. Users of other operating systems should add Python to their operating 
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system path, or else will need to run ESPSearch as "python espsearch.py" 
from the Python directory to invoke ESPSearch. Note that the Python 
interpreter may cause firewall software to ask if Python may have internet 
access; this is a normal Python process that you should allow (Python never 
actually accesses the network).
Then configure espsearch.ini as you wish (see Section D.2.1), create 
a target sequence database (see Section D.2.2), create or download a nucleic 
acid or protein sequence to search, and create any necessary directories. 
Then run espsearch.py. Note that if ESPSearch ever exits without 
prompting you to press ENTER or a general Python error is raised (as 
indicated by a detailed output that contains no clear indication of how to fix 
the problem), you have provided ESPSearch with a configuration or input 
that it is unable to handle. ESPSearch can handle common or simple 
problems gracefully, but is not designed to handle every possible issue.
D.2 Search Configuration
D.2.1 ESPSearch.ini
The ESPSearch configuration file, espsearch.ini, contains all search 
parameters and program options. espsearch.ini must be in the same 
directory as espsearch.py.
Two important notes:
 If multiple lines of the same type (e.g., Source File = ) are present, 
only the data from the last (lowest in file) will be remembered.
 Placing "#" before a line will cause ESPSearch to ignore it, allowing 
you to temporarily "disable" a line. 
D.2.1.1 File Locations
These settings indicate where input files reside and output should be 
directed.
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 Database File is the file name, and path if not in the current 
directory, for the file that contains the target sequences to be 
searched for. See Section D.2.2.
 Output Directory is the directory that output files will be created 
in. Note that this directory must already exist. A blank entry will be 
interpreted as the current directory. If ESPSearch detects files that 
will be overwritten in the directory, you will be prompted for 
confirmation that you wish to overwrite existing files.
 Rules File is the file name, and path if not in the current directory, 
for the file that contains the rules for the search (see Section D.2.4).
 Source Directory is the directory containing the Source File(s). If 
searching multiple Source Files, all files must be in the this 
directory. A blank entry will be interpreted as the current directory.
 Source File is a list of the files to be searched. Multiple files should 
be separated by commas, and requires that Create Directories (see 
Section D.2.1.2) is set to 1. See Section D.2.2 for more information. 
D.2.1.2 General Options
These settings allow control over global features of the search.
 Create Directories defaults to 0. ESPSearch has the ability to 
create directories within the Output Directory to avoid overwriting 
files and enable searching multiple Source Files at once. However, 
the "os" module in Python required for these operations is 
functional only for Windows, Macintosh, and UNIX operating 
systems as of this writing. Set Create Directories to 1 if you are 
using one of these operating systems and wish to have ESPSearch 
create directories based on the source file names. The effect of 
setting this to 1 for any other operating system is undetermined.
 Output Format defaults to 1. See Section D.3.1.
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 Standardize Name Length defaults to 0. A value of 1 means that 
ESPSearch will pad the ends of target sequence names with spaces 
as necessary to make them all the same length, for easier reading of 
the output in a fixed-width text editor (e.g., Microsoft Notepad). 
D.2.1.3 Target Sequence Options
These settings control mismatch behavior of target sequences.
 Maximum Mismatches per Segment defaults to 0, and indicates 
the maximum number of mismatches you wish to allow in each 
segment of a target sequence for it to be considered valid. See 
Section D.3.1.
 Maximum Total Mismatches defaults to 0, and indicates the 
maximum number of mismatches you wish to allow in a hit for it to 
be considered valid. This value must be at least as large as 
Maximum Mismatches per Segment. See Section D.3.1.
D.2.1.4 Pattern Options
These settings control the pattern matching behavior.
 Exact Sequence Pattern Match defaults to 0, and indicates 
whether a pattern hit is determined by the literal sequence or by 
the target sequences that recognize the source sequence. See 
Section D.2.5.2.
 Pattern contains the pattern, or a list of patterns separated by 
commas, that you wish to match. Leave this line blank if you do not 
wish to match a pattern. See Section D.2.5.
D.2.1.5 Performance Options
These settings modify the overall performance of ESPSearch, but 
generally can be left at the default values.
 Buffer defaults to 1000. It determines the number of positions read 
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at a time from the Source File. Lowering this value will usually lead 
to somewhat slower performance, but may also reduce the amount 
of RAM used; increasing it may have the opposite effect. Note that 
if a target sequence or pattern is longer than this value, it will 
automatically increase to compensate.
 RAM Warning Level defaults to 50. This is a qualitative indicator 
for when ESPSearch will issue a warning about the predicted 
amount of RAM to be used. This may be adjusted up or down as 
necessary to increase or decrease the warning threshold. This 
indicator is the RAM used in addition to the base 6-10 MB required 
of all searches (mostly by Python itself). 
D.2.2 Source Sequences
ESPSearch accepts plain-, FASTA-, EMBL-, or GenBank-formatted 
source sequences. Plain formatted files should contain only a single strand 
of the sequence to be searched (if DNA or RNA) and no headers; all other 
formats must meet standard requirements, except that either lower or upper 
case characters are accepted (everything is converted to upper case when 
read in). Blank lines, line numbers, and internal spaces are removed from 
the sequence when it is read. If multiple sequences are present in the file 
(allowed for all but plain format), the descriptor line for each sequence 
containing at least one match will be written into the output file(s). Note 
that sequences containing no matches will not have their information output, 
but they have been searched. Note also that a > will be placed at the 
beginning of the descriptor line, even if the source is EMBL or GenBank 
format. All other file formats, or incorrectly formatted files of the acceptable 
varieties, will be assumed to be plain-formatted and may generated 
unexpected output. All files should contain occasional line breaks to avoid 
loading the entire file at once, possibly leading to excessive use of RAM.
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D.2.3 Target Sequence Databases
Target sequences are loaded from a user-specified database file. This 
file should contain only the target sequences, but all lines not containing an 
"=" will be disregarded. Target sequences are entered according to the 
following format:
 Name of first sequence = First sequence
 Name of second sequence = Second sequence1, Second sequence2, 
etc.
 etc. 
If the same (case-insensitive) name is used more than once, 
ESPSearch will recognize that two or more sequences have the same name, 
and assume that they represent a single sequence that has multiple targets. 
Multiple targets may also be listed directly, by separating sequences with 
commas following the =. Acceptable characters are determined by the rules 
file (see Section D.2.4).
Gaps may be introduced into target sequences (but may not begin or 
end a sequence). Gaps are variable regions of the specified length, and are 
designated by the format "[minimum length:maximum length]" in the 
appropriate place in the target sequence, where lengths must be non-
negative integers (anything else is physically meaningless). Examples:
 First = AAA[0:2]GGG is equivalent to searching for AAAGGG, 
AAANGGG, and AAANNGGG simultaneously (and more efficiently)
 Second = AAA[0:0]AAA is equivalent to searching for AAAAAA 
(usually less efficiently than if no gap is present)
 Third = AAA[0:1]CCC[0:1]GGG is equivalent to searching for 
AAACCCGGG, AAANCCCGGG, AAACCCNGGG, and 
AAANCCCNGGG simultaneously
 Fourth = [0:5]AAA[0:5]AAA is invalid due to the initial gap. 
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The use of gaps creates "segments" within each target sequence, 
where a "segment" refers to the group of bases marked by a gap. For 
example, AAA and GGG are the two segments in First. The behavior of 
ESPSearch with respect to mismatches is affected slightly by the presence 
of segments. If only one segment is present (i.e., no gaps are used), the 
settings Maximum Mismatches per Segment and Maximum Total 
Mismatches are identical: the number of mismatches allowed in a target 
sequence. If more than one segment exists, these settings allow you to tune 
the mismatch behavior of the target sequences. Maximum Total Mismatches 
always refers to the maximum allowable mismatches in the entire target 
sequence. However, if Maximum Mismatches per Segment is set lower than 
Maximum Total Mismatches, the distribution of mismatches throughout the 
target sequence will be spread out. An example of where this is useful is 
when target sequences represent 2 monomers brought together into a dimer 
with some spacing (e.g., AAAA[0:2]GGGG). If each monomer can tolerate 1 
mismatch, but the dimer can tolerate 2, setting Maximum Mismatches per 
Segment to 1 and Maximum Total Mismatches to 2 will produce the desired 
behavior.
A single target may only have 64 explicit sequences assigned to it. 
This means that "Target = NNNN" is fine, but Target = "AAAA, AAAC, AAAG, 
...., TTTC, TTTG, TTTT" will lead to an error.
D.2.4 Search Rules
The rules file contains the characters expected to be found in the 
target and source sequences, and how they relate to each other. This file is 
divided into 3 sections, which should consist of a header line 
("Complements:", "Mismatches:", or "Wildcards:"), with a list of 
corresponding information below each header.
 Complements contains the expected complement character 
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relationships for nucleic acid searches. For protein searches, this 
area should be left blank (although the "Complements:" line must 
still exist). For example, to set the complement of "A" to "T" and 
vice versa, enter "A=T, T=A" (without quotes) below the 
"Complements:" line. All characters that you want to be interpreted 
as valid should be included in this list. All characters used here 
must be uppercase (lowercase letters will lead to missed hits when 
all targets & source sequences are converted to uppercase).
 Mismatches contains the single value representing "not" some 
position. For example, the IUPAC DNA representation for "not A" is 
"B." Therefore, enter "A=B" here for a standard nucleic acid 
mismatch. All letters used in this section must exist in the Wildcards 
section as well. Lowercase letters can be used here. It is very 
important that all characters present in the Complements section 
are also present here on the left side of each relationship. For 
protein searches, this section must contain all the valid characters 
you expect and their mismatches; if a character you wish to be valid 
is not listed in this section, ESPSearch will not recognize it as a 
valid character.
 Wildcards contains the "expansion" of all mismatch characters into 
equivalent characters in the Complements list. For example, "B" 
would be set to "B=CGT" to represent "not A." If you wish to be able 
to match wildcards in the source sequence, the Wildcards 
definitions must include themselves (i.e., to match "B" in the source 
sequence, use "B=BCGT"). Moreover, to match those wildcards, the 
same character must be used in the source sequence (i.e., 
ESPSearch cannot determine that Target=CT,GT,TT is the same as 
Target=BT, and they are in fact non-equivalent if you are trying to 
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match wildcards in the source sequence). Note that while lowercase 
letters are allowed on the left of an "=" (corresponding to a 
particular Mismatch character), they are not permitted on the right 
side (they will simply never lead to a match).
All sets of rules may also contain non-letter characters, because case 
is irrelevant. However, numbers should be avoided, because numbers on the 
ends of lines will be removed (ESPSearch cannot distinguish a number that 
represents something from a line number).
The ESPSearch website has a selection of rules files for standard 
DNA, RNA, and protein searches based on IUPAC definitions.
D.2.5 Patterns
Patterns are a technique for analyzing arrangements of target 
sequence hits. For example, if you are searching for 10 target sequences, 
but really want to know when some combination of 3 of those target 
sequences occur together, entering the appropriate pattern in 
espsearch.ini allows you to gather the desired information.
D.2.5.1 Entering Patterns
Patterns are entered as a series of letters, with gaps placed where 
appropriate. The following general rules apply:
 Letters are entirely arbitrary. The pattern AA means the same thing 
as the patterns ZZ and cc. Letters are case sensitive: the pattern Aa 
is not the same as AA, but is the same as AB.
 Letters do not indicate a particular target sequence, but identical 
letters mean that the hits in those positions must be the same. For 
example, the pattern AA means find two identical hits in a row, 
while ABC finds any three hits in a row.
 Letters that are different mean that hits in those can be, but are not 
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necessarily, different. For example, the pattern AB will find all hits 
from the pattern AA, as well as additional hits.
 Gaps are entered in the same manner as within target sequences: 
[minimum distance:maximum distance]. However, negative values 
are allowed (indicating overlapping target sequences). Negative 
values are often not physically meaningful, and will never match 
unless some targets have overlapping fragments. The magnitude of 
negative values must be less than the shortest possible target 
sequence entered (e.g., A[-5:0]B will raise an error if the target 
AA[0:2]AA is in the database, because the shortest version of that 
target is only 4 positions). As with target sequences, patterns may 
not begin or end with a gap.
 Patterns are limited to the letters of the English alphabet (52 
characters because of upper and lower case). See Section D.4.3 if 
you need to change this. 
In addition to letters and spaces, additional characters may be used to 
provide a better defined pattern:
 Placing ! (exclamation point) before a letter means that position in 
the pattern should be unique. Therefore, any hits in that pattern 
position that also match hits anywhere else in the pattern will be 
removed. The pattern A!B matches all the hits from the pattern AB 
except those also matching AA. Note that using ! ignores any 
similarity in letters. For example, the pattern A!A and A!B are 
identical, because the letter following ! is treated as unique, even if 
it is the same as letters elsewhere in the pattern. Note that if you 
want all positions to be unique, you must put ! before all (or all but 
one) of the letters in the pattern.
 > (greater than) and < (less than) mean that all following letters 
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are to be on the same strand. The patterns AB, >AB, >A>B, A>B, 
<AB, and <A<B are all equivalent; >A<B is not. ESPSearch 
assumes an initial > unless another character is provided at the 
beginning of the sequence.
 | (pipe) is used to indicate that the following hits can be on either 
strand. The pattern |AB is equivalent to the patterns >AB and 
>A<B combined. 
Note that for protein sequences, <, >, and | are ignored (they are 
irrelevant).
D.2.5.2 Determining Pattern Behavior
Pattern matching can function in two modes, illustrated by the 
following examples, which use 2 DNA target sequences, First = AAA and 
Second = GGG, GGC, and 1 pattern = AA.
 If Exact Sequence Pattern Match is set to 1, pattern matching 
analyzes the actual source sequences to determine pattern hits. 
This means that for the pattern to be true for First, the DNA 
sequence AAAAAA must be encountered. For the pattern to be true 
for Second, either the sequence GGGGGG or the sequence GGCGGC 
will produce a hit.
 If Exact Sequence Pattern Match is set to 0, pattern matching looks 
only at the target sequences to determine pattern hits. So for the 
pattern AA to be true, the sequence of hits First-First or Second-
Second must be encountered. First-First corresponds to the DNA 
sequence AAAAAA. Second-Second corresponds to 4 DNA 
sequences: GGGGGG, GGCGGC, GGGGGC, and GGCGGG. 
Note that the second case includes all hits from the first case, as well 
as additional hits. There are two sets of conditions under which the 
determination of a pattern hit by either method will yield exactly the same 
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set of results if either (or both) are true:
 The pattern does not contain any letter more than once (i.e., no 
positions need to be the same target sequence).
 The target sequences each refer to exactly 1 sequence (i.e., no 
wildcards, gaps, or multiple entries for any target) and there are no 
mismatches allowed. 
If the above conditions are not true, then consider carefully which 
approach to use. If you are unsure, set Exact Sequence Pattern Match to 0 
(the default), because at worst it will find more hits than you expected. To 
illustrate the difference when a single mismatch is allowed in a target 
sequence, consider an example using the target sequence AAA and the 
pattern AA: if Exact Sequence Pattern Match = 1, and 1 mismatch is 
allowed, the pattern will recognize AAAAAA and AATAAT as hits, but not 
AATAAA. If Exact Sequence Pattern Match = 0, AATAAA is found by the 
pattern.
If your target sequences contain gaps, Exact Sequence Pattern Match 
should always be set to 0, because gaps are by definition variable.
D.2.5.3 Example Patterns
All the following patterns can be entered in multiple equivalent ways; 
shown is the simplest possible way.
 A = a list of all hits.
 ABCDEF = any sequence of six sequential hits on a single strand.
 AB[0]AB = direct repeat of 2 hits with no gap on the same strand 
(equivalent to ABAB).
 AB[0:2]<BA = inverted and everted repeats of 2 hits with gaps of 0, 
1, or 2 bases.
 A|!B = all sequences of two different sequential hits, regardless of 
which strand each hit is on, equivalent to A!B and A<!B.
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 ABC[3:3]DEF, ABC[3:3]<DEF = any sequence of 3 hits on one 
strand, a 3 base gap, and any sequence of 3 hits on the same or 
other strand with a 3 base gap. Note this is different from ABC[3:3]|
DEF, because this last pattern also includes patterns such as 
ABC[3:3]<D>E<F.
 A[0:3]A, A[0:3]A[0:3]A, A[0:3]A[0:3]A[0:3]A = 2, 3, and 4 repeats of 
hit on the same strand, each separated by 0 to 3 bases. 
In many cases, alternate pattern forms will lead to equivalent hits, but 
presented differently. For example, >AA and <AA will give rise to the same 
hits, the output files for each pattern will differ in that the strands 
designated for each hit will be reversed (and therefore the sequences will all 
be reverse complements).
D.3 Running a Search
D.3.1 Interpreting the Target Sequence Output
All styles of output are tab-formatted for easy loading into 
spreadsheets for convenience of reading and analysis. Format numbers 
correspond to the number of files generated: format 0 is undetermined 
(based on the database used), format 1 produces a single file, and format 2 
produces 2 files (for nucleic acids; only 1 for proteins). Output file names are 
generated from a combination of the database used in the search and the 
output format.
In all cases, the search output indicates matches from the N-C and 
5'-3' (for the strand it is on). To match in the opposite direction, simply 
reverse your target sequences.
D.3.1.1 Format 0
In this format, every target sequence has its own file for output. 
Sequences recognized by more than one target sequence are therefore 
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output to multiple files. Each file consists of the position of each hit (the 
5'-most base or most N-terminal amino acid of the sequence), the specific 
sequence for each hit, the strand that each hit occurs on (+ = sense, - = 
antisense) if nucleic acid, and the number of mismatches in each hit. In 
addition, if the target sequence includes gaps, the value (in number of 
bases) for each gap will be listed.
Note that the position values of - strand hits may not proceed 
sequentially if one or more gaps exist within the target sequences; this is 
nothing to worry about, and is simply a reflection of the fact that ESPSearch 
is actually keeping the 5'-most sense base fixed (i.e., the 3'-most antisense 
base).
This format is constrained by inherent limits on the number of open 
files allowed in a given operating system, which varies considerably 
(typically around 500 on Windows systems and 1000 on Linux). If you are 
searching for very large numbers of sequences, you may have to switch to 
Format 1. This format also constrains the names of target sequences to 
strings that are acceptable as file names on your operating system (e.g., "*" 
is usually not a valid character in a file name, so don't use it in a target 
sequence if using this format). Unacceptable characters will cause 
ESPSearch to crash (error-checking is not performed because it is platform-
dependent).
D.3.1.2 Format 1
This format is the default. It produces a single file containing all hits 
in a similar style as format 0, except that an extra column is inserted at the 
beginning of the file indicating which target each entry corresponds to.
D.3.1.3 Format 2
In this format, 2 files are generated, corresponding to the sense 
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strand (defined as the sequence in the source file) and all hits on it, and a 
second corresponding to the antisense strand and all hits. The sense strand 
begins (with position 1) at the 5' end and ends with the 3' base. The 
antisense strand is written to complement the sense strand, meaning that 
position 1 is the 3' end, and the final base is the 5' end. Therefore, positions 
for either strand refer to the same base pair.
Within each file, hits are listed according to the frame they occur in, 
where Frame 1 is defined as the reading frame beginning with the first base. 
Hits are listed next to the 5'-most base they recognize. This means that in 
the sense output, hits recognize the base they are listed next to and the 
following bases going down, while in the antisense file hits recognize the 
base they are listed next to and the following bases going up.
For proteins, only a single file is output, annotated from the N- to C-
termini in an equivalent manner to the nucleic acid output without reading 
frames.
This format outputs no information regarding the mismatches in a hit 
if any exist, nor will it work if any target sequence contains a gap. If using 
nucleic acid rules, target sequences in the database must also all be the 
same length. If multiple hits recognize a single position, they will be listed 
sequentially, separated by a space.
D.3.2 Interpreting the Pattern Output
Each pattern is output to its own file, named using the letters in the 
pattern, the database, and a pattern number (represented as "p#"). Gaps are 
represented as "_" in the file name. Each file lists the position (5' most base 
or most N-terminal amino acid) of the pattern hit, the sequence the hit 
corresponds to, and the strand the hit occurs on if nucleic acid. Following 
this information is a breakdown of which target sequences occur in each 
position within the pattern for the hit, with the appropriate control character 
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in front. This file is tab-delimited for easy loading into a spreadsheet 
program. If multiple targets match a particular position in the pattern, they 
will be listed sequentially, separated by a space. Note that the position 
values of - strand hits may not proceed sequentially if one or more gaps exist 
within the target sequences; this is nothing to worry about, and is simply a 
reflection of the fact that ESPSearch is actually keeping the 5'-most sense 
base fixed (i.e., the 3'-most antisense base).
D.3.3 Tips for Optimizing Searches
ESPSearch typically scanned 500,000 to 2,500,000 positions/second 
on a Pentium IV 1.8 GHz PC running Windows 2000. Speeds on a Pentium III 
500 MHz PC were about half that. However, it is certainly possible to design 
a search that runs at only 50,000 positions/second or slower, and a few 
searches will run faster. The tips below will help keep your searches fast and 
memory-efficient.
 Run Psyco if available for your computer (see Section D.4.2).
 Use only the mismatches and wildcards needed. For example, try to 
represent "N" or "X" (for standard DNA/protein searches) as gaps. 
High mismatch levels and/or extensive use of wildcards (especially 
when also trying to match wildcards in the source sequence) can 
rapidly lead to high RAM use and may slow searches somewhat.
 The search speed is linearly dependent on the length of the source 
sequence and the amount of output generated, and approximately 
exponentially related to the number of partial target sequences 
found. To improve speed performance, use the search parameters to 
avoid unwanted output and consider redesigning target sequences 
to minimize wildcards and mismatches. Moreover, the length of the 
shortest first segment (and last if a nucleic acid search) is especially 
important; try to keep these sequences long enough and sufficiently 
189
non-variable to avoid finding many partial hits. For example, if 
searching for One=AAA and Two=GNNGGGGGGG, 17 out of every 
64 positions will lead to a partial hit: AAA & GNN.
 Avoid exceeding physical free RAM. Use of virtual memory is much 
slower and may lead to an effective halt of the search.
 Patterns are usually run quickly, but must run sequentially. 
Therefore, only search for the desired patterns, and try to combine 
patterns if possible (e.g., A>B and A<B can be combined to A|B to 
improve speed). In addition, try to design target sequences so gaps 
with a large difference in minimum and maximum value 
(approximately 50 or so) are placed into patterns rather than target 
sequences; patterns generally handle gaps much faster.
 Initialization time is usually less than 1 second. However, 
initialization time is roughly linearly proportional to RAM use, so 
performing a search that uses several hundred MB of RAM may 
take up to a minute to initialize. Initialization also takes longer for 
Output Format 0, but this is only noticeable when using a database 
containing a few hundred or more target sequences.
D.4 Inner Workings
D.4.1 Algorithms in ESPSearch
After ESPSearch loads the target sequence database, it generates all 
variations of target sequences due to wildcards and mismatches, and each 
sequence is assigned a unique memory address. Reverse complements to 
each sequence are also generated for nucleic acid searches, to identify 
matches on the complement strand without actually generating or searching 
the complement. ESPSearch reads the source sequence (the sequence to be 
searched) with a "window" that corresponds to the target sequence length; if 
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the current "window" sequence matches any sequence stored in memory, the 
appropriate output is generated. For patterns, ESPSearch assigns the first 
position of the pattern to the current hit, then searches forward through the 
pattern to determine if hits exist in the positions designated by the pattern. 
For example, to match the pattern ABAB, ESPSearch determines if a hit was 
found at the position immediately after the first hit, then if a hit identical to 
the first was found immediately after the second, and if a hit identical to the 
second was found immediately after the third, all on the same strand. Target 
sequences containing gaps are found in a method similar to patterns (i.e., 
ESPSearch identifies the target sequence one section at a time, only 
generating output when the entire sequence is located).
D.4.2 Psyco Acceleration
The optional "psyco" module for Python (available at 
http://psyco.sourceforge.net) can greatly accelerate the speed of ESPSearch. 
However, it is only available for Intel-386 compatible processors (386, 486, 
Pentium, AMD K6 & K7, etc.) as of this writing. Psyco will generally increase 
memory usage somewhat (2-5 megabytes), but will provide a boost of 
approximately 3-fold in processing time. Simply install Psyco according to its 
installation instructions and ESPSearch will automatically use it.
D.4.3 Modifying ESPSearch
ESPSearch has been extensively optimized for speed, but so as to 
allow for a wide range of inputs. It is certainly possible to refine the script to 
suit some specific need and improve performance. In general, the limiting 
factor is the name lookup (dictionary hash call in particular), which is a very 
fast C routine, so to generally improve performance, avoid dictionary calls. If 
you do modify this program, you must do so according to the terms of the 
GNU General Public License (http://www.gnu.org/licenses/old-licenses/gpl-
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2.0.html).
Specific sections of the code may be of interest for certain minor 
changes, and these are outlined below.
 Initialization file name: this is set by the "SettingsFile" variable in 
the main area, about line 1125.
 Output file names: these are assigned in 2 locations in the 
LoadDatabase routine, about line 900 (several lines) and line 1000.
 Adding source file formats: to add another format as acceptable 
input, lines checking for the appropriate indicators in the file should 
be added to the lines checking for current formats. These are in the 
FindSequences routine in two locations: about line 360 (to do an 
initial check to skip the first headers) and line 380 (for noting the 
end of a sequence to skip any following headers).
 RAM Warning Level conversion factor: this is a simple conversion to 
make the number for RAM Warning Level roughly equivalent to MB 
of RAM. This was calibrated under particular conditions, and if you 
wish to recalibrate, change constant in the "RAMThreshold = " line 
in the LoadDatabase routine, about line 860.
 Additional pattern characters: adding characters to the 
"PatternChars" string in DefineFunction, about line 70, will allow 
you to use additional characters to indicate pattern positions. Avoid 
using >, < |, !, [, and ], because they will be treated as control 
characters even if they are in PatternChars. 
ESPSearch is Copyright © 2004-2005 Terry J. Watt and Donald F. Doyle. It 
may be freely modified according to the terms of GNU GPLv2 or later.
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E APPENDIX E
ESPSEARCHGUI MANUAL
E.1 Introduction
E.1.1 What is ESPSearchGUI?
ESPSearchGUI, which stands for Exact Sequence and Pattern Search 
Graphical User Interface, is a user interface front-end for ESPSearch. If you 
don't know what ESPSearch is, you probably don't need to be using this 
program.
ESPSearchGUI is designed simplify your interactions with ESPSearch 
by creating an interactive environment for configuring searches. 
ESPSearchGUI also allows you to save settings for later use, making 
management of different settings sets easier. Finally, ESPSearchGUI is a 
graphical user interface, which in and of itself seems to make many people 
happy (and there's nothing wrong with that).
ESPSearchGUI does NOT add ANY functionality to ESPSearch. This is 
merely a settings management tool, and requires espsearch.py to be 
present in the same directory to actually perform any searches.
Version 1.01 is designed to work with version 1.01 of ESPSearch, 
although it will also work with v1.00. ESPSearchGUI should work with any 
operating system that supports TCl/Tk (Unix, Linux, and Windows, and some 
others) and has Python installed. However, at this stage it has not been 
thoroughly tested. USE THIS PROGRAM AT YOUR OWN RISK (but if it 
loads, it probably will work).
E.1.2 Installing and Running
Simply make sure that espsearchgui.py is in the same directory as 
espsearch.py (the ESPSearch Python file), and run espsearchgui.py 
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instead of espsearch.py. Python (version 2.3 or later) must also be installed 
on the system. When you start ESPSearch, the default settings will be 
loaded.
E.2 Loading and Saving
E.2.1 Loading Settings Files
The "Load Settings" button will open a dialog window to select a file. 
ESPSearchGUI performs no checking to confirm that the file is actually an 
ESPSearch configuration file, so choosing random files may cause 
ESPSearchGUI to crash. If the settings file is invalid or incomplete, the 
default settings will be inserted as needed.
E.2.2 Saving Settings Files
The "Save Settings" button allows you to save the current settings to a 
file other than espsearch.ini. These settings will not be used by ESPSearch 
unless you load the settings and run ESPSearch through ESPSearchGUI 
unless you save the settings as espsearch.ini. You do NOT need to save the 
settings before running ESPSearch, as espsearch.ini will automatically be 
written, but you do need to save the settings if you wish to keep them for 
later use. Note that ESPSearchGUI does not check to ensure the settings 
you have provided are valid.
E.3 Running ESPSearch
E.3.1 Starting a Search
The "Run Search" button will write the current settings (as displayed) 
to espsearch.ini (overwriting any existing settings in the file), and run 
ESPSearch. Note that ESPSearchGUI will not check for any errors in the 
settings, and relies on ESPSearch's load routines to do so. ESPSearch will 
run in a window over the settings window, locking the settings until 
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ESPSearch has completed. If ESPSearch exits normally for any reason (even 
an error in the settings), you can close this window and return to the 
settings window. If ESPSearch crashes, you may get locked out of the 
settings window and be unable to close it. Please send email to us if this 
occurs with a detailed explanation, but no promises of support are made.
E.3.2 Interacting with ESPSearch
While ESPSearch is running, it may occasionally require feedback 
(just as if you were running it without ESPSearchGUI). When this happens, a 
dialog box with an input box will appear. Simply enter the necessary 
information ("y", "n", or nothing, as appropriate), and press the ENTER key 
or click the OK button to continue. The CANCEL button or invalid input may 
cause ESPSearch to repeat its request.
ESPSearchGUI is Copyright © 2005 Terry J. Watt. It may be freely modified 
according to the terms of GNU GPLv2 or later.
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